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ZUSAMMENFASSUNG 
Im Jahr 1997 wurden der Orphan-G-Protein-gekoppelte Rezeptor 30 (GPR30) aus 
menschlichen Nabelschnur-Endothelzellen (HUVECs) kloniert, die Fluid Shear Stress (FSS), 
einer mechanischen Kraft, die auf Blutgefäße wirkt, ausgesetzt waren. In dieser Studie von 
Takada et al konnte gezeigt werden, dass die Expression von GPR30 durch die FSS-
Behandlung im Vergleich zu unbehandelten HUVEC-Zellen deutlich induziert 
wurde. Daraufhin wurde in einer Studie im dem Labor, in dem die Experimente für diese 
Arbeit durchgeführt wurden, die zelluläre und gewebsspezifische Expression von GPR30 in 
GPR30-LacZ Reportergen-Mäusen untersucht. Es konnte eine Expression von GPR30 
vorwiegend in den Endothelzellen der kleinen Arterien verschiedenster Gewebetypen 
nachgewiesen werden. 
Vor einigen Jahren wurde von zwei unabhängigen Gruppen postuliert, dass GPR30, 17-β-
Östradiol (E2) direkt binden kann und dadurch rasche nicht-genomische Signale 
vermittelt. Im Gegensatz dazu haben verschiedene andere Veröffentlichungen gezeigt, dass 
E2 nicht spezifisch an GPR30 bindet. Trotz der Kontroverse, ob es sich bei GPR30 um einen 
Östrogenrezeptor oder um einen Orphan-Rezeptor handelt, ist bislang nichts über seine 
Interaktion zu anderen Proteinen und deren Wechselwirkung bekannt. Deswegen, und 
aufgrund der Tatsache, dass mehrere Berichte darauf hindeuten, dass GPCRs mit mehreren 
Proteinen (neben denen, die in der traditionellen Vorstellung mit heterotrimeren G-Proteine 
wechselwirken) interagieren bzw. von diesen reguliert werden, war ein Ziel dieser Arbeit, 
Interaktionspartner von menschlichen GPR30 zu identifizieren und folglich ein humanes 
vaskuläres in vitro Modell zu etabliren, um die potentiellen Interaktionen von GPR30 sowie 
die downstream-Effekte der Wechselwirkung zwischen GPR30 und den neuen 
Interaktionspartner des vaskulären Modells auf Transkriptebene zu evaluieren. 
Ein Screening einer humanen kardiovaskulären cDNA-Bibliothek mit Hilfe des Hefe-2-Hybrid 
(Y2H)-Systems führte zur Identifizierung mehrerer Interaktionspartner für GPR30, darunter 
das PALS1-assoziierten Tight Junction-Protein (PATJ) und das FUN14 domain containing 2-
Protein (FUNDC2). Durch anschließende Ko-Immunopräzipitation (CoIP)-Experimente 
konnte die Interaktion von GPR30 mit PATJ validiert werden. Zusätzlich wurde eine teilweise 
zelluläre Ko-Lokalisation gefunden. Des Weiteren konnte in dieser Arbeit die Wirkung von 
FSS auf die Expression von GPR30 in HUVEC-Zellen bestätigt und ebenfalls in weiteren 
anderen Endothelzellen gezeigt werden. So wurde eine Hoch-regulierung der Expression 
von GPR30 induziert durch FSS in humanen arteriellen Nabelschnul-Endothelzellen 
(HUAECs), humanen Aorten-Endothelzellen (HAoECs) und in humanen mikrovaskulären 
Endothelzellen (HMEC-1) gefunden, was darauf hindeutet, dass GPR30 in der Tat eine 
wichtige Rolle in der vaskulären Physiologie spielt. Abschließend wurde die Rolle von 
GPR30 und PATJ bei der Reaktion auf FSS auf transkriptioneller Ebene in HMEC-1-Zellen 
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genomweit untersucht. Interessanterweise war eine Gruppe von Genen aufgrund von FSS in 
Zellen, die GPR30 überexprimierten dereguliert, als alleine durch FSS. Darunter waren 
Gene, die zum einen eine wichtige Rolle bei verschiedenen Funktionen und der 
Morphogenese von Gefäßen spielen, z.B. Plexin D1 (PLXND1) und Troponin I Typ 3 (TNNI3) 
und zum anderen an der Entwicklung und der Funktion des endokrinen Systems beteiligt 
sind, z.B. der ras-related and E2-regulated growth inhibitor (RERG), der in der E2-
Signalkaskade involviert ist. Zusammenfassend zeigt diese Arbeit zum ersten Mal die 
Interaktion von GPR30 und PATJ und beschreibt ein Modell, mit dessen Hilfe die Funktion 
von GPR30 in Endothelzellen weiter untersuchen könnte. 
Schlagwörter: GPR30, fluid shear stress, PATJ, endothelzellen. 
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ABSTRACT 
In 1997, the orphan G protein-coupled receptor 30, GPR30 was cloned using human 
umbilical vein endothelial cells (HUVECs) exposed to fluid shear stress (FSS), one of the 
mechanical forces acting on blood vessels. Takada et al. have shown that the level of 
GPR30 expression was markedly induced in response to FSS. Subsequently, in a study 
performed in the laboratory where the work for this thesis was carried out, the cellular and 
tissue distribution of GPR30 were investigated in GPR30-LacZ reporter mice and the 
expression was found predominantly in the endothelial cells of small arteries in several tissue 
types. GPR30, was claimed some years later to bind 17-β-estradiol (E2) directly and to 
mediate rapid non-genomic signalling. In contrast, various reports have indicated that E2 fails 
to bind GPR30 in a specific manner. Despite the controversy on whether GPR30 is an 
estrogen receptor or still an orphan receptor, nothing is known at present about its relation 
and interaction with other proteins. Therefore, also according to several reports suggesting 
that GPCRs interact with and are regulated by several other proteins beyond the established 
role of heterotrimeric G proteins, the aim of the work described in this thesis was to identify 
human GPR30 protein interaction partners and to establish a human vascular in vitro model 
in order to evaluate the potential role of GPR30 and the downstream effects of the interaction 
between GPR30 and new interaction partners in a vascular model at transcript level. The 
screening of a human heart cDNA library using the yeast two-hybrid (Y2H) assay led to the 
identification of several interaction partners for GPR30, among them PALS1-associated tight 
junction protein (PATJ) and the FUN14 domain containing 2 (FUNDC2). These interactions 
were verified by co-immunoprecipitation (CoIP) experiments and the interaction of GPR30 
with PATJ could be confirmed. The effect of FSS on the expression of GPR30 was confirmed 
in HUVECs and was detected in other endothelial cell types. In Human Umbilical Arterial 
(HUAECs), Human Aortic (HAoECs) and Human Microvascular Endothelial Cells (HMEC-1) 
GPR30 was also found up-regulated upon FSS, suggesting that GPR30 may indeed play a 
key role in vascular physiology. Finally, the role of GPR30 and PATJ in the FSS response 
was investigated at the genome-wide transcript level in HMEC-1 cells. Interestingly, a 
different panel of genes was deregulated owing to FSS in cells over-expressing GPR30 
compared to FSS alone. These included genes that play an important role in vascular 
function and morphogenesis, e.g. plexin D1 (PLXND1) and troponin I type 3 (TNNI3), and in 
the development and function of the endocrine system, e.g. the ras-related and E2-regulated 
growth inhibitor (RERG), which is involved in E2 signalling. Taken together, this study 
provides evidence for the first time for an interaction between GPR30 and PATJ and 
proposes a model to further evaluate the role of GPR30 in endothelial cells. 
Keywords: GPR30, fluid shear stress, PATJ, endothelial cells. 
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1     INTRODUCTION 
 
1.1   G protein-coupled receptors (GPCRs) 
 
G protein-coupled receptors (GPCRs) – also known as seven transmembrane domain 
receptors, 7TM receptors, and heptahelical receptors – represent one of the largest gene 
families. In humans, these membrane proteins control different physiological processes and 
also mediate most cellular responses to hormones, biogenic amines, peptides, lipids and 
neurotransmitters. Indeed, they are responsible for cellular metabolism, growth and 
inflammatory responses as well as for vision, olfaction and taste (Pierce et al., 2002). 
Two main features identify a receptor as a GPCR. The first structural requirement common to 
all GPCRs is the presence of seven transmembrane sequences with about 25–35 
consecutive amino-acid residues responsible for the protein's high hydrophobicity. These 
seven α-helices segments span, in a counter-clockwise manner, the membrane connected 
by alternating intracellular and extracellular loop (ICL and ECL) regions and with an amino 
terminus located on the extracellular side and a carboxy terminus on the intracellular side 
(Figure 1). The second feature is the ability of the receptor to bind a G protein, allowing the 
activation of various signalling pathways within the cell. Because of their ability to recruit and 
regulate the activity of intracellular heterotrimeric G proteins, they have been named GPCRs. 
For many GPCRs the interaction with G proteins has not yet been demonstrated, and it 
would therefore be more correct to name these receptors 7TM receptors, but the term GPCR 
is in more common use (Fredriksson et al., 2003), (Kristiansen, 2004). 
 
 
 
Figure 1: GPCRs structure 
Seven α-helices segments span the membrane connected by intra- and extra-cellular loops (ICL and 
ECL). Adapted from Kristiansen et al. 2004 (Kristiansen, 2004). 
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So far, in humans, more than 1000 genes encoding GPCRs have been identified, of which 
over 400 are olfactory and 356 non-olfactory GPCRs, according to the International Union of 
Pharmacology (IUPHAR) database (http://www.iuphar-db.org/index.jsp) (Harmar et al., 
2009). Among the non-olfactory receptors 134 are annotated as orphan GPCRs. These 
orphan receptors lack an endogenous ligand and for this reason are of great 
pharmacological interest as potential new drug targets (Chung et al., 2008). Indeed, GPCRs 
also represent therapeutic drug targets (≈50% of modern pharmaceuticals) of choice in 
cancer, cardiac dysfunction, diabetes, inflammation, pain, etc. (Vassilatis et al., 2003). 
 
1.1.1 Classification of GPCRs 
Significant sequence homology is found within several groups. Thus, on the basis of 
sequence similarity, all known GPCRs have been classified into three major families: 
Family A: Receptors related to the rhodopsin and the β2-adrenergic receptor. This group 
contains most of the 7TM receptor types, including the olfactory subgroup.  
Family B: Receptors related to the glucagon receptor. This family comprises only about 25 
members, including the receptors for the gastrointestinal peptide hormone family (secretin, 
glucagon, vasoactive intestinal peptide), calcitonin and parathyroid hormone. 
Family C: Receptors related to the metabotropic neurotransmitter receptors. This quite small 
group contains, besides the metabotropic receptor GABAB, the calcium-sensing receptor and 
some taste receptors (Pierce et al., 2002), (Gether, 2000), (Jassal et al.). 
 
In a second classification system, based on phylogenetic analysis, 342 unique, non-olfactory, 
human GPCRs were classified into five families: 
Family G: the glutamate receptor family, 
Family R: the rhodopsin receptor family, 
Family A: the adhesion receptor family, 
Family F: the frizzled/taste2 receptor family, 
Family S: the secretin receptor family. 
 
Common to both classifications are three of these families, the rhodopsin (A), secretin (B) 
and glutamate (C) families, while families F and S are not included in the previous 
classification (Fredriksson et al., 2003). The GPCR investigated in the present study, the 
7TMR GPR30 belongs to the class A (rhodopsin-like) receptors, sub-family peptide 
receptors, sub-sub-family chemokine receptor-like 2, which contains only GPR30 
orthologues of different species. 
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1.1.2 Activation and termination of GPCR signalling 
The activation of GPCRs is related to the structure of a ternary complex, which comprises 
the receptor, the ligand and the G protein. This complex is maintained in an equilibrium 
between the active and inactive states. Once the ligand binds the receptor, there is a 
conformational change of the receptor leading to the activation of the G protein. The G 
proteins (short for “guanine-nucleotide-binding proteins”), make up a family of heterotrimeric 
proteins consisting of three subunits called α, β and γ. They function as “molecular switches” 
activating the second messenger cascades. In particular, the activated G protein favours the 
release of GDP from the α subunit and its replacement with GTP. At this stage the G protein 
complex dissociates into the α subunit and a βγ dimer, both of which modulate a variety of 
cellular responses. Subsequently, hydrolysis of GTP to GDP leads to re-association of the G 
protein subunits (Figure 2) (Pierce et al., 2002). 
 
 
 
Figure 2: GPCRs signalling scheme 
Once the agonist binds the receptor, the G protein complex dissociates into α subunit and a βγ dimer, 
both of which modulate a variety of cellular responses. Adapted from Ritter et al. 2009 (Ritter und Hall, 
2009). 
 
In humans, there are 21 Gα subunits encoded by 16 genes, 6 Gβ subunits encoded by 5 
genes, and 12 Gγ subunits. Generally, the G proteins are referred to their respective Gα 
subunit, divided into four main classes based on similarity of their sequences: Gαs, Gαi, Gαq 
and Gα12. Thus the Gs heterotrimeric complex contains Gαs, the Gi contains Gαi, and so on. 
Members of the Gs (stimulatory G protein) family activate adenylyl cyclase (AC) which 
synthesises intracellular cyclic adenosine monophosphate (cAMP), a second messenger 
able to interact with and to activate protein kinase A (PKA). PKA can then phosphorylate 
numerous downstream targets. Relaxation of blood vessels, gene regulation and modulation 
of ion channels are results of the Gαs-induced signalling cascade. In contrast, members of 
the Gi (inhibitory G protein) family inhibit the cAMP-dependent pathway by inhibiting AC 
activity; additionally, Gi act mainly by directly regulating ion channels. Stimulation of growth 
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and contraction of blood vessels are the results of Gαi-induced signalling. Many GPCRs 
function through a Gq protein by activating phospholipase C-β (PLCβ), which catalyses the 
hydrolysis of phosphatidylinositol-4,5-biphosphate (PIP2) into inositol triphosphate (IP3) and 
diacylglycerol (DAG). IP3 then promotes the mobilisation of intracellular calcium (Ca2+), while 
DAG stimulates the activity of protein kinase C. As in the case of Gi, Gq-induced signalling is 
involved in the contraction of blood vessels. Gα12 is a family of proteins that can activate a 
guanine nucleotide exchange factor (GEF) that in turn activates a monomeric GTPase of the 
Rho family (regulation factors family in the transcription of DNA to RNA). Once dissociated 
from the Gα subunit, the Gβγ subunits can also bind to and regulate downstream effectors, 
such as phospholipase C-γ (PLCγ) and ion channels (Wilkie et al., 1992), (Ritter und Hall, 
2009). 
 
After ligand stimulation, most GPCRs show a rapid loss of responsiveness, also called 
desensitisation. Termination of a G protein-mediated signalling occurs through GPCR 
kinases (GRKs)-β-arrestin system. The GRKs as well as the arrestins are encoded from 
different genes: so far, seven different genes are known for GRKs and four genes for 
arrestins, of which some are exclusively expressed in specific cell-type while some are 
ubiquitously distributed. Only after ligand binding, the receptor, in its activated conformation, 
can be phosphorylated and recruits an arrestin molecule, which interacting with clathrin and 
clathrin adaptor protein 2 (AP2) drives GPCR internalisation into endosomes. Subsequently, 
GPCRs can be transported either to lysosomes, where they are degraded, or to recycling 
endosomes, where they can be sent back to the plasma membrane to start a new round of 
signalling (Krupnick und Benovic, 1998), (Jalink und Moolenaar). 
Recent findings indicate that β-arrestins are also involved in the activation of distinct arrestin-
mediated signalling pathways by serving as multiprotein scaffolds for a number of signalling 
molecules, e.g. extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases 
(JNKs) (Figure 3), (DeWire et al., 2007). 
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Figure 3: GPCRs desensitisation schema 
Termination of a G protein-mediated signalling occurs through GPCR kinases (GRKs)-β-arrestin 
system. Adapted from Ritter et al. 2009 (Ritter und Hall, 2009). 
 
1.1.3 GPCR interacting proteins 
Over the last years, evidence has accumulated suggesting that GPCRs interact with, and are 
regulated by, several other proteins (GPCR-interacting proteins, GIP), in addition to the 
specific intramolecular interactions that define the activation states of the receptor, such as 
the established role of the interaction with heterotrimeric G proteins and the association with 
GRKs and β-arrestins. GPCRs can interact with another GPCR or with a wide range of GIPs: 
transmembrane proteins, ionic channels, ionotropic receptors, single transmembrane 
proteins or soluble proteins.  
Indeed, it is widely accepted that many GPCRs can interact with another identical 
(homodimer) or different (heterodimer) GPCR unit (Milligan, 2009). The potential roles and 
implications of the formation of such receptor dimers might represent the rule rather than the 
exception for this important class of receptors. For instance, the use of co-
immunoprecipitation approaches with differentially epitope-tagged receptors provided direct 
biochemical evidence for β2-adrenergic receptor homodimers (Hebert et al., 1996). Since 
then, similar co-immunoprecipitation approaches have been used to document the 
dimerisation of several GPCRs, including the neurotransmitter gamma-aminobutyric acid 
class B (GABAB) (White et al., 1998), metabotropic glutamate receptor 5 (mGluR5) (Romano 
et al., 1996), δ-opioid (Jordan und Devi, 1999), and calcium sensing (CaSR) (Bai et al., 
1998) receptors. The role of dimerisation is not yet clear: either it controls signalling 
specificity and efficacy, or it simply serves as chaperone to escort the receptors from the 
different cellular compartments (Milligan, 2009).  
So far, mainly GPCRs with known ligands and functions have been studied, but recent 
findings show clearly that the idea of GPCRs dimerisation can also be extended to orphan 
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GPCRs (i.e. those without a known ligand) (Civelli et al., 2006) with consequent ligand-
independent properties, which provides a novel concept for the elucidation of the function of 
orphan GPCRs (Levoye et al., 2006). Related to this issue, there is also the possibility that 
some orphan GPCRs may require the expression of special accessory proteins for their 
activity. This has been shown in the case of the calcitonin GPCR, which necessitate the 
presence of receptor activity-modifying proteins (RAMPs) for inducing its signalling pathway 
(Hay et al., 2006). Other examples of GIPs are PDZ domain-containing proteins which are 
soluble proteins interacting with the C-terminal domain of GPCRs. So far more than 50 GIPs 
have been identified binding through their PDZ domain (a sequence of 80–90 amino acids 
first identified in the three proteins PSD95, DlgA and ZO-1) the PDZ ligand (sequence 
expressed in the last 3–4 C-terminal residues) of GPCRs (Sheng und Sala, 2001). These 
proteins can be involved in different processes, depending on the cell in which the GPCR is 
expressed. For instance, the so-called ‘protein interacting with protein kinase C’ (PICK1) 
plays a crucial role in the axonal clustering of the metabotropic glutamate receptor mGluR7a, 
which localises specifically to presynaptic active zones and interacts with PICK1 (Boudin et 
al., 2000). Another example of interaction between GPCR and GIP is in Drosophila 
photoreceptor neurons, where the multivalent PDZ protein INAD serves as a scaffold to 
assemble different components of the phototransduction pathway, in a protein complex 
directly binding the C terminus of the GPCR rhodopsin together with a Ca2+ channel, 
phospholipase C-β and calmodulin (Chevesich et al., 1997). In conclusion, the elucidation of 
the nature of these interactions in different cell types is opening up the possibility to design 
new pharmacological drugs that can disrupt the GPCR-GIP interaction in a tissue without 
affecting other interactions (Bockaert et al., 2004). 
 
1.2   The G protein-coupled receptor GPR30 
 
The story of GPR30 started during the years 1996–97, when it was cloned by different 
groups using six independent approaches. Five of these clonings were performed using 
degenerated polymerase chain reaction (PCR) primers to amplify the transmembrane 
domains of new GPCRs from cDNA of Burkitt’s lymphoblasts (Owman et al., 1996), B cells 
(Kvingedal und Smeland, 1997), human umbilical vein endothelial cells (HUVECs) stimulated 
with fluid shear stress (FSS) (Takada et al., 1997) and human genomic DNA (Feng und 
Gregor, 1997), (O'Dowd et al., 1998) or by using differential cDNA library screening between 
estrogen receptors (ERs)-positive MCF-7 and ERs-negative MDA-MB-231 breast cancer cell 
lines (Carmeci et al., 1997). During the years, other names identifying GPR30 were also 
used: CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, LERGU, LERGU2, LyGPR and GPER. 
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The GPR30 gene, well conserved in different species, is localised on human chromosome 
7p22.3 and to date four transcripts, with 2 or 3 exons, are known encoding the same GPR30 
protein of 375 amino acids. The protein is highly conserved in mammals, with 87% sequence 
identity between human and mouse. 
 
1.2.1 GPR30: a new estrogen receptor or still an orphan receptor? 
Because of the sequence homology of GPR30 with the IL-8 receptor, with other members of 
the chemoattractant receptor family formylpeptide-like receptor (FPRL)-1 and FPRL-2 and 
with the chemokine receptor CXCR1, it has been suggested that the endogenous ligand 
would be a chemokine or a peptide (Owman et al., 1996), (Feng und Gregor, 1997). 
However, none of these hypothetical ligands provoked a response in cells transfected with 
GPR30.  
 
A few years later, the orphan GPR30 was found to mediate ERK-1/-2 activation in response 
to 17-β-estradiol (E2 or beta-estradiol) in ER-negative SKBr3 breast cancer cells by 
transactivation of the epidermal growth factor (EGF) receptor (Filardo et al., 2000).  In 
another study, the same group demonstrated that, in addition, GPR30, after estrogen 
stimulation, could also activate the adenylate cyclase and cAMP-mediated inhibition of ERK-
1/-2 (Filardo, 2002). Furthermore, they observed that estrogen was not the only substance 
able to act as an agonist for GPR30, but that the antagonist molecules of the estrogen 
receptors fulvestrant (ICI 182,780) and tamoxifen could also do this. In both studies, 
however, an assay demonstrating the clear binding of GPR30 with E2 was missing. It was 
only in 2005 that two independent groups postulated that GPR30 is a new receptor, directly 
binding E2 and able to mediate rapid non-genomic signalling (Thomas et al., 2005), 
(Revankar et al., 2005).  
 
In the first study, Thomas et al. described the specific binding between GPR30 and estradiol 
using tritium-labelled E2 ([3H]-E2) in SKBr3 cells and in GPR30-transfected human 
embryonic kidney (HEK)293 cells. The dissociation constant (Ki) was approximately 3 nM. 
The binding sites were absent in untransfected HEK293 cells and in SKBR3 cells with small 
interfering RNA (siRNA)-mediated knock-down of GPR30. Although dose–response curves 
were not produced, the authors suggested that the binding was specific, since progesterone, 
testosterone, and cortisol were unable to compete with [3H]-E2) (Thomas et al., 2005). In the 
following study, the group of Prof. Prossnitz used monkey kidney fibroblasts (COS-7) 
transfected with ERα or GPR30, both conjugated to green fluorescent protein (GFP), and E2 
linked to the fluorescent dye Alexa for the binding assays, instead of the standard cell-
membrane-permeating, radioactive E2. Indeed, since E2-Alexa does not permeate the 
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membranes, cells were permeabilised with saponin. A linear relationship between the 
fluorescent signal for E2-Alexa binding and the amount of GPR30 expressed was shown by 
competitive binding to be ≈6 nM, but not by a specific, saturable binding assay of E2 to 
GPR30 (Revankar et al., 2005).  
 
Only one year later, the first evidence against the role of GPR30 as an estrogen receptor 
was published. Pedram et al., using endothelial cells (ECs) expressing GPR30 from 
ERα/ERβ-deficient mice (DERKO mice), demonstrated that only the classical estrogen 
receptors (but not GPR30), mediated estrogen-nongenomic signalling responses. In addition, 
a significant binding of radioactive estradiol in SKBr3 cells, positive for GPR30, could not be 
shown (Pedram et al., 2006).  
 
Subsequently, in 2008 two different reports supported these data. In the first accurate 
quantitative study using different cellular lines (U2OS, CHO, and COS-7) over-expressing 
ERα or GPR30, ERα was observed to bind [3H]-E2 specifically, whereas GPR30 did not do 
so. The same effect was observed in cells endogenously expressing GPR30 (MDA-MB231 
and HEC50). Furthermore, the signalling in response to E2 involving GPR30 showed in the 
earlier studies could not be reproduced (Otto et al., 2008). In line with these data, a third 
group provided additional evidence that MCF-7 breast cancer cells treated with the estrogen 
antagonist ICI 182,780 – or with ERα knock-down using siRNA – abolished estrogen-
mediated gene stimulation, whereas GPR30 knock-down or treatment with the newly 
identified selective GPR30 agonist G1 (Bologa et al., 2006) did not influence the gene 
expression. In this setting, rapid extranuclear estradiol signalling was exclusively mediated 
by the classical ERs (Madak-Erdogan et al., 2008).  
In the latest data questioning the role of GPR30 mediating non-genomic estrogen signalling, 
the involvement of an ERα variant, ER-α36, was introduced. Kang et al. demonstrated that 
GPR30 over-expression in cells not expressing it endogenously could induce the expression 
of ER-α36, by activating its promoter. Furthermore, this study provided evidence that the 
GPR30-selective agonist G1 could activate ER-α36, previously described to be mainly 
expressed at the plasma membrane of ER-negative breast cancer cells and mediating non-
genomic estrogen signalling (Wang et al., 2005). Most importantly they demonstrated high-
affinity, specific binding with both E2 and G1, by using a saturation and binding assay in 
HEK293 cells that over-expressed ER-α36. With these results, they concluded that ER-α36, 
but not GPR30, is responsible for the non-genomic E2 signalling (Kang et al.). 
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In conclusion, the question of whether GPR30 is a new estrogen receptor involved in the 
non-genomic signalling remains controversial, suggesting that it may still be an orphan 
receptor. 
 
1.2.2 GPR30 signalling 
Despite the strong controversy about GPR30 as an estrogen receptor, to date the number of 
publications considering GPR30 as a new estrogen receptor is almost ten times greater than 
in 2006 (in August 2010 circa 200). Already in 2007, GPR30 was renamed “G protein-
coupled estrogen receptor (GPER)” in most databases (e.g. www.ensembl.org or 
www.ncbi.nlm.nih.gov). Thus, most studies were conducted considering estrogen to be a 
ligand for GPR30. As mentioned above, Filardo et al. proposed for the first time that GPR30 
may play a role in the rapid activation of MAPKs by estrogen in breast cancer cells through 
the transactivation of EGFR. In particular, the Gβγ subunit promotes a non-receptor tyrosine 
kinase (Src)-mediated, metalloproteinase (MMP)-dependent cleavage and release of 
heparin-binding EGF-like growth factor (HB-EGF) from the cell surface, resulting in the 
activation of the ERK-1/-2 pathway. On the other hand, the Gα subunit stimulates AC, which 
leads to PKA-mediated suppression of EGF-induced ERK-1/-2 activity (Filardo et al., 2000), 
(Filardo, 2002). 
 
Subsequently, another group provided evidence that estrogen or phytoestrogens induced the 
expression of the proto-oncogene c-fos in various cancer cells (breast, endometrium, thyroid 
cancer, ovarian) and cell lines lacking nuclear ERs. In addition, over-expression of GPR30 in 
BT-20 breast cancer cells could activate the up-regulation of c-fos upon estrogen stimulation, 
and anti-sense RNA against GPR30 blocked the up-regulation of c-fos (Maggiolini et al., 
2004), (Vivacqua et al., 2006), (Vivacqua et al., 2006), (Albanito et al., 2007). 
Concerning the association of GPR30 with G proteins, main transduction mechanisms have 
been suggested to be through Gs or through Gq. The coupling of GPR30 to Gαs was 
assumed, because stimulation of AC and subsequent cAMP production were observed 
(Filardo, 2002) and, moreover, direct interaction between these was demonstrated (Filardo et 
al., 2007). Since estrogen-mediated Ca2+ mobilisation mediated by PLC through GPR30 was 
found in an independent study, association of GPR30 with Gq was suggested (Figure 4), 
(Revankar et al., 2005), (Prossnitz et al., 2008). 
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Figure 4: Model of the mechanisms of estrogen-mediated signalling via GPR30 
Adapted from Prossnitz et al. 2008 (Prossnitz et al., 2008). 
 
In contrast to these data, as reported earlier in the section on studies aimed at demonstrating 
whether GPR30 is an estrogen receptor, Pedram and co-workers were unable to show cAMP 
or ERK activation in response to E2 in GPR30-positive, ER-negative breast cancer cells 
(Pedram et al., 2006). Another study failed to reveal elevation of Ca2+ or cAMP activation in 
COS-7 cells transiently transfected with GPR30 or in MDA-MB231 and HEC50 expressing 
higher endogenous levels of GPR30 (Otto et al., 2008). 
 
1.2.3 GPR30 cellular localisation 
Apart from the fact that there is some controversy regarding GPR30’s function as an 
estrogen receptor, there is also some dispute regarding its cellular localisation, with no less 
importance for the function of the receptor itself. An intracellular sublocalisation implies for 
instance that the ligand has to be membrane-permeating, defining a relevant biochemical 
characteristic of the putative ligand. 
 
In 2005 the first report showed the expression of GPR30 at the plasma membrane of SKBr3 
cells or from healthy human placental tissue after a centrifugation-series procedure (Thomas 
et al., 2005). Supporting these data, one year later, the localisation of GPR30 was observed 
at the plasma membrane by the use of an anti-GPR30 antibody in HeLa cells expressing 
FLAG-GPR30, even though no staining of subcellular markers was conducted (Funakoshi et 
al., 2006). The same conclusion was also reached by Filardo et al., who demonstrated the 
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presence of GPR30 at the cell surface by using a specific plasma membrane marker (Filardo 
et al., 2007). 
 
In contradiction to these data, Revankar and colleagues could show by different approaches 
the expression of GPR30-GFP in the endoplasmic reticula of different cell lines (Revankar et 
al., 2005). Since the evidence regarding the subcellular site of GPR30 started to be 
contradictory, other groups tried to clarify this aspect and the group of Otto also detected the 
expression of GPR30 in the endoplasmic reticulum (Otto et al., 2008). 
 
In conclusion, since the idea that other GPCRs could be located on intracellular 
compartments has been already contemplated (Gobeil et al., 2006), it is certainly possible 
that under specific conditions, intracellular GPR30 can exist in, or translocate to, the cell 
membrane (Prossnitz et al., 2007). 
 
1.2.4 GPR30 in vivo studies 
Besides the results on GPR30's function based on cell assays, several studies were 
performed to clarify the role of GPR30 in vivo by using rats, hamsters or GPR30-knockout 
(KO) mice. Currently, four different GPR30-KO mouse models have been realised (Isensee 
et al., 2009), (Martensson et al., 2009), (Otto et al., 2008), (Wang et al., 2008) and an 
overview of the major results is given in Table 1 (Langer et al.). 
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Table 1: GPR30 knockout mice overview. Adapted from Langer et al. (Langer et al.). 
Parameter  
 
Mouse model described 
by Wang et al. 
 
Mouse model described 
by Martensson et al. 
 
Deltagen mouse model 
described by Isensee et al. 
 
Artemis mouse model 
described by Otto et al. 
 
 Analysed lege artis  3′-integration analysed lege  artis  Analysed lege artis  Analysed lege artis 
 
 
 5′- and 3′-    
integration of   
the targeting  
vector 
 
  5′-integration not analysed by Southern blot   
 Single 
integration of 
the targeting 
vector 
 
 Not analysed  Not analysed lege artis  Analysed lege artis  Analysed lege artis 
 Targeting 
strategy 
 Replacement of exon 3 by 
neomycin resistance cassette  Deletion of exon 3 
 Replacement of amino acids 20–
136 of GPR30 by a LacZ 
reporter/neomycin resistance 
cassette 
 Deletion of exon 3 
 Neomycin 
resistance 
cassette left in 
genome? 
 
 Yes  No  Yes  No 
 SvEv ES cells  129X1/SvJx129S1 ES cells  129/OlaHsd ES cells  C57BL/6N ES cells  Genetic 
background  3× backcross in C57BL/6  6× backcross in C57BL/6  6× backcross in C57BL/6  C57BL/6 background 
 Mating scheme 
for generation of 
experimental 
animals 
 
 Homozygous intercrosses 
 Heterozygous intercrosses and 
use of age-matched C57BL/6 
mice as control 
 Heterozygous intercrosses  Heterozygous intercrosses 
 Involvement of GPR30 in 
mediation of estradiol-induced 
thymic atrophy 
 Reduced body weight and 
skeletal growth in female 
mutants 
 No effects on body weight or 
glucose tolerance 
 No effects on body weight, 
visceral adiposity, glucose 
tolerance or fertility in 
mutant mice from both 
genders 
 
 Increased body weight and 
visceral adiposity in female 
and male mutant mice [Ref. 
[23]] 
 Impaired glucose tolerance in 
6 months old female mutants 
 Lower frequency of CD4+ and 
CD8+ T cells in peripheral blood 
of mutant mice 
 Estrogenic responses in the 
uterus and the mammary 
gland were completely 
maintained in female mutant 
mice 
 
 No effects on body weight 
[Ref. [41]] 
 Elevated mean arterial blood 
pressure in 9 months old 
female mutants 
 
 
 Amount of CD4+ and CD8+ 
T cells in peripheral blood is 
unchanged in mutant mice 
 Described 
phenotypes 
 Vasodilatory effects of 1 µM 
G1 were not present in carotid 
arteries of mutant mice 
 Increased media thickness in 
second-order mesenteric 
arteries 
  
 
The first study in vivo aimed to investigate the physiological function of GPR30 as a new 
estrogen receptor. It was conducted on rats, applying a trauma-haemorrhagic shock (THS) 
model (based on mechanical and controlled bleeding followed by pharmacological 
resuscitation). First of all, hepatic injury was evaluated at the plasma α-glutathione S-
transferase (αGST) level, and treatment with E2 after THS was able to reduce it. Secondly, 
knock-down of GPR30 by transfection of siGPR30 attenuated the E2-dependent activation of 
PKA and inhibition of the pro-apoptotic B-cells lymphoma 2 gene (Bcl2). In conclusion, the 
hepatic injury could have been reduced in response to estrogen by way of GPR30-mediated, 
and not ERα-mediated, anti-apoptotic signalling (Hsieh et al., 2007). 
 
With the first KO mouse for GPR30, an immunological study was proposed. Indeed, the 
estrogen-induced thymic atrophy, which normally occurs during pregnancy or prolonged 
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estrogen treatment, was analysed comparing GPR30-deficient mice with ERα KO (AERKO) 
and ERβ KO (BERKO) mice. Previous studies with ERα-, ERβ-deficient mice showed that 
ERα was to some extent involved in the reduction of thymus size, whereas ERβ was not 
relevant (Erlandsson et al., 2001). Although E2-treated female GPR30-KO mice showed 
alleviated (but not completely reversed) thymic atrophy and in ERα-KO mice the atrophic 
effect resulted rather abolished, it was possible to distinguish between the contribution of 
GPR30 and ERα in mediating thymic atrophy. Bearing in mind that the maturation of 
thymocytes to T cells (a process that occurs in the thymus) is characterised by different 
stages based on the expression of cell-surface markers such as CD4 and CD8, which can be 
expressed not at all (double negative, DN) or one at a time (single positive, SP) or doubly 
(double positive, DP), Wang et al. suggested that ERα exclusively mediates an early 
developmental stage of thymocytes DN after E2 treatment, whereas GPR30 was 
indispensable for apoptosis of a special class (TCR β-chain-/low) of DP thymocytes (Wang et al., 
2008). Subsequently, in the same mouse model used in another study, an increased body 
weight and visceral fat deposits were found in both female and male animals (Haas et al., 
2009). Furthermore, in this study GPR30 was considered to be involved in the regulation of 
vascular tone and blood pressure in line with previous observations about an up-regulation of 
GPR30 in endothelial cells upon fluid shear stress (FSS) (Takada et al., 1997) and the 
expression of GPR30 in small vessels (Isensee et al., 2009). 
 
In contrast to the mouse model described by Wang et al., the analysis of the mouse model of 
Martensson et al., which was restricted to female animals, showed a reduction in body 
weight and skeletal growth in three-months-old mice. In female mice aged six and nine 
months, impaired glucose tolerance and an elevation of arterial blood pressure were 
reported, respectively (Martensson et al., 2009). 
 
In a third mouse model (GPR30 KO mice, generated by Artemis), questioning again the role 
of GPR30 involved in the E2-response, Otto et al. observed no significant difference in body 
weight or impairment in fertility. In addition, E2 responses in ovariectomised (ovx) KO mice 
treated with E2 were maintained in the uterus and the mammary gland. On the other hand, 
administration of the proposed GPR30 agonist G1 (Bologa et al., 2006) did not stimulate any 
estrogenic response in the uterus or in the mammary gland of wild type mice (Otto et al., 
2008), (Otto et al., 2009).  
 
Another approach used to unravel the in vivo function of GPR30 was the production of a KO 
mouse for GPR30 by Deltagene with the insertion of a LacZ/neomycin cassette into the open 
reading frame (ORF) of GPR30. With these mutant mice Isensee et al. could provide, 
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besides a general phenotypic analysis, a broad and detailed screening about the tissue 
distribution at the cell-type level. Indeed, according to the Artemis GPR30 KO model, no 
significant difference in body weight was noticed in a comparison of wild-type with mutant 
animals, even after a high-fat diet. Interestingly, the expression of GPR30, identified by 
colocalisation of LacZ along with cell-type-specific markers, was observed in endothelial cells 
of small arterial vessels of various tissues; smooth muscle cells, pericytes, and neuronal 
subpopulations in the brain; gastric chief cells in the stomach; and chromaffin cells in the 
adrenal glands. Since prominent expression of GPR30 was found in endothelial and smooth-
muscle-cell subpopulations, the authors concluded by considering the involvement of GPR30 
in vascular diseases, such as hypertension, arteriogenesis or vascular injury (Isensee et al., 
2009). 
 
1.3   Blood vessels in the vascular circulatory system 
 
The function of the entire vascular system is the rapid transport of oxygen, glucose, amino 
acids, fatty acids, vitamins and water to appropriate tissues and to remove metabolic waste 
products such as CO2, urea and creatinine. Furthermore, the circulatory system is part of the 
control system for hormone distribution, and it plays a vital role in the temperature regulation 
of the body (Risau, 1997). The function of the vascular system is of such importance that 
minor disorders can lead to severe disability and death. Cardiovascular diseases are the 
leading cause of death in industrialised countries, among which stroke is the third most 
common cause of death and lasting disability. Even so, therapeutic options are still limited 
(Jones und Peterson, 2008), (Lloyd-Jones et al., 2009). 
 
1.3.1 The structure of the blood-vessel wall 
With the exception of capillaries, all vessel types have a characteristic wall structure 
organised in three layers: the tunica intima, tunica media and tunica adventitia. 
The tunica intima is a flat layer of endothelial cells (ECs) covering a thin layer of connective 
tissue, delimiting the vessel wall towards the lumen of the vessel. This endothelial layer is the 
main barrier for plasma proteins and may, by the mechanical sensitivity of the endothelial 
cells, secrete many vasoactive products. Beneath the connective tissue, the internal elastic 
lamina delimits the tunica intima from the tunica media, and through this information from the 
endothelial cells is transferred to smooth muscle cells. The tunica media consists of smooth 
muscle cells (SMCs), which are embedded in a matrix of elastin and collagen strands. A 
second layer of elastic fibres, the external elastic lamina, is located under the SMCs. The 
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tunica adventitia is a connective tissue layer; it serves to anchor the blood vessel and blends 
with the connective tissue surrounding the vessel (Figure 5) (Levick, 1995).  
 
 
 
Figure 5: Structure of blood vessels 
The division of the wall into three layers is the common structural pattern in all blood vessels with the 
exception of capillaries. 
Adapted from http://www.lab.anhb.uwa.edu.au/mb140/corepages/vascular/vascular.htm. 
 
1.3.2 Endothelial cells, a multi-functional cell layer of the blood vessel 
wall 
The main function of endothelial cells is to form a barrier between blood and tissue for a 
rapid transfer of metabolites and signalling molecules. The endothelium, by the mediation of 
various transfer channels for different classes of substances, balances and regulates blood 
composition. Fat-soluble molecules such as O2 or CO2 diffuse through the phospholipids, 
and small insoluble substances such as glucose, amino acids and pharmaceuticals can 
penetrate with water through the intercellular gap. As a result of these different functions, the 
endothelial cells can modulate a multitude of blood-vessel-related processes, including 
regulation of blood pressure, vasodilation, vasoconstriction, regulation of the water volume in 
the blood stream, adhesion and transmigration of leukocytes, release of pro- and anti-
thrombotic factors, growth factors and vasoactive substances (Traub und Berk, 1998). 
Impairment of these endothelial-cell-mediated processes plays an important role in the 
pathogenesis of the vessels (Ross, 1993). If, for instance, a reduction in the ambient of O2 
concentration – hypoxia – occurs, a variety of functional responses in vascular ECs, 
including cell proliferation, angiogenesis and cell death, are compromised; and tissue 
perfusion is reduced being the O2 availability insufficient to meet tissue metabolic 
requirements (Rey und Semenza), (Chen et al., 2008). Another function of endothelial cells is 
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the regulatory response to different parameters of blood flow, as these are exposed directly 
to the blood stream. These comprise not only factors circulating in the blood, but also 
mechanical forces originating from the blood flow: pressure, tension and shear stress 
(Garcia-Cardena und Gimbrone, 2006).  
 
1.3.3 Fluid shear stress, a biomechanical force acting on the vessel wall 
Biomechanical forces significantly affect the structure, the growth and the functions of the 
blood vessel wall, resulting in a variety of intracellular molecular changes in the endothelial 
cells and smooth muscle cells. Biomechanical forces which have an influence in the blood 
vessel are: (a) the hydrostatic pressure, which is caused by blood pressure, (b) the tension, 
caused by the deformation of the vessel wall and (c) fluid shear stress (FSS), which results 
from the friction of blood against the vessel surface (Lehoux et al., 2002). Whereas pressure 
and tension are transferred to the whole vessel wall due to their vertical orientation, the 
tangentially aligned FSS is sensed mainly by the endothelium (Figure 6). 
 
 
 
Figure 6: Mechanical forces on the vessel wall 
Here are shown the blood pressure (p) and the FSS (τ ). Adapted from Hahn et al. 2009 (Hahn und 
Schwartz, 2009). 
 
In vessels, the flowing blood exerts a force on the endothelial cell surface acting in the 
direction of flow. The FSS arising can be calculated by using the Hagen–Poiseuilles law, 
which is valid for ideal Newtonian fluids and laminar flows in stiff tubes. FSS is proportional to 
blood flow velocity and inversely related to the cube of the vessel's radius. Hence, an 
increased blood flow velocity results directly in an increased FSS (Schaper et al., 1976).  
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The Hagen–Poiseuille equation: 
 
= 4!Q
!r3
"
": shear stress [N/m2], [1N=105 dyn], [10 dyn/cm2]
!:   blood viscosity [N ·s/m2]
Q:  blood flow rate [m3/s]
r:    vessel radius [m]
 
 
In blood vessels, the Poiseuille equation is only restrictedly applicable. The equation can be 
applied in vivo with the following assumptions: (i) the blood is considered as a Newtonian 
fluid, (ii) the vessel's cross-section is cylindrical, (iii) the vessel is straight with inelastic walls, 
and (iv) the blood flow is stable and laminar (Papaioannou und Stefanadis, 2005).  
 
The FSS varies depending on heart minute volume, heart period and differences in vessel 
geometry. The FSS, which acts directly on the endothelial cells in arterial vessels, is of the 
order of 15–30 dyn/cm2, much higher compared with the corresponding value in venous 
vessels of about 1–5 dyn/cm2. Under physiological conditions, the mean shear stress to 
which the vascular endothelium is exposed is close to 10–15 dyn/cm2 (Lehoux et al., 2002). 
Flow disturbances can occur in arterial irregularities – such as curvatures or bifurcations – or 
upstream and downstream of a stenosis. Differences in shear stress may contribute to 
altered endothelial gene expression (Morawietz et al., 2000). 
 
FSS originating from the mechanical effects of blood flow on the vascular endothelium is not 
only considered a protective mechanism against the localisation of atherosclerotic plaques, 
but it is also involved in angiogenesis and arteriogenesis. The term angiogenesis describes 
the growth of blood vessels de novo, while arteriogenesis indicates the process by which 
pre-existing collateral arteries increase in size (Prior et al., 2004). More evidence suggests 
that arteriogenesis may be triggered mainly by fluid shear stress, which is induced by the 
altered blood flow conditions after an arterial occlusion. Arteriogenesis involves endothelial 
cell activation, basal membrane degradation, leukocyte invasion, proliferation of vascular 
cells, neointima formation (in most of the species studied), changes of the extracellular 
matrix, and cytokine participation. In particular, increases in FSS in vivo induce capillary 
profileration and increase in artery diameter (Hudlicka, 1994), while decreases in shear 
stress lead to a reduction in artery diameter and ECs apoptosis (Cho et al., 1995). 
 
A number of in vitro studies using cone-and-plate devices and cultured ECs (e.g. Human 
Umbilical Vein Endothelial Cells, HUVECs, or Human Coronary Endothelial Cells, HCAECs) 
have demonstrated that ECs stimulated with FSS are affected in the production of bioactive 
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molecules involved in the regulation of vascular tone, such as nitric oxide (NO) (Korenaga et 
al., 1994), in cell growth control, such as heparin-binding epidermal growth factor (HB-EGF) 
(Morita et al., 1993), in blood coagulation and fibrinolysis, such as thrombin receptors 
(Nguyen et al., 2001), and in cell-to-cell adhesion, such as intercellular adhesion molecule-1 
(ICAM-1) (Nagel et al., 1994). Moreover, it has recently been reported that mechanical 
stretching of cells can activate several pathways that lead to the activation of transcription 
factors (e.g. AP-1 and NFκB) in which various molecules such as ion channels and GPCRs – 
for instance, the angiotensin type I (Zou et al., 2004) and human B2 bradykinin (Leeb-
Lundberg et al., 2005) – are involved. In addition, in the past ten years several groups, in 
order to discover new shear-stress-responsive genes and co-regulated pathways responsive 
to the mechanical environment of the cell, have started to perform global gene analyses 
using DNA microarray techniques. In one study, looking at changes in gene expression of 
shear-stressed HUVECs, several previously unreported shear-stress-responsive genes were 
identified. For instance, argininosuccinate synthetase (involved in the synthesis of endothelial 
nitric oxide synthase, eNOS) or elastin peptide (which through binding to its receptor 
increases intracellular Ca2+) were found up-regulated, and the expression of both genes lead 
to the release of NO. Thus, on the basis of this information it proved possible to develop new 
hypotheses on how shear stress regulates the synthesis of NO (McCormick et al., 2001). 
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1.4   Aims of the study 
 
With the background of clear evidence about the expression of GPR30 (Isensee et al., 2009) 
and its involvement (Haas et al., 2009) in vascular function, the aim of the work described in 
this thesis was to contribute to the elucidation of the role of GPR30 signalling in blood 
vessels. Despite the controversy regarding whether GPR30 is an ER or still an orphan 
receptor, still very little is known about its relation to and its interaction with other proteins. 
Therefore, the aims of the present study were: 
 
(1)  To identify and confirm hitherto new human interaction partners for GPR30:  
-  establishing a western blotting protocol for GPR30; 
-  verifying potential candidates from a yeast two-hybrid screening (Y2H) with CoIP; 
- investigating the cellular localisation of GPR30 and the confirmed interaction   
partner(s) by over-expression. 
 
(2) To establish a human cellular system to evaluate the potential role of GPR30 in a 
vascular model:  
-   by measurement of the expression of GPR30 in the hypoxia/reperfusion model and 
the FSS stimulation model; 
- by characterisation of the model system by gene expression and cellular 
morphology; 
-   by determination of the cell type where GPR30 is regulated. 
 
(3)  To evaluate the downstream effects of the interaction between GPR30 and/or the newly 
identified interaction partners in the vascular model at the transcript level: 
-  over-expressing GPR30 and/or interaction partners in the model system chosen;  
- analysing the genome-wide gene expression of the different experimental groups 
(e.g. ± FSS); 
-  identifying differentially expressed genes and pathway analysis.  
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2     MATERIALS AND METHODS 
 
METHODS 
2.1   Cloning 
 
Standard protocols for various techniques in molecular biology were followed, according to 
Molecular Cloning (3rd edition, Sambrook & Russell, Cold Spring Harbor Laboratory Press, 
2001). Overview tables of all constructs and primers are given in Sections 2.10 and 2.11. 
Detailed cloning strategies for constructs generated within the scope of this thesis are 
described in Section 2.1.8 
  
2.1.1 Polymerase chain reaction (PCR) 
PCR reactions for cloning approaches were performed with Pfx50 DNA polymerase 
(Invitrogen), since this enzyme possesses proofreading exonuclease activity. If 3’-A 
overhangs were necessary (e.g. for TOPO cloning), Platinum Taq DNA polymerase 
(Invitrogen) was used. Analytical PCR reactions were conducted with standard Taq DNA 
Polymerase. 
 
2.1.2 Agarose gel electrophoresis 
DNA molecules were separated by gel electrophoresis in gels containing 0.8–1.4% agarose. 
Standard electrophoresis grade agarose (Invitrogen) was used for analytical gels. If gel 
extraction of the DNA fragment was required for cloning purposes, gels were prepared with 
SeaKem GTC agarose (Cambrex). The electrophoresis was performed in a custom system 
(Bächler Feintech) at 50 V for 20–40 min. The buffer system was TBE (45 mM Tris-borate, 
1 mM EDTA, pH 8.3) in case of analytical gels and TAE (40 mM Tris-acetate, 1 mM EDTA, 
pH 8.0) for cloning approaches. Ethidium bromide (50 µg/l) was included in the buffer and gel 
to visualise DNA bands by UV light (Syngene). 
 
2.1.3 PCR Purification and gel extraction 
PCR products were purified by QIAquick PCR Purification Kit (QIAGEN) and eluted in 50 µl 
double-distilled water (ddH2O). Restricted DNA fragments were separated from linearised 
vectors by gel electrophoresis, cut from the gel, extracted using the QIAquick Gel Extraction 
Kit (QIAGEN), and eluted in 50 µl ddH2O.  
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2.1.4 Ligation 
DNA inserts and linearised vectors were ligated with T4 DNA ligase (Biolabs) according to 
the manufacturer’s protocol. Ligations were incubated for 1 hour at 16  C or overnight (o/n) at 
room temperature (RT). 
 
2.1.5 E. coli strains 
Electrocompetent DH5α (Invitrogen) and chemically competent Top10 were used for the 
propagation of standard vectors and routine subcloning. Bacteria were grown in standard LB 
medium (QBIOgene) or LB agar (MP Biomedicals) at 37  C unless noted. 
 
2.1.6 Transformation of electro- and chemically competent bacteria 
Electrocompetent DH5α cells (100 µl) were thawed on ice and mixed with 10 µl ligation 
reaction. The reaction was transferred into pre-chilled 0.1 cm electroporation cell (BioRad) 
and pulsed in an electroporator (BioRad). The cells were resuspended in 1 ml SOC medium. 
For transformation of chemically competent cells, 100 µl cell suspension was mixed with 
ligation reaction. The reaction was chilled on ice for 30 min, heat-shocked for 1 minute at 42  
C, and placed on ice for an additional 5 min. Subsequently, 0.5 ml SOC medium was added. 
Either the cells were electro- or chemically competent, were regenerated at 37  C for 1 h 
while shaking and finally plated onto selection agar plates which were incubated at 37  C o/n. 
 
2.1.7 Plasmid isolation 
For small-scale plasmid isolations (max. 10 µg), 3 ml LB medium including antibiotics was 
inoculated with one colony and cultured o/n at 37  C under shaking (225 rpm). Cells growing 
in o/n culture were pelleted and plasmids were isolated by using the QIAprep Spin Miniprep 
Kit (QIAGEN) according to the manufacturer’s protocol and eluted in 50 µl ddH2O. If larger 
amounts (max. 500 µg) of plasmid DNA were desired, 100–200 µl of the o/n cultures was 
used to inoculate 200 ml LB medium. The next day, plasmids were isolated with the QIAGEN 
Plasmid Maxi Kit (QIAGEN) according to the instruction manual. Plasmids were eluted in 
500 µl ddH2O and stored at –20  C. 
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2.1.8 GPR30 constructs 
GPR30/pcDNA3-EGFP 
Two OmicsLinkTM clones encoding GPR30 with C-terminal His-tag (EX-M0792-M01) or 
GFP-tag (EX-M0792-M03) were obtained from the German Resource Center for Genome 
Research (RZPD). The constructs are based on the vectors pReceiver-M01 or pReceiver-
M02, respectively. Sequencing of the constructs revealed a frame shift mutation in the His-
tagged clone and several point mutations in the GFP-tagged one. However, no mutations 
were found in the sequences encoding the N- or C-terminal domain in EX-M0792-M03. 
Therefore, the clone was used to construct bait vectors for yeast two-hybrid screening (Y2H). 
Furthermore, a construct encoding GPR30 tagged with EGFP based on pcDNA3 (i.e. 
pcDNA3-GPR30-EGFP) was kindly provided by Prof. Eric Prosnitz (University of New 
Mexico, Albuquerque, USA). 
 
pcDNA3.1(+)/GPR30 
For this construct, GPR30/pcDNA3-EGFP was used as a template to amplify GPR30 by PCR 
and to subclone the product into pcDNA3.1(+) for native expression without tag. The forward 
primer P13 included a HindIII site and the reverse primer P14 included a NotI site, 
respectively. In addition, the reverse primer had a two-bp mismatch to introduce a stop 
codon. The PCR was performed using Pfx50 DNA polymerase (annealing temperature 
45 °C). The 1185-bp product was purified (QIAquick PCR purification), cut using HindIII and 
NotI according to the instruction manual, again purified by gel extraction, and finally ligated 
with linearised pcDNA3.1(+) by using T4 DNA ligase at 16 °C for 1 h. Electrocompetent 
DH5α was transformed by the ligation reaction and plated onto selection agar plates 
containing 100 µg/ml ampicillin. Plasmids were isolated from positive clones and controlled 
by restriction-endonuclease digestion and sequencing. 
 
pTL1-HA2/GPR30 
This construct was easily obtained by cutting GPR30 from pcDNA3.1(+)/GPR30, using 
HindIII and NotI, purification by gel extraction and ligation in pTL1-HA2, to put in frame with 
the HA (haemagglutinin) tag. 
 
2.2   Mammalian cell culture 
2.2.1 Cell lines and primary cells 
Cell lines HeLa, HEK293, SKBR3 and EAhy926 were cultured in DMEM (Dulbecco's 
Modified Eagle Medium, Biochrom, FG 0435) containing 10% FBS including antibiotics 
(penicillin/ streptomycin, Biochrom A 2213). 
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HMEC-1 (Human Microvascular Endothelial Cells) were cultured in MCDB 131 medium 
(GIBCO, 10372) containing 7.5% FBS and 200 mM L-glutamine. 
HUVECs (Human Umbilical Vein Endothelial Cells), HUAECs (Human Umbilical Arterial 
Endothelial Cells) and HAoECs (Human Aortic Endothelial Cells) were cultured in Endothelial 
Cell Basal Medium (Promocell, C-22220) with Supplement Pack (2% FCS, 0.4% ECGS/H, 
0.1 ng/ml epidermal growth factor, 1 µg/ml hydrocortisone, 1 ng/ml basic fibroblast factor, 
Promocell, C-39210). All cells were cultured in a humidified incubator with 5% CO2 at 37 °C. 
 
2.2.2 Transfections 
Mammalian cell lines were transfected with either FuGENE 6 reagent (Roche Applied 
Science) or polyethylenimine (PEI, 50% solution in H2O, Sigma P3143). For transfection with 
FuGENE 6 reagent, the cells were seeded 24 h before transfection at a density of 10,000-
20,000 cells/cm2. For transfections in 10-cm plates (55 cm2 surface area, 10 ml medium), 
18 µl FuGENE 6 reagent was diluted in 582 µl serum-free medium (OptiMEM, GIBCO) and 
incubated for 5 min at RT. Then 6 µg plasmid DNA was added, vortexed for a second, and 
incubated for at least 15 min at RT. Finally the transfection complex was added to the cell-
culture vessel in a dropwise manner while swirling. The expression of transfected constructs 
was assayed 24 or 48 hours later. 
For co-immunoprecipitations (CoIP) and HMEC-1 over-expression for the microarray 
experiment, PEI transfections were performed in 10-cm plates. About 3x106 HEK293 cells 
(for CoIP) or 2x106 of HMEC-1 cells (for microarray) were seeded per plate and grown over 
night. Before starting the transfection, the standard medium was replaced with 10 ml DMEM 
containing 2% FBS. Then 475 µl serum-free OptiMEM was mixed with 25 µl PEI (1 mg/ml, 
pH 7.0) and 10 µg DNA (DNA concentration = 0.5–2 µg/µl) and incubated for 10 min at RT. 
The transfection mixture was added in a dropwise manner while swirling. The expression of 
transfected constructs was assayed 24 h later. 
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2.3   Fluid shear stress in vitro model 
 
Cells were subjected to laminar shear stress at different physiological levels (1, 15, and 
30 dyn/cm2) in a cone-and-plate viscometer in a humidified environment with 5% CO2 at 
37 °C over a plate seeded with a confluent monolayer of endothelial cells (Bartling et al., 
2000). Cells were rinsed twice with warmed PBS and afterwards PBS was replaced by 
warmed culturing medium containing 5% dextran (Roth, 9228.2). As shown in Figure 7, the 
viscometer consists of a cone with an angle of 0.58 rotating on top of a cell-culture dish. The 
cone is driven by a computer-controlled stepper motor. A control dish accompanied each 
cell-culture dish from the same human endothelial cell preparation, which was incubated 
without application of shear stress. For each set of experiments, four identical flow devices 
were used simultaneously. 
 
 
 
Figure 7: Cone and plate apparatus (photograph, scheme and controller). 
 
2.4   Hypoxia/re-oxygenation in vitro model 
 
Cells were seeded out in 10-cm plates 24 h beforehand. Hypoxia was generated in a 
dedicated, humidified gas-tight incubator (INVIVO2 400, Ruskinn Technologies, Bridgend, 
UK) and flushed with gas of the following composition: 5% CO2, 85% N2, and 10% H2. 
During oxygen glucose deprivation (OGD; 1, 2, 3, 6, 12, 24 h) oxygen tensions in the media 
were below 1 mmHg (polarographic probe, Licox GSM). Cells were rinsed twice with warmed 
PBS and placed in OGD chamber. In the chamber, PBS was replaced by warmed balanced 
salt solution (BSS0; containing 143.8 mM Na+, 5.5 mM K+, 1.8 mM Ca2+, 1.8 mM Mg2+, 125.3 
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mM Cl-, 26.2 mM HCO3-, 1.0 mM PO43- and 0.8 mM SO42-, pH 7.4) which was put into the 
chamber 6-12 hours prior to the performance of the experiment. The experiment was 
terminated by taking the culture plates out of the OGD chamber and replacing BSS0 by 
warmed cell culturing medium. Subsequently, culture plates were returned to normoxic cell 
culture incubator for re-oxygenation (1, 2, 3, 6 h). In control experiments the medium was 
replaced by BSS20 (BSS0 containing 4.5 gm/l glucose) after being washed with PBS, and 
cells were incubated in a normoxic atmosphere containing 5% CO2, for the same duration as 
for the experiment, followed by return of the cell culturing medium. 
 
2.5   Immunocytochemistry 
 
The cells were cultured and transfected in chamber slides (BD Biosciences) or 6 well plates 
and fixed with 4% paraformaldyde in PBS (Riedel-de Haen) for 10 min at RT. The fixed cells 
were rinsed twice for 2 min in washing buffer (PBS, 0.05% Tween 20, pH 7.2) and incubated 
in serum blocking buffer (2% serum, 1% BSA, 0.1% fish skin gelatine, 0.1% Triton X-100, 
0.05% Tween 20) for 30 min at RT or o/n at 4 °C. The serum used was derived from the 
same species as the secondary antibody (normally goat). The fixed cells were incubated with 
the primary antibody diluted in PBS with 1% BSA (100 µl per chamber) for 1 hour at RT or 
o/n at 4 °C. The cells were rinsed several times in washing buffer and then incubated with 
the secondary antibody (Alexa Fluor 568- or Alexa Fluor 488 conjugated, Molecular Probes) 
diluted 1:500 in PBS for 30 min at RT. Cell nuclei were counterstained with DAPI (0.2 ng/µl). 
Slides were coverslipped with aqueous Antifade fluorescent mounting medium (Vector Labs) 
or Fluoromount-G (Southern Biotech) and sealed with nail polish. 
 
2.6   Western blotting and co-immunoprecipitation 
2.6.1 Standard SDS-PAGE protocol 
For SDS-PAGE, the samples were mixed with 6x loading buffer (300 mM Tris pH 6.8, 12% 
SDS, 0.6% bromophenol blue, 60% glycerol, 12% fresh β-mercaptoethanol), denatured by 
heating briefly to 100 °C or at 37 °C for 15 min (GPR30 only), loaded onto a polyacrylamide 
gel composed of a 4% stacking gel and a 10–15% separating gel, and separated by gel 
electrophoresis (BioRad) in Laemmli buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) 
at 90 V until the sample focussed in the stacking gel and then at 120 V until the dye ran off 
the gel. The separated proteins were transferred onto a PVDF membrane (Hybond-P, 
Amersham) using a semi-dry blotter (Bio Rad). PVDF membranes were equilibrated in 
methanol for 30 sec. The gel, the PVDF membrane, and extra thick Whatman 3MM papers 
were pre-soaked in Towbin buffer (25 mM Tris, 192 mM glycine, 200 ml/l methanol) for 1 min 
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before use. The transfer was conducted at 100 mA per gel for 1 h at RT. The membrane was 
blocked in TBST (125 mM Tris-HCl, 625 mM NaCl, 0.05% Tween 20, pH 8.0) containing 5% 
low-fat milk powder for 1 h and incubated with the primary antibody dissolved in blocking 
buffer for 1 h at RT or at 4 °C over night while shaking. The membrane was washed 6x in 
TBST for 5 min and incubated with the secondary antibody diluted in TBST (sheep anti-
mouse peroxidase conjugated, Amersham, 1:7500; goat anti-rabbit peroxidase conjugated, 
Calbiochem, 1:7500) for 1 h at RT. The immune complexes were detected with an ECL 
detection system according to the manufacturer’s protocol (Amersham). 
 
2.6.2 Western blotting to detect GPR30 in HeLa cell lysates 
Total cell lysates were prepared from cells grown on 10-cm plates. Cells were lysed 48 h 
after transfection in either 300 µl urea-SDS lysis buffer (100 mM Tris-HCl pH 8.0, 2% SDS, 
3.2 M urea) supplemented with 64 mM DTT, 0.5 mM phenylmethylsulphonyl fluoride, and 1X 
complete protease inhibitor mixture (Roche) or urea-Triton lysis buffer (40 mM Tris-HCl 
pH 8.0, 4% Triton, 8.0 M urea) supplemented with 50 mM DTT, 0.5 mM phenylmethyl-
sulphonyl fluoride and 1X complete protease inhibitor mixture (Roche). After 5 min incubation 
on ice, cell lysates were sonicated for 20 sec (4 times for 5 sec each) on ice and mixed with 
loading buffer. Finally, the cell lysates were denatured at 37 °C for 15 min and separated by 
SDS-PAGE in a 10% polyacrylamide gel (see Section 2.6.1). The blocked membranes were 
incubated with the different anti-GPR30 antibodies diluted 1:500 at 4 °C o/n. 
 
2.6.3 Co-immunoprecipitation of GPR30 
The day before transfection, 3 x 106 HEK293 cells were seeded in a 10-cm dishes. The cells 
were transfected with HA-GPR30 (pTL1-HA2/GPR30), myc-PATJ (pRK5myc/PATJ), GFP, or 
empty vector pcDNA3.1(+) using the PEI transfection procedure with 10 µg plasmid DNA in 
total (see Section 2.2.2). The transfection efficiency was controlled by inspection of the GFP 
transfection and in general was about 70–80%. 48 h after transfection, cells were washed 
twice with cold PBS and harvested directly from the dish with a cell scraper (Nalge Nunc 
International) in 5 ml PBS on ice. The cells were collected in 15-ml Falcon tubes by 
centrifugation (500 g for 5 min) and stored at –80 °C. After 4 days the cells were lysed in 
500 µl RIPA-buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 
1 mM EDTA, 1 mM EGTA) freshly supplemented with 0.5% sodium deoxycholate and 1x 
protease inhibitors (complete Mini, Roche). The tube was rotated for 1 h at 4 °C and then 
centrifuged at 8000 g for 10 min. The supernatant was transferred into a new tube; 40-µl 
aliquots were stored for total lysate (input) western blots. The remaining 440 µl supernatant 
was incubated with 2 µg of primary antibody (mouse monoclonal anti-myc, Santa Cruz) for 
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4 h at 4 °C on a roller shaker, centrifuged at 16,000 g for 10 min, and transferred into a new 
tube. In parallel, 50 µl of a protein G–Sepharose bead slurry was prepared by mixing 25 µl 
protein G–Sepharose beads (GE Healthcare, solution in 20% ethanol) with 25 µl lysis buffer. 
The beads were washed with lysis buffer (3x 1 ml lysis buffer, 1000 rpm for 1 min), added to 
the lysate, and incubated at 4 °C over night. Subsequently, the beads were washed with lysis 
buffer (3x 1 ml, 1000 rpm for 1 min) and resuspended in 40 µl 2x Laemmli sample buffer. The 
samples were denatured at 37 °C for 10 min. Finally, the beads were removed by 
centrifugation (1000 g, 1 min) and the supernatant was analysed by SDS-PAGE (see 
Section 2.6.1), (Rondou et al., 2008). 
 
2.7   Protein–protein interaction bioinformatic tools 
 
STRING is a database of known and predicted protein interactions. 
The interactions include direct (physical) and indirect (functional) associations; they are 
derived from four sources: 
Genomic context   High-throughput experiments   (Conserved) co-expression   Previous knowledge   
    
  
 
     
 
STRING quantitatively integrates interaction data from these sources for a large number of 
organisms, and transfers information between these organisms where applicable. The 
database currently covers 2,590,259 proteins from 630 organisms. 
 
PIPs is a database of predicted human protein–protein interactions. The predictions have 
been made using a naïve Bayesian classifier to calculate a “score of interaction”. There are 
37606 interactions with a score ≥1, indicating that the interaction is more likely to occur than 
not to occur. The probability of interaction between two proteins is calculated by combining 
different features, including:   
Gene Co-expression  Orthology  Domain Co-occurrence 
 
 
 
  
Co-localisation  Post Translational Modification  Network Analysis (Transitive) 
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2.8   Real-time PCR 
2.8.1 Total RNA isolation 
Total RNA from cells cultivated in 10-cm plates was extracted by using Trizol ultrapure 
reagent (Invitrogen), according to the manufacturer’s instructions. The concentration of total 
RNA was measured and its integrity was assessed by using an RNA 6000 Nano LabChips 
Kit and Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) according to the 
manufacturer’s instructions. 
2.8.2 DNase treatment 
If amplification products are detected from the PCR reaction in the absence of reverse 
transcriptase (no RT control), it may be necessary to eliminate residual genomic DNA from 
the RNA sample.  
For 1 µg of total RNA, 1 U of DNAse I (Invitrogen, Cat. No. 18047-019) was used in 10 µl 
DEPC-treated water. After incubating at RT for 15 min, the reaction was terminated by 
adding 1 µl 25 mM EDTA and heating for 10 min at 65 °C. This mixture was used directly for 
reverse transcription. 
 
2.8.3 cDNA synthesis 
Approximately 1 µg total RNA was reverse-transcribed by using 50 U of Multi-Scribe RT of 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Cat. No. 4368814) 
with random primers in 20-µl reactions. Reactions were carried out for 10 min at RT and for 
2 h at 37 °C. Finally, cDNAs were diluted to 1 ng/µl and stored at –20 °C. 
 
2.8.4 Real-time PCR 
Real-time PCR (qRT-PCR) reactions were performed in triplicate using SYBR-Green I 
master mix (Applied Biosystems) and 10 ng cDNA as template in 25-µl reactions. No 
template and no reverse transcriptase controls were included, and products were analysed 
by gel electrophoresis. As housekeeping gene the human hypoxanthine-guanine 
phosphoribosyl transferase (HPRT1) was assayed. Normalised expression levels of target 
genes were calculated by dividing the corresponding relative quantity by expression level of 
HPRT1. Gene-specific primers were designed by using the Primer 3 software (Rozen und 
Skaletsky, 2000); sequences are given in Section 2.11. 
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2.8.5 Statistical analysis 
Statistical significance was assessed by using a two-sided t test assuming unequal variance 
of the biological replicates. The significance level was fixed at 5%, and null hypothesis were 
rejected of the p value was below 0.05. 
 
2.9   Microarray RNA analysis 
2.9.1 Experimental design 
For RNA extraction, 2 x 106 HMEC-1 cells were seeded and, after 24 hours, transfected with 
one of four different vectors. Twenty-four hours after transfection, fluid shear stress 
stimulation (30 dyn/cm2) was applied.  Identical transfected cells plates, but without any 
application of shear stress, were used as the control group. 
RNA isolation for gene-expression analysis was performed for eight different groups: 
 
Table 2: Gene chip hybridisation experiment study design 
 
 24h control (0 dyn/cm
2) 
 
24h FSS (30 dyn/cm2) 
 
pTL1-HA2 
 
6 6 
pTL1-HA2/GPR30 
 
6 6 
pRK5myc/PATJ 
 
6 6 
pTL1-HA2/GPR30 
pRK5myc/PATJ 
 
6 6 
 
2.9.2 Isolation of total RNA 
HMEC-1 cells were scraped in Trizol immediately after fluid shear stress stimulation and 
stored at –80 °C, during the time of performing the 6 biological replicas (7 weeks). Total RNA 
from the 48 samples was obtained according to the manufacturer’s protocol. The RNA was 
stored at –80 °C in RNase-free water. 
 
2.9.3 Chip hybridisation, reverse transcription and fluorescent labelling 
Four chip (HumanHT-12 v3 Expression BeadChip, Cat. No. BD-103-0203) hybridisations 
were performed with RNA from all the samples mentioned above. The high-value content on 
the HumanHT-12 Expression BeadChips provides genome-wide transcriptional coverage of 
well-characterised genes, gene candidates, and splice variants, with a significant portion 
targeting well-established sequences supported by peer-reviewed literature. Each array on 
the HumanHT-12 Expression BeadChip targets more than 25,000 annotated genes with 
more than 48,000 probes (27,455 coding transcripts, well-established annotation; 7870 
coding transcripts, provisional annotation; 446 non-coding transcripts, well-established 
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annotation; 196 non-coding transcripts, provisional annotation; and 12,837 experimentally 
confirmed mRNA sequences that align to EST clusters). 
 
Illumina Gene Expression protocols feature a first- and a second-strand reverse transcription 
step, followed by a single in vitro transcription (IVT) amplification that incorporates biotin-
labelled nucleotides. Subsequent steps include array hybridisation, washing, blocking, and 
finally staining with streptavadin-Cy3. Direct hybridisation gene expression assays are run on 
the iScan system or BeadArray Reader. Fluorescence emission by Cy3 is quantitatively 
detected for downstream analysis. GenomeStudio software provides results in standard file 
formats that can readily be processed with most commercial expression-analysis software 
programs (performed by Aydah Sabah, Max Planck Institute for Molecular Genetics, Berlin). 
 
 
Figure 8: Schematic representation of Illumina chip hybridisation 
 
2.9.4 Normalisation 
Normalisation is the process of adjusting raw microarray data to remove systematic variation 
of non-biological origin. BeadStudio software offers three algorithms for normalising data 
generated from Illumina Gene Expression BeadChips and panel sets. 
 
Three major assumptions are made when one is normalising microarray data: 
(1) The effect of any systematic error will be uniform over the spatial distribution of bead 
types; 
(2) The majority of genes will not be differentially expressed; 
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(3) The normalisation will remove systematic variation while leaving biological variation 
intact. 
 
For the normalisation the rank invariant method was adopted. This is an appropriate 
selection in which the investigator can assume that a reasonable percentage of the genes in 
an experiment is not differentially expressed. For rank invariant normalisation, a subset of 
probes whose rank does not change across the experiment are identified and serve to define 
the normalisation parameters. 
 
2.9.5 Detection of differentially expressed genes 
For the identification of differentially expressed genes in the comparison of two sets of 
conditions with microarrays, Significance Analysis of Microarrays (SAM) was used. The SAM 
statistic identifies significant changes in gene expression by performing a set of gene-specific 
t tests. For each gene, a score is calculated on the basis of expression change relative to the 
standard deviation of repeated measurements for that gene. Genes with scores greater than 
a threshold delta were defined as significantly deregulated. Manual adjustment of this 
threshold delta allows the identification of smaller or larger gene cohorts. In addition, on the 
basis of random permutations of all measurements, a ‘false discovery’ rate was estimated. 
 
 
 
Figure 9: SAM plot example 
 
__________________________________________________________________ MATERIALS AND METHODS 
   32 
2.9.6 Functional annotation and pathway analysis 
In order to understand molecular and biological relations of candidate genes, significantly 
deregulated genes were functionally annotated using the web-based Database for 
Annotation, Visualisation, and Integrated Discovery (DAVID), (Dennis et al., 2003). 
 
Significantly deregulated genes were further analysed by using Ingenuity Pathways Analysis, 
IPA 3.0, which identifies physical, transcriptional, and enzymatic interaction networks. 
Ingenuity Pathways Analysis is a web-based software application containing most literature 
knowledge of biological interactions between gene products 
(http://www.ingenuity.com/products/pathways_analysis.html). In this study, the gene 
expression profile is presented by the networks generated by Ingenuity: the significantly 
deregulated genes are displayed in list form together with the corresponding Illumina gene 
identification number and ‘n-fold change’ expression values.  
Networks are scored on the basis of the number of Network Eligible Molecules that they 
contain. The higher the score, the lower the probability of finding the observed number of 
Network Eligible Molecules in a given network by random chance. 
Ingenuity Pathways Analysis calculates a significance score for each network. The score is 
generated using a p-value calculation, and is displayed as the negative decadic logarithm of 
that p value. 
This score indicates the likelihood that the assembly of a set of focus genes in a network 
could be explained by random chance alone. A score of 2 indicates that there is a 1 in 100 
chance that the focus genes are together in a network because of random chance. 
Therefore, networks with scores of 2 or higher have at least a 99% confidence of not being 
generated by random chance alone: p score  =  –log10 (p value) 
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MATERIALS 
2.10   Vectors and constructs 
Table 3: Vectors and constructs 
No. Construct    Selection Description 
Empty vectors  
17 pcDNA3.1(+)   AR, NR  Empty vector (Invitrogen) 
49 pTL1-HA2*   AR,   Empty vector for N-term HA-tag fusion 
10 pEGFP-N1   KR   Empty vector for N-term EGFP fusion 
GPR30 constructs 
13 GPR30-EGFP/pcDNA3** AR, NR  Expression of GPR30 with C-term EGFP tag 
18 pcDNA3.1(+)/GPR30  AR, NR  Expression of full-length GPR30 
45 pTL1-HA2/GPR30  AR   Expression of GPR30 with N-term HA-tag 
PATJ constructs 
44 pRK5myc/PATJ***  AR  Expression of PATJ with N-term myc-tag 
 
*    provided by Dr. Markus Ralser, Max-Planck Institut für Molekulare Genetik, Berlin.   
**  provided by Prof. Eric Prossnitz, University of New Mexico, Albuquerque, USA. 
*** provided by Prof. Ben Margolis, University of Michigan Medical School, Ann Arbor, 
Michigan, USA. 
 
Abbreviations: AR, ampicillin resistance; KR, kanamycin resistance; NR, neomycin 
resistance. 
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2.11   Primers 
 
All primers were obtained from MWG Biotech in a quantity of 0.01 µmol (HPSF purification) 
and were resuspended in H2O to give a stock concentration of 100 pmol/µl (100 mM). Equal 
amounts of forward and reverse primer were combined and diluted with ddH2O to 5 µM each. 
Table 4: Primers  
No. Sequence (5’ → 3’)  Comment 
P69  CGACCACTTTGTCAAGCTCA  qRT-PCR, human GAPD 
P70  TTACTCCTTGGAGGCCATGT  qRT-PCR, human GAPD 
P73  TTGTTGTAGGATATGCCCTTGA  qRT-PCR, human HPRT1 
P74  GGCTTTGTATTTTGCTTTTCCA  qRT-PCR, human HPRT1 
P120 TTGAGGTGTTCAACCTGCAC qRT-PCR, human GPR30, ORF 
P121 GAGGAAGAAGACGCTGCTGT qRT-PCR, human GPR30, ORF 
P128 TTCCAGGCTCCTCTGTCAGT qRT-PCR, human PATJ 
P129 CTGCTGCCCCTTCTTCATAG qRT-PCR, human PATJ 
P186 CCCCTGCACTATGGAGTCTG qRT-PCR, human eNOS 
P187 AGTGCCTGGACCCACCAG qRT-PCR, human eNOS 
P188 CGCTGAGCTCCTCTGCTACT qRT-PCR, human ICAM-1 
P189 GATGACTTTTGAGGGGGACA qRT-PCR, human ICAM-1 
P203 GGCCACGTCATGTCTCTAAA qRT-PCR, human GPR30, 3´UTR 
P204 CTGTGTGAGGAGTGCAAGGT qRT-PCR, human GPR30, 3´UTR 
P213 
CCCAAGCTTGCCACCATGGAT 
GTGACTTCC Cloning of pcDNA3(+)/GPR30, HindIII  
P214 
TAGTTTAGCGGCCGCACGTTAG 
CACCTGCATTACCTACACGGCACTGCTG Cloning of pcDNA3(+)/GPR30, NotI  
KLF-2-f3 CTTTCGCCAGCCCGTGCCGCG qRT-PCR, human KLF-2 
KLF-2-r3 AAGTCCAGCACGCTGTTGAGG qRT-PCR, human KLF-2 
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2.12   Antibodies 
Table 5: Primary and secondary antibodies 
Antibody       Company  Cat#   Dilution 
Primary antibodies 
rabbit polyclonal anti-GPR30 N-ter domain   Acris   SP4209P  1:500 
rabbit polyclonal anti-GPR30 1st extracellular domain  MBL   LS-AA1184  1:500 
rabbit polyclonal anti-GPR30 3rd extracellular domain MBL   LS-A4271  1:500 
rabbit polyclonal anti-GPR30 C-ter domain antiserum MBL  LS-A4272 1:500 
rabbit polyclonal anti-GPR30 C-ter domain antiserum  provided by E. Prossnitz  1:1000 
goat polyclonal anti-GPR30 internal domain  Santa Cruz sc-48524 1:500 
mouse monoclonal anti-GFP     Roche  11814460001  1:750 
rabbit polyclonal anti-Myc     Sigma   C3956   1:2000 
mouse monoclonal anti-Myc, clone 9E10   Santa Cruz  sc-40   1:1000 
mouse monoclonal anti-HA, clone F-7    Santa Cruz  sc-7392  1:1000 
mouse monoclonal anti-HA, clone 16B12   Covance  MMS-101R  1:1000 
Secondary antibodies for immunofluorescence 
Alexa Fluor 488 goat anti-rabbit IgG (H+L)   Mol. Probes  A-11008 1:500 
Alexa Fluor 568 goat anti-rabbit IgG (H+L)   Mol. Probes  A-11011  1:500 
Alexa Fluor 488 goat anti-mouse IgG (H+L)   Mol. Probes  A-11001  1:500 
Alexa Fluor 568 goat anti-mouse IgG (H+L)   Mol. Probes  A-11004  1:500 
Secondary antibodies for western blotting 
sheep anti-mouse peroxidase conjugated   Amersham  NXA931  1:5000 
goat anti-rabbit peroxidase conjugated    Calbiochem  DC03L   1:5000 
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3     RESULTS 
 
3.1   Detection of GPR30 protein by western blotting 
 
Since GPR30 is a heptahelical transmembrane receptor with strong lipophilic properties, its 
solubilisation, e.g. for western blotting, represents a challenging task. Although GPR30 could 
be solubilised and therefore detected by several investigators (Thomas et al., 2005), 
(Vivacqua et al., 2006), (Filardo et al., 2007), these protocols never gave successful results 
in the laboratory where the present project was carried out. Therefore, many protocols were 
re-evaluated and optimised using different antibodies. First, GPR30 fused to EGFP 
(Enhanced Green Fluorescent Protein) was detected using an anti-GFP antibody as well as 
a specific anti-GPR30 antibody. Finally, endogenous GPR30 could be detected with the 
same specific anti-GPR30 antibody. 
 
3.1.1 Detection of GPR30-EGFP using an urea-SDS protocol and GFP 
antibody 
All the experiments were performed in the HEK (Human Embryonic Kidney) 293 cell line, 
since it is one of the most commonly used cell lines on account of its high transfection 
efficiency and, more importantly, because it does not express GPR30. Therefore, HEK293 
cells were transfected with a vector expressing EGFP as a positive control (pEGFP-C1) or a 
vector expressing GPR30 fused to EGFP (GPR30/pEGFP-C1) in order to visualise the 
successful transfection. Mock cells (cells that receive the same reagent treatment but without 
fluorescent label) were used as a negative control. Since no specific anti-GPR30 antibody 
was initially available to detect and evaluate GPR30 expression, an antibody against EGFP 
was used to detect the GPR30-EGFP fusion protein in western blotting.  
 
To detect endogenous as well as over-expressed GPR30 by western blotting, the first step 
was the solubilisation of GPR30. Many different protocols for the solubilisation of GPCRs  
were evaluated: one used RIPA buffer (Vivacqua et al., 2006), one crude membrane 
preparations or cell fractionation (Nagamatsu et al., 1992), (Moore et al., 2000). The first 
successful result was obtained using a urea–SDS-based protocol (an important step was the 
incubation of lysates at 37  C for 15 min, to avoid GPR30 aggregation), (Edinger et al., 2003) 
and a commercially available anti-GFP antibody. As shown in Figure 10, lane 3, a specific 
band corresponding to GPR30-EGFP with a molecular weight of 71 kDa was detected. In 
lane 6, in which a urea-Triton lysis buffer was used, it was not possible to detect a specific 
band for GPR30-EGFP, demonstrating that only the combination of urea and SDS – and not 
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urea in combination with Triton – was successful in solubilising the extremely hydrophobic 
GPR30 protein. In lanes 2 and 5, where pEGFP-C1 was transfected as a positive control, 
two bands are detected for EGFP (29 kDa and >29 kDa) indicating a mature and a pre-
processed form of the protein (Waller et al., 2000); the smaller of these corresponded to the 
expected molecular weight of GFP, whereas the larger is consistent with the size of a mono-
ubiquitylated GFP molecule, (Riess et al., 2005). 
 
 
 
Figure 10: Detection of GPR30-EGFP in HEK293 cells using an urea-SDS lysis buffer. 
Note that in lanes 2 and 5 EGFP expression (bands <37 kDa) was detected using two different buffers 
(SDS and Triton), while in lane 3 GPR30-EGFP (71 kDa) could only be detected using a urea-SDS 
buffer, but not under urea–Triton conditions (lane 6). 
 
3.1.2 Detection of GPR30 by western blotting using a specific anti-GPR30 
antibody 
After successful expression and solubilisation of GPR30 in HEK293 cells, the next goal was 
to optimise a western blotting protocol for GPR30 detection. Therefore, several commercially 
available antibodies against different epitopes (N terminus, C terminus, different extra- or 
intra-cellular domains) and an antiserum detecting the C terminus (kindly provided by Prof. 
Eric Prossnitz, University of New Mexico, Albuquerque, USA) of GPR30 were tested. In 
Figure 11 an in silico prediction of the secondary structure of GPR30 (generated with the 
SOSUI free online tool) is shown and the binding sites of the six antibodies tested are 
depicted.  
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Figure 11: In silico prediction of the domain of GPR30 using the program SOSUI 
Expected binding sites of the six different GPR30 antibodies are depicted. 
 
In order to test these antibodies, HEK293 cells were transfected with an empty vector 
(pcDNA3.1(+)), as a negative control, with a vector expressing EGFP, as a transfection  
control (pEGFP-C1), and a vector expressing GPR30 fused to EGFP (GPR30/pEGFP-C1) or 
full-length GPR30 (pcDNA3.1(+)/GPR30). Cells were then lysed using the urea–SDS-buffer 
protocol described above, and a new RIPA-buffer-based protocol (Filardo et al., 2007). The 
blots were probed with an antibody directed against EGFP to check for successful over-
expression and lysis, and with the six different antibodies against GPR30. Two of the six 
antibodies tested produced a specific signal at the expected size (an example is shown in 
Figure 12). In combination with the urea–SDS-based lysis protocol, the antibody against the 
3rd extracellular domain (MBL) and the polyclonal antibody against the C-terminal domain 
(Prof. E. Prossnitz laboratory) detected both full-length and EGFP-fused GPR30 (Figure 12). 
In contrast, when the antibody against an internal domain of GPR30 (Santa Cruz) was used 
along with various lysis conditions, no specific band for GPR30 was observed (Figure 12, 
panel A, left and right sides). As a positive control, the anti-GFP was used to check, first, the 
solubilisation properties of the lysis buffers used (lane 4, panels D, left and right) and, 
second, to detect the expression of GPR30-EGFP (lane 2, panels B, C and D). 
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Figure 12: Detection of GPR30 in HEK293 cells by using different anti-GPR30 and anti-GFP 
antibodies 
Cells were lysed by using either a urea/SDS buffer (left panels) or a RIPA buffer (right panels). GPR30 
could be detected specifically using a urea/SDS buffer and anti-GPR30 antibodies against the 3rd 
extracellular domain (left panel B) as well as against the C terminus (left panel C). As a positive 
control, pEGFP could be detected in the corresponding samples (left panel D, lane 2, and both panels 
D, lane 4). 
 
3.1.3 Detection of endogenously expressed GPR30 
Subsequently, the western-blotting protocol was successfully applied to detect GPR30 in a 
cell line expressing it endogenously, in order to prove the absence of endogenous GPR30 in 
GPR30-LacZ mutant mice (PhD of Jörg Isensee). Therefore, SkBr3 breast cancer cells that 
were ER-negative (estrogen receptor α and β) (Vladusic et al., 2000) but GPR30-positive 
were transfected with an expression vector for an N-terminally HA-tagged GPR30 (pTL1-
HA2/GPR30). Transfected cells were used as a positive control to compare GPR30 over-
expression with the endogenous expression of GPR30 in SkBr3 cells. 
 
In Figure 13 (left panel), using the anti-GPR30 against the 3rd extracellular domain antibody 
(MBL), specific bands are shown for endogenous GPR30 in non-transfected SkBr3 cells 
(lane 2) as well as in the transfected SkBr3 cells over-expressing HA-GPR30 (lane 1). Using 
an anti-HA antibody (right panel) a band with a molecular weight of 42 kDa corresponding to 
over-expressed HA-GPR30 is observed, but only in transfected cells (lane 3). 
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Figure 13: Detection of endogenous GPR30 using a specific anti-GPR30 antibody 
The detection of endogenous GPR30 was achieved using a specific anti-GPR30 antibody against an 
epitope present in the 3rd extracellular domain (lane 2) in SkBr3 cells. In lanes 1 and 3 the over-
expression of HA-GPR30 as a positive control is shown. Anti-GPR30 (left panel) or anti-HA (right 
panel) antibodies were used. 
 
This optimised protocol was evaluated in wild-type and in GPR30-deficient mouse tissue 
samples, but without success. These findings underline the difficulty of detecting murine 
GPR30 protein in tissues, probably due to low expression levels, to the lipophilic properties 
as a 7TMR, and most importantly, to the lack of mouse antibodies. 
 
3.2   Detection of GPR30 protein by immunocytochemistry 
 
In order to look at the cellular expression of GPR30 and to test whether the two antibodies 
(3rd extracellular domain antibody obtained from the MBL and C-terminal domain antiserum 
obtained from the laboratory of Prof. E. Prossnitz) detecting the protein by western blotting 
were also suitable for immunocytochemistry, HeLa cells were transfected with a vector 
expressing GPR30 fused to EGFP (GPR30/pEGFP-C1), fixed and then probed with the two 
antibodies. As shown in Figure 14, the cells showed a cellular localisation of GPR30-EGFP 
(left panels) at the level of endoplasmic reticulum, according to the results of others 
(Revankar et al., 2005), (Otto et al., 2008). When the cells were stained with the two anti-
GPR30 antibodies (3rd extracellular domain and C-terminal domain; upper and lower middle 
panels, respectively) again a specific signal was detected. In the right-hand panels, the 
merged pictures showed co-localisation of the EGFP signal and both antibodies. 
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Figure 14: Detection of GPR30 by immunocytochemistry 
HeLa cells transiently transfected with GPR30-EGFP and stained with antibodies detecting the 3rd 
extracellular domain (upper panel) or C-terminal domain (lower panel) of GPR30. The EGFP signal 
(green) and the antibody signal (red) co-localised for both antibodies (yellow signal in the merged 
images). Scale bar: 10 µm. 
 
3.3   GPR30 interacts specifically with PATJ in mammalian cells 
 
To understand better the potential involvement of GPR30 in cell signalling, the next step was 
to identify intracellular proteins able to interact with GPR30. Therefore, Y2H screenings were 
performed in a preliminary study (PhD project of Jörg Isensee) using the N- or the C-terminal 
domain of the human GPR30 as baits.  
Briefly, the N- and C-terminal domains were chosen, since most interactions with other 
proteins are expected to occur within these regions. Bait vectors were generated encoding 
amino acids 1–54 for the N-terminal construct and amino acids 330–375 for the C-terminal 
construct, respectively. A human heart cDNA library was subcloned into a prey vector and 
co-transformed with either bait vector. Interaction of bait and prey proteins leads to the 
formation of an active transcription factor complex that induces the expression of the two 
reporter genes HIS3 and LacZ in LV40 yeast cells. For both bait vectors, more than 200 
colonies were obtained in two independent screens, of which 20 (N-terminal bait) and 30 
clones (C-terminal bait) were randomly selected. Informative results of the sequencing 
analysis were obtained for only 19 clones from the N- and 22 clones from the C-terminal 
GPR30-EGFP 
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screen, respectively. BLAST (Basic Local Alignment Search Tool) analysis of these 
sequences against the human genome revealed that most clones mapped to five genes and 
two encoded genomic sequences without homology to known genes. Further controls were 
performed to check these candidate genes, but finally only two were validated and 
considered for further analysis. Both came from the C-terminal screen: one mapped to the 
Pals1-associated tight junction protein (PATJ) and the other to FUN14 domain-containing 2 
(FUNDC2) protein.  
 
To confirm the interaction between GPR30 and the newly identified interacting proteins in a 
mammalian system, co-immunoprecipitation (CoIP) studies were performed. First, the cDNA 
encoding full-length GPR30 was cloned into the pTL1-HA2 vector in-frame with an HA tag 
fused at its N-terminus. The cDNA encoding N-terminally myc-tagged PATJ was kindly 
provided  by Dr. Margolis (University of Michigan) and the cDNA for FUNDC2 was obtained 
from the German Resource Center for Genome Research (RZPD, IOH40818-pdEYFP-
C1amp) and cloned into the N-terminally myc-tagged expressing vector pEXP475 (FUNDC2 
cloning was performed by Jörg Isensee). Second, several CoIP protocols (Devost und Zingg, 
2003), (Okuma und Reisine, 1992), (Harvey et al., 2001), were evaluated (data not shown) 
before solubilisation and co-immunoprecipitation of GPR30 was successful. Therefore, to 
validate the interaction between GPR30 and PATJ or FUNDC2, HEK293 cells were 
transfected with HA-GPR30 and either myc-PATJ or myc-FUNDC2 expression plasmids. 
Forty-eight hours after the transfection, cells were lysed by using a RIPA-buffer based 
protocol (Rondou et al., 2008) and myc-PATJ or myc-FUNDC2 were immunoprecipitated by 
using a monoclonal anti-myc antibody. As shown in Figure 15, GPR30 was detected in total 
cell lysates (INPUT, lanes 1 and 3 in the bottom left panel and lanes 2 and 4 in the bottom 
right panel). Note that in addition to the specific 42-kDa band, a second band was observed. 
This band may represent a degraded form of GPR30 and has also been observed by other 
investigators (Rondou et al., 2008). PATJ and FUNDC2 were also detected in total cell 
lysates (Figure 15, INPUT lanes 2 and 3 in the left panel and lanes 3 and 4 in the right 
panel). 
 
For immunoprecipitation purposes an anti-myc antibody was used. Myc-PATJ and myc-
FUNDC2 were found to bind to protein G Sepharose beads and could be detected with the 
anti-myc antibody (Figure 15, IP: anti-myc, lanes 2 and 3 in the left panel and lanes 3 and 4 
in the right panel). Note that GPR30 could only be detected when co-expressed with PATJ 
(Figure 15, IP: anti-HA, lane 3 in the left panel). The interaction of GPR30 with FUNDC2 
could not be verified in HEK293 cells, as shown by the absence of a band using an anti-HA 
antibody (Figure 15, IP: anti-HA, lane 4 in the right panel). 
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Figure 15: Detection of the interaction of GPR30 with PATJ 
HEK293 cells transiently co-expressing N-terminally HA-tagged GPR30 (HA-GPR30) with N-terminally 
either myc-tagged PATJ (myc-PATJ) or myc-tagged FUNDC2 (myc-FUNDC2). A specific band for 
GPR30 is shown only in the CoIP lysates over-expressing HA-GPR30 and myc-PATJ (lane 3, left 
panel). Note the absence of a specific band for GPR30 co-immunoprecipitated when co-expressed 
with myc-FUNDC2 (lane 4, right panel). 
 
Since no specific interaction between GPR30 and FUNDC2 was found, the focus in 
subsequent studies was only on the interaction of PATJ with GPR30. 
 
3.4   GPR30 partially co-localises with PATJ 
 
The next step was to investigate the localisation of the interaction between GPR30 and PATJ 
at the cellular level. Since the function of PATJ was predominantly investigated in epithelial 
cell types (Roh et al., 2003; Roh et al., 2002; Roh et al., 2002), (Lemmers et al., 2002) and 
GPR30 was found to be expressed in the epithelial cancer cell line SkBr3, epithelial HeLa 
cells were used for further studies. HeLa cells were transfected simultaneously with GPR30-
EGFP and myc-PATJ. After 48 hours the cells were fixed and then probed with an anti-myc 
antibody to visualise myc-PATJ. DAPI (4′.6-Diamidin-2-phenylindol, blue signal) staining was 
performed in order to visualise cell nuclei. In Figure 16 the merge of both signals 
representing the corresponding expression patterns indicates a partial co-localisation of 
GPR30 with PATJ, probably at the level of the endoplasmic reticulum, as already described 
for GPR30 (Revankar et al., 2005), (Otto et al., 2008). 
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Figure 16: Co-localisation of GPR30 and PATJ 
HeLa cells were co-transfected with PATJ-Myc (red) and GPR30-EGFP (green). Note the partial co-
localisation of PATJ and GPR30 in the rightmost panel. Scale bar: 10 µm. 
 
3.5   GPR30 becomes up-regulated in endothelial cells upon fluid 
shear stress (FSS) 
 
The blood vessels in the body are responsible for the transport of oxygen, blood and plasma 
throughout the body and they are characterised by different cell types. In particular the inner 
layer of the blood vessels is made up of endothelial cells directly in contact with the flowing 
blood. Blood vessel occlusion can lead for instance to an increase of fluid shear stress (FSS) 
caused by the strong difference between the high pre-occlusive and the very low post-
occlusive pressure regions (Schaper, 2009). In addition, during a vessel constriction tissue 
are exposed to prolonged hypoxic conditions and this phenomenon leads to cellular 
remodelling (Rey und Semenza).  
 
In 1997, in one of the first cloning approaches, GPR30 was found to be up-regulated in 
Human Umbilical Vein Endothelial Cells (HUVECs) exposed to fluid shear stress. Isensee et 
al. have shown that GPR30 is expressed in small arterial vessels of numerous tissues (e.g. 
kidney, heart, peritoneum, genital tract), in particular in an endothelial cell subpopulation 
(Isensee et al., 2009), and in a previous publication from another group the expression of 
GPR30 mRNA was reported for human internal mammary arteries and saphenous veins 
(Haas et al., 2009). Moreover, GPR41 (orthologue of GPR30) was found to be up-regulated 
in a rat cardiac cell line (H9c2, cardiomyocyte-like cells derived from embryonic myocardium) 
after 2 hours of post-ischemic re-oxygenation (Kimura et al., 2001). 
 
For these reasons, the second part of this thesis focusses on the relation between GPR30 
and either the ischemia/reperfusion (I/R) or the FSS model. The first model evaluated was an 
in vitro approach of I/R namely hypoxia/re-oxygenation using primary endothelial cells 
(HUVECs) and their derived cell line (EAhy926). The cells were exposed to oxygen glucose 
myc-PATJ GPR30-EGFP Merge 
_________________________________________________________________________________ RESULTS  
   45 
deprivation (OGD) in an hypoxic chamber (0.5% oxygen) for different time points (in 
collaboration with Dr. Dorette Freyer Department of Experimental Neurology, Charité, Berlin), 
(Ruscher et al., 2002). With this model only a minimal (and statistically not significant) 
change in the expression of GPR30 was detected, probably due to the use of a different cell 
type, i.e. endothelial cells instead of cardiomyocytes. Therefore this model was not followed 
up within the scope of this thesis. 
 
Subsequently, the FSS model was considered as a second approach. Takada et al. showed, 
using a semi-quantitative RT-PCR (reverse transcription PCR), that GPR30 expression was 
5-fold higher under a FSS of 1.5 dyn/cm2, reaching an 8-fold up-regulation at 15 dyn/cm2 for 
24 hours, compared with unstimulated cells. Stimulation of the cells for shorter periods 
(8 hours) but under the same FSS conditions induced a lower up-regulation (Takada et al., 
1997). Thus, HUVECs were used to verify these findings before the analysis was extended 
to other endothelial cells. First, the morphological changes were evaluated by microscopical 
analysis and, as shown in Figure 17, the cells were found to be aligned in the flow direction 
only when a shear stress of 30 dyn/cm2 was applied. Secondly, a significant up-regulation 
comprising a 4.57-fold increase in GPR30 expression (p = 0.016) was detected by qRT-PCR 
(quantitative real-time PCR) in cells stimulated for 24 hours with 30 dyn/cm2 shear stress. 
The effect of FSS conditions on gene expression regulation was validated by measuring the 
transcript level of Intercellular Adhesion Molecule-1 (ICAM-1) as a positive control (8.62-fold 
change at 30 dyn/cm2, p = 0.019) (Nagel et al., 1994). 
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Figure 17: GPR30 is up-regualted in HUVECs upon FSS 
HUVECs morphological changes upon increasing fluid shear stress (FSS 0, 1 and 30 dyn/cm2), in the 
upper panel. Note the elongation of the cells under high FSS (30 dyn/cm2). Scale bar: 50 µm. The 
figure shows relative gene expression levels of GPR30 (lower panel, left) and ICAM-1 (lower panel, 
right) by real-time PCR in HUVECs exposed to different FSS conditions. GPR30 was found to be 
significantly up-regulated (4.57-fold at 30 dyn/cm2) as well as the positive control ICAM-1 (8.62-fold at 
30 dyn/cm2). Gene expression of GPR30 and ICAM-1 was measured relative to HPRT levels. * 
p < 0.05 (n = 5, t test).  
 
To assess whether the effect of FSS on the expression of GPR30 was a phenomenon 
related only to HUVECs, other human endothelial cells were subjected to it and analysed. 
Therefore, primary cells Human Umbilical Arterial Endothelial Cells (HUAECs) and Human 
Aortic Endothelial Cells (HAoECs) were used, and in all cases GPR30 was found to be 
expressed and to behave in the same way under conditions of FSS. 
 
In Figure 18, morphological changes of HUAECs with FSS are shown. Only when stimulated 
with FSS at 30 dyn/cm2 were the cells found to respond to shear stress. In these cells, 
GPR30 and ICAM-1 were found to be up-regulated, with changes of 1.99-fold and of 3.67-
fold respectively, but – possibly owing to the lack of a large number of samples (only three 
replicates) – these factors were statistically not significant (p = 0.06 for GPR30 and 0.16 for 
ICAM-1). 
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Figure 18: GPR30 is up-regualted in HUAECs upon FSS 
HUAECs morphological changes upon increasing fluid shear stress (FSS 0, 1 and 30 dyn/cm2), in the 
upper panel. Scale bar: 50 µm. The figure shows relative mRNA expression levels of GPR30 (lower 
panel, left) and ICAM-1 (lower panel, right) in HUAECs. Note that GPR30 was found to be up-
regulated upon FSS (30 dyn/cm2), but not significantly, as was also the case for ICAM-1 (p = 0.06 and 
0.16, respectively). Gene expression of GPR30 and ICAM-1 was measured relative to HPRT levels. 
 
Human Aortic Endothelial Cells (HAoECs) were also investigated. When subjected to FSS 
for 24 hours, they showed the same morphological changes as HUVECs and HUAECs (data 
not shown). Here, gene expression levels of GPR30 also appeared up-regulated at 
30 dyn/cm2 of shear stress, with a change of 6.43-fold and p = 0.019. Up-regulation of 
ICAM-1 (4.01-fold change, p = 0.045), used as a positive control, demonstrated again the 
effect of FSS. Although up-regulation of GPR30 and ICAM-1 was statistically significant at  
30 dyn/cm² of FSS, a rather high standard deviation was observed among the four biological 
replicates analysed. The heterogeneity among samples may be related to the different 
origins of these cells (vein and arterial vs. aortic). 
 
Since GPR30 is expressed in small arterial vessels, a Human Microvascular Endothelial Cell 
(HMEC-1, microvascular cells immortalised by SV40 transformation, (Ades et al., 1992)) line 
was investigated, in order to verify the expression of both GPR30 and PATJ and their 
response to FSS and possibly to make use of this in future experimental approaches. When 
subjected to FSS, HMEC-1 cells showed changes in morphology, cellular alignment and 
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elongation in the direction of flow that were similar to the changes already seen in the other 
endothelial cells tested (Figure 19). 
 
 
 
Figure 19: Morphological changes of HMEC-1 cells upon FSS 
Note the elongation of the cells at 30 dyn/cm². Scale bar: 50 µm. 
 
More importantly, using RT-PCR, HMEC-1 cells were found to express GPR30 as well as 
PATJ, which would allow in future approaches to e.g. knock down or over-express either of 
the genes or gene products and to perform microarray analysis. Cells transfected with an 
empty vector (as a control for further experiments) expressed GPR30 and PATJ at basal 
levels (0 dyn/cm²) and up-regulation of GPR30 (2.05-fold change, n = 2) upon FSS was 
found as well as up-regulation of PATJ (3.51-fold change, n = 2). Furthermore, the 
expression of ICAM-1, used as a positive control to validate the effects of shear stress, was 
limited (1.65-fold change, n = 2), probably owing to a different expression level of this cell 
type, but expression of Krueppel-like factor 2 (KLF-2), another FSS responsive gene (Dekker 
et al., 2002), was found clearly up-regulated at 30 dyn/cm² (5.34-fold change, n = 2), (in 
collaboration with Dr. Kerstin Lehmann, laboratory of Prof. Ivo Buschmann, Charité, Berlin).  
 
3.6   Gene-expression profiling in human microvascular endothelial 
cells 
 
To evaluate the effects of GPR30 and of its interaction with PATJ in endothelial cells under 
FSS conditions at gene expression level, a suitable cellular system was established. First, it 
was necessary to decide upon the best cell type and approach (knock-down or over-
expression) to use. Thus, HUVECs were evaluated for RNA interference (knock-down of 
GPR30 transcript or lamin A/C, used as positive control), and also for transfection (over-
expression of pEGFP-1). For neither approach was it possible to obtain any substantive 
result. Indeed, the RNA interference was effective only for lamin A/C and the transfection 
0 dyn/cm² 30 dyn/cm² 
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efficiency of these cells was very low (Appendices 6.1.1 and 6.1.2). Secondly, the endothelial 
cell line HMEC-1 was chosen to test the same methods. In this case too, the silencing did not 
lead to the expected reduction at transcript level of GPR30, but the transfection efficiency 
was much higher compared to the efficiency in HUVECs (Appendices 6.1.3 and 6.1.4). 
Therefore, HMEC-1 cells were chosen as a cellular system for over-expression and the RNA 
interference approach had to be discarded. 
 
Once a reliable and reproducible cellular system for (a) biomechanical stimulation (FSS) 
using the HMEC-1 cells and (b) GPR30 and PATJ over-expression had been established, a 
microarray experiment was performed to investigate the overall gene expression pattern in 
these cells to gain insight into GPR30 and/or PATJ molecular effects. Therefore, HMEC-1 
cells were transfected with GPR30-HA and/or PATJ-myc and were subjected to 30 dyn/cm² 
of FSS for 24 hours in six biological replicates. As shown in the Materials and Methods 
section (Table 2) the experimental design was as follows and included eight experimental 
groups: 
 
Experimental groups  
- FSS + FSS 
Empty vector 1 2 
GPR30 3 4 
PATJ 5 6 
GPR30 + PATJ 7 8 
 
After cell transfection total RNA was isolated and, before proceeding with the microarray 
assay, successful over-expression of GPR30 and PATJ was tested and confirmed: a 1500-
fold up-regulation of both GPR30 and PATJ was found by real-time PCR. The up-regulation 
of KLF-2 as a positive control was also determined by real-time PCR to validate the effects of 
FSS (4.9-fold change, p = 0.003). In addition, the successful application of FSS was 
assessed and could be confirmed on the basis of morphological changes in the eight 
experimental groups and six replicates. 
The microarray assay was performed by using the Illumina platform (Materials and Methods, 
Section 2.9.3) which targets more than 25,000 annotated genes with more than 48,000 
probes for human genes. The normalisation to adjust the raw data was done by the rank 
invariant method (Materials and Methods, Section 2.9.4). 
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3.6.1 Effects of FSS on HMEC-1 cells 
To identify differentially expressed genes, significance analysis of microarrays (SAM) 
(Materials and Methods, Section 2.9.5) was applied and a ‘false discovery’ rate (FDR) less 
than 5% was considered. 
When the gene’s expression in cells transfected with an empty vector and under FSS (24 
hours) conditions (group 2) was compared with the gene’s expression in cells transfected 
with an empty vector but without any shear stress stimulation (group 1), 217 genes were 
found to be up-regulated and 6 down-regulated (Appendix 6.2). A selection of 30 significantly 
up-regulated genes known to be responding to shear stress or vascular remodelling, e.g. 
VEGF C, KLF2, JAG1 (Thi et al., 2007), (Dekker et al., 2002), (McCormick et al., 2001) is 
shown in Table 6. 
Table 6: Selection of thirty genes regulated upon FSS in HMEC-1 cells 
Changes are indicated as ratios (x-fold changes) in the column Ratio and q values at a ‘false 
discovery’ rate (FDR) of < 5%. 
 
ILLUMINA_ID Gene ID Gene Name Ratio 
q-
value(%) 
ILMN_1787186 NOV NEPHROBLASTOMA OVEREXPRESSED GENE 4.12 0.00 
ILMN_1802205 RHOB RAS HOMOLOG GENE FAMILY, MEMBER B 3.81 0.00 
ILMN_1735930 KLF2 KRUPPEL-LIKE FACTOR 2 (LUNG) 2.83 0.00 
ILMN_2137789 KLF4 KRUPPEL-LIKE FACTOR 4 (GUT) 2.59 0.00 
ILMN_1679929 KLF13 KRUPPEL-LIKE FACTOR 13 2.52 0.00 
ILMN_1701461 TIMP3 
TIMP METALLOPEPTIDASE INHIBITOR 3 (SORSBY FUNDUS 
DYSTROPHY, PSEUDOINFLAMMATORY) 2.52 0.00 
ILMN_1760778 ENG ENDOGLIN (OSLER-RENDU-WEBER SYNDROME 1)  2.47 0.00 
ILMN_1775501 IL1B INTERLEUKIN 1, BETA 2.03 0.00 
ILMN_1703531 EDG3 
ENDOTHELIAL DIFFERENTIATION, SPHINGOLIPID G-PROTEIN-
COUPLED RECEPTOR, 3 1.99 0.00 
ILMN_2050183 MYLK2 MYOSIN LIGHT CHAIN KINASE 2, SKELETAL MUSCLE 2.51 0.91 
ILMN_1652185 IL4R INTERLEUKIN 4 RECEPTOR 2.25 0.91 
ILMN_1762106 MMP2 
MATRIX METALLOPEPTIDASE 2 (GELATINASE A, 72KDA 
GELATINASE, 72KDA TYPE IV COLLAGENASE) 2.24 0.91 
ILMN_1701204 VEGFC VASCULAR ENDOTHELIAL GROWTH FACTOR C 1.86 0.91 
ILMN_2359287 ITGA6 INTEGRIN, ALPHA 6 1.86 0.91 
ILMN_1661194 CLDN14 CLAUDIN 14 3.40 2.36 
ILMN_1711566 TIMP1 TIMP METALLOPEPTIDASE INHIBITOR 1 1.83 2.52 
ILMN_1658709 LAMB1 LAMININ, BETA 1 1.46 2.52 
ILMN_1654563 EFNB1 EPHRIN-B1 1.87 2.65 
ILMN_1713499 WISP1 WNT1 INDUCIBLE SIGNALING PATHWAY PROTEIN 1 1.91 2.89 
ILMN_1731736 RIN3 RAS AND RAB INTERACTOR 3 1.56 3.37 
ILMN_1743966 BCL9L B-CELL CLL/LYMPHOMA 9-LIKE 2.13 3.54 
ILMN_1719236 CDH5 CADHERIN 5, TYPE 2, VE-CADHERIN (VASCULAR EPITHELIUM) 1.78 3.54 
ILMN_1796755 ITGB5 INTEGRIN, BETA 5 1.75 3.54 
ILMN_2214910 EPHB4 EPH RECEPTOR B4 1.66 3.54 
ILMN_2318638 TGIF1 TGFB-INDUCED FACTOR (TALE FAMILY HOMEOBOX) 1.46 3.54 
ILMN_1691376 JAG1 JAGGED 1 (ALAGILLE SYNDROME) 1.87 4.47 
ILMN_1758542 BMP1 BONE MORPHOGENETIC PROTEIN 1 1.83 4.47 
ILMN_1735052 ULK1 UNC-51-LIKE KINASE 1 (C. ELEGANS) 1.65 4.47 
ILMN_2374340 PLAUR PLASMINOGEN ACTIVATOR, UROKINASE RECEPTOR 1.39 4.47 
ILMN_2212878 ESM1 ENDOTHELIAL CELL-SPECIFIC MOLECULE 1 9.92 4.71 
_________________________________________________________________________________ RESULTS  
   51 
Global gene expression profiles raise the difficulty of handling, ordering, filtering and/or  
sorting large amounts of data to focus e.g. on a particular cellular function with a view to 
questioning an initial hypothesis. Therefore, after the identification of differentially expressed 
genes, several bioinformatic software tools were used to organise the data obtained. Genes 
deregulated were grouped using the DAVID (Database for Annotation, Visualisation and 
Integrated Discovery), an enrichment analysis for Gene Ontology (GO)-categories (Materials 
and Methods, Section 2.9.6).  
DAVID was applied to identify gene ontology categories with an over-representation of 
genes. The summary for the biological function annotation revealed that most genes were 
assigned to the GO-categories: ‘organ and tissue development’, ‘vasculature development’, 
‘blood vessel morphogenesis’ and ‘angiogenesis’. For example, genes involved in ‘organ and 
tissue development’ were Krueppel-like factor 4 (KLF4) and cadherin 5 (CDH5). In the 
category ‘angiogenesis’ some of the genes involved were interleukin 1-beta (IL1B), ras 
homologue gene family member 2 (RHOB) and vascular endothelial growth factor C 
(VEGF-C). 
To further analyse the genes regulated upon FSS, these were grouped into networks by 
knowledge-based analysis of physical, transcriptional, or enzymatic interactions using the 
Ingenuity Pathway Analysis (IPA) software tool (Materials and Methods, 2.7.7). Deregulated 
genes could be clustered into 23 functional networks using this tool and top networks are 
shown in Figure 20. 
 
 
 
Figure 20: Top networks from the IPA analysis for the deregulated genes of the analysis HMEC-
1 without FSS versus HMEC-1 with FSS 
 
Top networks are, for example, Network 1 which comprises “Cardiovascular system 
development and function”, “Organism development”, “Cellular development” (score = 44, 
focus molecules = 24, e.g. Krueppel-like factor 2, KLF2 and Actin gamma 2, ACTG2), 
Network 2 with genes involved in “Cellular movement”, “Skeletal and muscular system 
development and function”, “Cell-to-cell signalling and interaction” (score = 34, focus 
molecules = 20, e.g. Laminin beta 1, LAMB1 and Nephroblastoma over-expressed gene, 
NOV) or Network 4 related to “Cell death”, “Inflammatory response”, “Molecular transport” 
(score = 31, focus molecules = 20, e.g. CDH5, IL1B). Networks 1 and 4, designed by IPA, 
are represented in Figure 21. 
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Figure 21: IPA of deregulated genes in HMEC-1 cells upon FSS 
Genes were grouped into 23 different functional networks, of which two are represented here (upper 
panel, network 1; lower panel, network 4). The legend at the right side explains the meaning of the 
symbols in the networks. Grey-filled symbols indicate focus molecules (from the deregulated gene list) 
while white-filled symbols are molecules involved in the networks but not present in the deregulated 
gene lists. 
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3.6.2 Effects of GPR30 over-expression in HMEC-1 cells  
To identify gene regulation effects that are related to the over-expression of GPR30 but are 
independent of FSS, the GPR30-overexpressing cells (group 3) were analysed in 
comparison with the cells transfected with the empty vector (group 1). Surprisingly, no genes 
were found to be deregulated at an FDR below 5%. Subsequently, all groups of cells over-
expressing GPR30 (groups 3, 4, 7 and 8) were compared with all groups not expressing 
GPR30 (groups 1, 2, 5 and 6). By this approach, only a very small number of genes were 
found to be deregulated, with very low ratios of change. As expected, a strong up-regulation 
of GPR30 (136-fold) was found and six additional up-regulated genes were identified 
(SAM < 5%), shown in Table 7. 
 
Table 7: List of genes deregulated in HMEC-1 cells over-expressing GPR30.  
Note the high induction of the expression of GPR30 and the rather limited number and only slightly 
deregulated genes. 
 
ILLUMINA_ID Gene ID Gene Name Ratio 
q-
value(%) 
ILMN_1665435 GPER/GPR30 G PROTEIN-COUPLED RECEPTOR 30 136.11 0.00 
ILMN_1806165 HSPA6 HEAT SHOCK 70KDA PROTEIN 6 (HSP70B') 5.10 0.00 
ILMN_1838319 LOC730249 IMMUNORESPONSIVE 1 HOMOLOG (mouse) 1.62 0.00 
ILMN_1790136 C20orf20 MRG-BINDING PROTEIN (MRGBP) 1.54 0.00 
ILMN_2393968 SYNJ1 SYNAPTOJANIN 1 1.50 0.00 
ILMN_1801122 LOC401317 HYPOTHETICAL LOC401317 1.42 0.00 
ILMN_1779225 C7orf33 CHROMOSOME 7 OPEN READING FRAME 33 1.34 0.00 
 
The low number of identified genes could not be further analysed neither with DAVID nor 
with IPA software tool.  
 
3.6.3 Effects of GPR30 over-expression in HMEC-1 cells upon FSS 
This analysis was performed in order to see whether the effect of fluid shear stress was 
influencing the gene expression of HMEC-1 cells over-expressing GPR30 in a different 
manner compared with cells stimulated only by FSS or only over-expressing GPR30. 
Therefore, HMEC-1 cells over-expressing GPR30 and subjected to FSS (group 4) were 
compared with cells over-expressing GPR30 but unstimulated (group 3). In this group 201 
deregulated genes were identified, in particular 198 genes as up-regulated and 3 as down-
regulated (Appendix 6.3). In this group, 159 genes present (shown in grey in Appendix 6.3) 
are different from the list of genes deregulated in cells stimulated with FSS alone (Appendix 
6.2). A selection of genes, present only in this group and different from the list shown in 
Table 6, is shown in Table 8. 
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Table 8: Selection of genes deregulated only in HMEC-1 cells over-expressing GPR30 after 
stimulation with FSS 
ILLUMINA_ID Gene ID Gene Name Ratio 
q-
value(%) 
ILMN_1692177 TSC22D1 TSC22 domain family, member 1 3.55 0.00 
ILMN_2276952 TSC22D3 TSC22 domain family, member 3; GRAM domain containing 4 2.03 0.00 
ILMN_1747314 MYO5B 
similar to acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-
Coenzyme A thiolase); similar to KIAA1119 protein; myosin VB 1.16 0.00 
ILMN_1715863 MLKL mixed lineage kinase domain-like 2.36 1.05 
ILMN_1758067 RGS4 regulator of G-protein signalling 4 2.20 1.05 
ILMN_1757825 ZNF230 zinc finger protein 230 2.03 1.05 
ILMN_1839422 JRK jerky homolog (mouse) 1.98 1.05 
ILMN_1692967 AXIN1 axin 1 1.84 1.05 
ILMN_1746359 RERG RAS-like, estrogen-regulated, growth inhibitor 1.73 1.05 
ILMN_2316278 MAGED4B melanoma antigen family D, 4B; melanoma antigen family D, 4 1.45 1.05 
ILMN_1769201 ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 4.58 2.52 
ILMN_1810864 PMP22 peripheral myelin protein 22 3.60 2.52 
ILMN_1802646 EPHB6 EPH receptor B6 2.98 2.52 
ILMN_1805466 SOX9 SRY (sex determining region Y)-box 9 2.13 2.52 
ILMN_2113490 NTN4 netrin 4 2.12 2.52 
ILMN_1695773 STK24 serine/threonine kinase 24 (STE20 homolog, yeast) 2.07 2.52 
ILMN_2361181 C1QTNF6 C1q and tumour necrosis factor related protein 6 1.89 2.52 
ILMN_1785768 PDE4A 
phosphodiesterase 4A, cAMP-specific (phosphodiesterase E2 dunce 
homolog, Drosophila) 1.65 2.52 
ILMN_1706644 BDNF brain-derived neurotrophic factor 1.42 2.52 
ILMN_1738707 S100A13 S100 calcium binding protein A13 1.42 2.52 
ILMN_1807050 SHC4 SHC (Src homology 2 domain containing) family, member 4 1.34 2.52 
ILMN_1675819 FAM101A family with sequence similarity 101, member A 1.27 2.52 
ILMN_1758597 NAGS N-acetylglutamate synthase 1.21 2.52 
ILMN_1652525 FAM125B family with sequence similarity 125, member B 1.20 2.52 
ILMN_1670959 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 1.14 2.52 
 
After the identification by SAM, the relevant deregulated genes were functionally annotated 
using DAVID and IPA. 
  
For the biological function annotation with DAVID, most genes were assigned to the same 
GO-categories found for deregulated genes of samples subjected only to FSS, e.g. ‘organ 
and tissue development‘, ‘vasculature development’ and ‘blood vessel morphogenesis’. For 
example, genes involved in ‘blood vessel morphogenesis’ are plexin D1 (PLXND1) and 
troponin I type 3 (TNNI3). 
To continue the analysis, the genes deregulated in cells over-expressing GPR30 and upon 
FSS, were grouped into 17 networks by IPA. The top networks identified by this second tool 
were different, as shown in Figure 22, from those designed for cells subjected to FSS, 
probably owing to the over-expression of GPR30 in these samples. 
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Figure 22: Top networks from the IPA analysis for the deregulated genes of the analysis HMEC-
1/GPR30 without FSS versus HMEC-1/GPR30 with FSS 
 
Of note are, for example, Network 1 which comprises “Neurological disease”, “Reproductive 
System Development and Function”, “Tissue development” (score=45, focus molecules=23, 
e.g. AXIN1 and SRY (sex-determining region Y)9, SOX9) and in particular Network 4, related 
to “Neurological disease”, “Drug metabolism”, “Endocrine system development and function”, 
(score = 21, focus molecules = 13, e.g. RAS-like, estrogen-regulated, growth inhibitor, RERG 
and S100 calcium binding protein A13, S100A13). In Figure 23 Networks 1 and 4 are shown. 
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Figure 23: Ingenuity pathway analysis of deregulated genes in HMEC-1 cells over-expressing 
GPR30 upon FSS 
Genes were grouped into 17 different functional networks, of which two are represented here (left 
panel, network 1; right panel, network 4). In network 4, beta-estradiol is highlighted in a red circle. 
 
3.6.4 Effects of PATJ over-expression in HMEC-1 cells  
Since PATJ was found to interact with GPR30, and it was previously shown that the 
Amot/PATJ/Syx complex controls the migration of endothelial cells and zebrafish 
angiogenesis (Ernkvist et al., 2009), the gene expression of HMEC-1 cells over-expressing 
PATJ (group 5) was also analysed. The SAM (FDR < 5%) was performed comparing this 
beta-estradiol 
Network 1 
Network 4 
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group with cells transfected with empty vector (group 1); neither group was subjected to FSS. 
As expected, we found a strong up-regulation of PATJ, also called INADL (Inactivation No 
Afterpotential Drosophila-Like), (633-fold for one Illumina probe or 45-fold for a second 
Illumina probe, both identifying the same INADL gene). From this analysis the 28 up-
regulated genes identified are shown in Table 9. 
 
Table 9: List of genes deregulated in HMEC-1 cells over-expressing PATJ. 
 
ILLUMINA_ID Gene ID Gene Name Ratio 
q-
value(%) 
ILMN_1773312 INADL/PATJ InaD-like (Drosophila) 633.16 0.00 
ILMN_1747318 INADL/PATJ InaD-like (Drosophila) 44.83 0.00 
ILMN_1691048 SLC22A18AS 
solute carrier family 22 (organic cation transporter), member 18 
antisense 1.63 0.00 
ILMN_1745570 KLK7 kallikrein-related peptidase 7 1.50 0.00 
ILMN_1786559 FLJ46020 FLJ46020 protein 1.49 0.00 
ILMN_1658883 ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1.23 0.00 
ILMN_2048647 NBEA neurobeachin 2.25 3.49 
ILMN_1698753 PRDM13 PR domain containing 13 1.97 3.49 
ILMN_2278590 MEST mesoderm specific transcript homolog (mouse) 1.87 3.49 
ILMN_2262957 WIPF1 WAS/WASL interacting protein family, member 1 1.77 3.49 
ILMN_2100046 IL22 interleukin 22 1.63 3.49 
ILMN_1798837 PTPN20B 
protein tyrosine phosphatase, non-receptor type 20B; protein tyrosine 
phosphatase, non-receptor type 20A 1.62 3.49 
ILMN_1682176 CLEC3B C-type lectin domain family 3, member B 1.46 3.49 
ILMN_1806189 C16orf3 chromosome 16 open reading frame 3 1.45 3.49 
ILMN_1699170 LOC51149 chromosome 5 open reading frame 45 1.40 3.49 
ILMN_1652946 LOC387804 chromosome 11 open reading frame 90 1.40 3.49 
ILMN_2413508 CD97 CD97 molecule 1.39 3.49 
ILMN_1765373 LOC644686 hypothetical protein LOC644686 1.39 3.49 
ILMN_1679600 ACOT8 acyl-CoA thioesterase 8 1.36 3.49 
ILMN_1771348 ACN9 ACN9 homologue (S. cerevisiae) 1.35 3.49 
ILMN_1789338 SORBS3 sorbin and SH3 domain containing 3 1.34 3.49 
ILMN_2186108 DGCR6 DiGeorge syndrome critical region gene 6 1.34 3.49 
ILMN_1766793 C9orf23 chromosome 9 open reading frame 23 1.32 3.49 
ILMN_1780591 FAT3 FAT tumour suppressor homolog 3 (Drosophila) 1.31 3.49 
ILMN_1664773 C11orf49 chromosome 11 open reading frame 49 1.30 3.49 
ILMN_1704065 LOC400768 hypothetical gene supported by BC051808 1.28 3.49 
ILMN_2144574 CTBS chitobiase, di-N-acetyl- 1.26 3.49 
ILMN_1708041 PLEKHF1 
pleckstrin homology domain containing, family F (with FYVE domain) 
member 1 1.25 3.49 
 
Owing to the small number of deregulated genes it was not possible to perform an 
enrichment analysis using the DAVID software tool. Instead, the analysis with IPA was 
possible, although the networks associated with this list of genes were only two: network 1, 
“Gene expression”, “Cellular growth and proliferation”, “Tissue morphology” (score = 27, 
focus molecules = 11) and network 2, “Cell cycle”, “Cellular development”, “Cardiovascular 
system development and function” (score = 21, focus molecules = 9), (Figure 24).  
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Figure 24: Top networks from the IPA for the deregulated genes of the analysis HMEC-1/PATJ 
versus HMEC-1/empty vector 
The two networks 1 and 2 are shown in the lower panel. 
 
Network 1 
Network 2 
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3.6.5 Effects of PATJ over-expression in HMEC-1 cells upon FSS 
Once genes differentially regulated in HMEC-1 cells over-expressing PATJ had been 
identified, the next step was to look at the influence of the fluid shear stress applied to the 
same group of transfected cells. Therefore, cells over-expressing PATJ and subjected to 
FSS (group 6) were compared with the cells that over-expressed PATJ but were not 
stimulated (group 5). With an FDR of <5%, 69 genes were found to be up-regulated 
(Appendix 6.4). In Table 10 the 20 genes with the highest relative changes are shown. 
 
Table 10: Selection of genes deregulated in HMEC-1 cells over-expressing PATJ after 
stimulation with FSS  
 
ILLUMINA ID Gene ID Gene Name Ratio 
q-
value(%) 
ILMN_1766264 PI16 peptidase inhibitor 16 6.11 0.00 
ILMN_1787186 NOV nephroblastoma overexpressed gene 4.97 0.00 
ILMN_1802205 RHOB ras homolog gene family, member B 3.29 0.00 
ILMN_2189027 LIPG lipase, endothelial 3.21 0.00 
ILMN_2307861 COL6A3 collagen, type VI, alpha 3 3.11 0.00 
ILMN_1799575 IL19 interleukin 19 3.11 0.00 
ILMN_1738742 PLAT plasminogen activator, tissue 3.03 0.00 
ILMN_2137789 KLF4 Kruppel-like factor 4 (gut) 3.01 0.00 
ILMN_1665035 KRT14 keratin 14 2.97 0.00 
ILMN_1844408 PLXNA2 plexin A2 2.94 0.00 
ILMN_1763837 ANPEP alanyl (membrane) aminopeptidase 2.80 0.00 
ILMN_2314169 PTHLH parathyroid hormone-like hormone 2.79 0.00 
ILMN_2150851 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 2.75 0.00 
ILMN_1659856 C1orf90 family with sequence similarity 167, member B 2.71 0.00 
ILMN_1696048 C13orf33 chromosome 13 open reading frame 33 2.69 0.00 
ILMN_2043306 EPB41L5 erythrocyte membrane protein band 4.1 like 5 2.59 0.00 
ILMN_1765446 EMP3 epithelial membrane protein 3 2.51 0.00 
ILMN_1709674 GFPT2 glutamine-fructose-6-phosphate transaminase 2 2.45 0.00 
ILMN_2413158 PODXL podocalyxin-like 2.44 0.00 
ILMN_1735930 KLF2 Kruppel-like factor 2 (lung) 2.44 0.00 
 
Using DAVID for the whole list, the genes were gathered in the similar gene ontology 
categories designed for all the other lists of genes, when the cells were stimulated with FSS.  
IPA was used to create networks for cells over-expressing PATJ upon fluid shear stress. The 
five top networks are presented in Figure 25. 
 
 
 
Figure 25: Top networks from the IPA for the deregulated genes of the analysis HMEC-1/PATJ 
without FSS versus HMEC-1/PATJ with FSS 
_________________________________________________________________________________ RESULTS  
   60 
   
 
The number of networks found, by IPA analysis for the genes over-expressing PATJ and 
upon FSS, was 11 and, although grouping some functional pathways already pointed out for 
the previous lists of genes, here presented new associated network functions, i.e. network 2 
for “Cell morphology”, “Skeletal and muscular system development and function”, 
“Respiratory disease” (score = 29, focus molecules = 14) and network 4 for “Genetic 
disorder, “Skeletal and muscular disorders”, “Connective tissue development and function” 
(score = 12, focus molecules = 7). Networks 2 and 4 are represented in Figure 26. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Top networks from the IPA for the deregulated genes of the analysis HMEC-1/PATJ 
without FSS versus HMEC-1/PATJ with FSS 
 
3.6.6 Effects of GPR30 and PATJ over-expression in HMEC-1 cells  
The last aim was to analyse the gene-expression pattern in cells over-expressing GPR30 
and PATJ in order to find out more about this new interaction. First, the groups without shear 
stress stimulation were examined; for this purpose, HMEC-1 over-expressing GPR30 and 
PATJ (group 7) were compared with HMEC-1 over-expressing the empty vector (group 1). 
Network 2 Network 4 
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Table 11: List of genes deregulated in HMEC-1 cells over-expressing GPR30 and PATJ 
ILLUMINA ID Gene ID Gene Name Ratio 
q-
value(%) 
ILMN_1773312 INADL/PATJ InaD-like (Drosophila) 560.84 0.00 
ILMN_1665435 GPER/GPR30 G protein-coupled estrogen receptor 1 116.56 0.00 
ILMN_1789502 GPC4 glypican 4 1.68 0.00 
ILMN_1695711 FAM105A family with sequence similarity 105, member A 1.94 0.00 
ILMN_1740041 LOC645197  hypothetical LOC645197 1.63 0.00 
ILMN_1720496 GUCY1A2 guanylate cyclase 1, soluble, alpha 2 1.43 0.00 
 
In this case, only 4 genes, besides PATJ and GPR30, were found to be deregulated. 
Similarly to the other groups with too few genes, it was not possible to perform any further 
bioinformatic analysis using either DAVID or IPA. 
 
3.6.7 Effects of GPR30 and PATJ over-expression in HMEC-1 cells upon 
FSS 
The last group of deregulated genes obtained with the microarray experiment and presented 
in this thesis is the result of the comparison of cells over-expressing GPR30 and PATJ with 
FSS stimulation (group 8) versus cells over-expressing GPR30 and PATJ but without FSS 
(group 7). With SAM analysis (FDR < 5%) 246 genes were found to be up-regulated and 4 to 
be down-regulated (Appendix 6.5). In this group, 148 genes are different from those in the list 
of genes deregulated in cells stimulated with FSS alone (Appendix 6.2). Table 12 shows a 
selection of 20 genes differentially regulated and present only in this group. 
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Table 12: Selection of genes deregulated in HMEC-1 cells over-expressing GPR30 and PATJ 
after stimulation with FSS  
 
ILLUMINA ID Gene ID Gene Name Ratio 
q-
value(%) 
ILMN_1736760 KRT16 
KERATIN 16 (FOCAL NON-EPIDERMOLYTIC PALMOPLANTAR 
KERATODERMA) 10.95 0.00 
ILMN_1766264 PI16 PEPTIDASE INHIBITOR 16 5.27 0.00 
ILMN_1799575 IL19 INTERLEUKIN 19 3.30 0.00 
ILMN_1762529 SLC12A8 HYPOTHETICAL PROTEIN FLJ23188 2.90 0.00 
ILMN_2327860 MAL MAL, T-CELL DIFFERENTIATION PROTEIN 2.54 0.00 
ILMN_1693338 CYP1B1 CYTOCHROME P450, FAMILY 1, SUBFAMILY B, POLYPEPTIDE 1 2.53 0.00 
ILMN_2387214 PALM PARALEMMIN 2.35 0.00 
ILMN_1711786 NFE2 NUCLEAR FACTOR (ERYTHROID-DERIVED 2), 45KDA 2.28 0.00 
ILMN_1688780 S100A4 
S100 CALCIUM BINDING PROTEIN A4 (CALCIUM PROTEIN, 
CALVASCULIN, METASTASIN, MURINE PLACENTAL HOMOLOG) 2.26 0.00 
ILMN_1769201 ELF3 
E74-LIKE FACTOR 3 (ETS DOMAIN TRANSCRIPTION FACTOR, 
EPITHELIAL-SPECIFIC ) 2.20 0.00 
ILMN_2148527 H19 H19, IMPRINTED MATERNALLY EXPRESSED UNTRANSLATED MRNA 2.17 0.00 
ILMN_1758067 RGS4 REGULATOR OF G-PROTEIN SIGNALLING 4 2.13 0.00 
ILMN_1701424 LAMC2 LAMININ, GAMMA 2 2.11 0.00 
ILMN_2308903 WFDC3 WAP FOUR-DISULFIDE CORE DOMAIN 3 2.00 0.00 
ILMN_2113490 NTN4 NETRIN 4 1.97 0.00 
ILMN_1726597 C6orf32 CHROMOSOME 6 OPEN READING FRAME 32 1.95 0.00 
ILMN_2150851 SERPINB2 SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 2 1.95 0.00 
ILMN_1774685 IL24 INTERLEUKIN 24 1.94 0.00 
ILMN_2356578 TH TYROSINE HYDROXYLASE 1.94 0.00 
ILMN_1761968 PPP1R14A 
PROTEIN PHOSPHATASE 1, REGULATORY (INHIBITOR) SUBUNIT 
14A 1.89 0.00 
 
In this case too, it was reasonable to use the bioinformatic software tools DAVID and IPA. 
In DAVID analysis, the summary for the biological function annotation revealed that most 
genes were again assigned to the same GO-categories found for the other groups described 
above. 
 
To obtain new hints, the Ingenuity Pathway Analysis software tool was also considered. It 
proved possible to cluster the deregulated genes into 19 functional networks using this tool, 
and the top five networks are presented in Figure 27. 
 
 
 
Figure 27: Top networks HMEC-1 cells over-expressing GPR30 and PATJ with FSS stimulation 
 
These networks showed most of the network functions that had already appeared for the 
other gene sets. Nevertheless, the association between networks in each analysis was 
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different. For example, network 1 for “Cellular movement”, “DNA replication, recombination 
and repair”, “Cellular growth and proliferation” (score = 57, focus molecules = 29) and 
network 8 for “Cancer”, “Cell cycle”, “Reproductive system, development and function” 
(score = 19, focus molecules = 13) presented a different number of genes if compared with 
the same networks but with a different list of genes, as shown in the next picture (Figure 28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Top networks from the IPA for the deregulated genes of the analysis HMEC-
1/GPR30/PATJ without FSS versus HMEC-1/GPR30/PATJ with FSS 
In network 8, beta-estradiol is highlighted in a red circle. 
 
 
Network 1 
Network 8 
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4     DISCUSSION 
 
More than 800 G protein-coupled receptors (GPCRs) are transcribed in the human genome 
(Kroeze et al., 2003) and are involved in a wide range of physiological processes and, 
therefore, are exploited as drug targets in a multitude of therapeutic areas (Pierce et al., 
2002). 
 
After binding a specific ligand, activated GPCRs can initiate cellular signalling, but for many 
of them no endogenous ligand has yet been found, and, therefore, these are currently 
designated as orphan receptors (Oh et al., 2006). The orphan G protein-coupled receptor 30, 
GPR30, was claimed in 2005 by two independent groups to bind directly to 17-β-estradiol 
(E2 or beta-estradiol) and to mediate rapid non-genomic signalling (Revankar et al., 2005), 
(Thomas et al., 2005). In contrast, various reports indicate that E2 fails to bind GPR30 in a 
saturable or specific manner and in consequence exerts only a modest signal-transduction 
effect (Thomas et al., 2005) compared with the dramatically stronger actions of physiological 
E2 at classical estrogen receptor (ER)α, (Otto et al., 2008). Thus, the function of GPR30 as 
an ER remains under discussion. 
 
In a recent study performed in the laboratory of Prof. Ruiz-Noppinger, where the work for this 
thesis was carried out, the cellular and tissue distribution of GPR30 in mouse was 
investigated in a very broad screen. For this purpose, a mutant mouse was generated by 
inserting a LacZ/neomycin resistance cassette into the exon 3 encoding the ORF of the 
GPR30 gene. The strength of this mouse model was the presence of a LacZ reporter in the 
GPR30 locus that allowed the identification of cells expressing GPR30 protein in vivo. 
Predominantly GPR30 was expressed in endothelial cells of small arteries in several tissues 
(Isensee et al., 2009). 
 
Independently of the controversy about whether GPR30 is an ER or is still an orphan 
receptor, in 1997 one of the cloning approaches for GPR30 used human umbilical vein 
endothelial cells (HUVECs) exposed to fluid shear stress (FSS), the driving force of 
arteriogenesis. In this study it was shown that the GPR30 mRNA level is increased markedly 
in response to FSS after 24 hours (Takada et al., 1997). In another study it was found that 
the expression of GPR41 (orthologue of GPR30 in the rat) in H9c2 cells (a rat-heart-derived 
cell line) is induced during post-ischaemic re-oxygenation with a peak at 2 hours after 
re-oxygenation (Kimura et al., 2001). Ischaemia is present during development or can be 
caused, for instance, by blockage of an artery leading to a temporarily decreased supply of 
oxygen and nutrients from the blood, and it induces angiogenesis. 
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With the background of a clear evidence about the expression of GPR30 (Isensee et al., 
2009) and its involvement (Haas et al., 2009) in the vascular tissue, the overall goal of this 
project was to elucidate the role of GPR30 signalling in blood vessels. Despite the 
controversy about whether GPR30 is an ER or is still an orphan receptor, nothing is known at 
present about its relation to and its interaction with other proteins. Therefore, also according 
to several reports suggesting that GPCRs interact with and are regulated by several other 
proteins, beyond the established role of heterotrimeric G proteins, the first aim of this project 
was to identify new interaction partners and to gain information about the signalling complex 
of human GPR30 at the molecular level (I). The second aim was to establish a human cell 
model to evaluate the potential role of GPR30 in a vascular model (II) and finally the third aim 
was to evaluate the downstream effects of the interaction between GPR30 and newly 
identified interaction partners in the vascular model at the transcript level (III). 
 
4.1   Detection of GPR30 by western blotting and co-
immunoprecipitation 
 
GPCRs are characterised by seven transmembrane domains. Therefore, solubilisation of 
GPR30 with its strong lipophilic properties represented a challenging task, but it was a 
prerequisite for the detection of GPR30 by western blotting and CoIP. 
This step was important for two reasons:  
1)  to detect both endogenous and over-expressed GPR30 by western blotting (i.e. to 
confirm the absence of GPR30 protein in the GPR30/LacZ mouse mutant); 
2) to confirm the interaction between GPR30 and potential interaction partners in 
mammalian cell lines by CoIP. 
 
For these two purposes, the choice of solubilisation conditions was very important. To detect 
GPR30 at the protein level by western blotting it was necessary to use a lysis buffer with 
strong denaturing characteristics, to solubilise a large proportion of the expressed protein for 
quantitative measurements. For a CoIP the detergent to be used in such lysis buffer had to 
be strong enough to extract GPR30 from the native membrane, but not so strong as to 
denature the receptor and disrupt protein–protein interactions that might be of physiological 
interest. 
 
Therefore, several protocols for western blotting were considered, including some specific for 
detecting human GPR30 (Thomas et al., 2005), (Vivacqua et al., 2006), (Filardo et al., 2007). 
In parallel, other protocols designed to solubilise proteins, without considering the possible 
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strong denaturing conditions (and therefore not useful for CoIP), were evaluated (Nagamatsu 
et al., 1992), (Moore et al., 2000), (Edinger et al., 2003). The choice of the right antibody is 
another critical step in any western blotting; therefore, in a search for a specific antibody 
against GPR30, first trials were performed using an anti-GFP (Green Fluorescent Protein) 
antibody able to recognise the fusion protein of GPR30 tagged with EGFP (Enhanced Green 
Fluorescent Protein). A second reason to choose an anti-GFP in the beginning was to have 
the possibility to check for transfected cells, in order to visualise GPR30-EGFP in such cells 
under the microscope before attempting to extract proteins for western blotting. 
 
One of the first published protocols evaluated, showing a specific band for GPR30 in western 
blotting, was the protocol from the publication of Vivacqua et al. in 2006 where the lysis 
buffer used was a simple RIPA-buffer, with a detergent that was not too strong and was 
therefore possibly suitable also for CoIP (Vivacqua et al., 2006). Following this protocol, in 
the laboratory where this work was carried out, no band for GPR30-EGFP was detected, but 
since an anti-GFP antibody − instead of a commercial anti-GPR30 antibody − was used to 
detect GPR30, it was reasonable to hypothesise that the cause of the negative result could 
have come from the use of a different antibody. Therefore, other western blotting protocols, 
where the goal was the solubilisation of other GPCRs using different antibodies, hence 
suitable using an anti-GFP antibody, were screened. Among various protocols, two in 
particular were considered, and only one of these led to a first successful result. In this 
protocol the lysis buffer contained a combination of two compounds, urea and SDS, both 
powerful denaturants that disrupt the non-covalent bonds within proteins and therefore not 
suitable for the CoIP (Edinger et al., 2003) (Results 3.1.1). In this experiment, using pEGFP-
C1 as a positive control, two bands were detected instead of the single band expected. The 
presence of the two bands could indicate a mature and a pre-processed form of the protein 
(Waller et al., 2000); the smaller of these corresponded to the expected molecular weight of 
GFP whereas the larger was consistent with the size of a mono-ubiquitylated GFP molecule, 
suggesting that a proportion of over-expressed GFP in the cells might be turned over by 
normal cellular mechanisms of protein degradation (Riess et al., 2005). 
 
Subsequently, many other protocols for GPR30 western blotting were assessed, by using 
human GPR30 antibodies. In total six different antibodies were screened. None of these 
protocols led to positive results, but two of these antibodies (3rd extracellular domain 
antibody and C-terminal domain antiserum, from the laboratory of Prof. E. Prossnitz), and 
only in combination with the previously adjusted urea–SDS-based protocol, detected GPR30 
(full-length and fused with EGFP) by western blotting (Results, Section 3.1.2). Although two 
antibodies could detect over-expressed GPR30, once again this was with the urea–SDS lysis 
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buffer and was therefore not useful for CoIP experiments, since the strong denaturing 
conditions set out in the protocol would not allow the detection of potential interacting 
proteins. Nevertheless, this protocol in combination with one of those anti-GPR30 antibodies 
could be helpful for other approaches, e.g. to demonstrate the absence of GPR30 in GPR30-
LacZ mutant mice. Therefore, the next step was to detect the endogenously expressed 
GPR30 with the urea–SDS lysis buffer and an anti-GPR30 antibody (i.e. against the 3rd 
extracellular domain antibody). Indeed, under these conditions it proved possible to detect a 
specific band for endogenous human GPR30 (Results, Section 3.1.3) in SkBr3 breast cancer 
cells that were negative for ER (estrogen receptor α and β) but positive for GPR30 (Vladusic 
et al., 2000). 
 
The last goal was to transfer this protocol established to detect human endogenous GPR30 
cells to the mouse system. Therefore, the protocols optimised were evaluated in wild-type 
(wt) and in GPR30-deficient mouse tissue samples but without success. These findings 
underline the difficulty of detecting murine GPR30 protein in tissues, which is probably due to 
low expression levels, the lipophilic properties as a 7TMR and, most importantly, the lack of 
mouse antibodies. Indeed, the antibodies so far mentioned were produced to recognise 
specifically human GPR30 and not epitopes of the mouse receptor. Therefore, the only way 
to tackle the question about the expression of GPR30 in mice was to investigate the 
expression of a LacZ reporter in GPR30-lacZ mice and characterise the cell types identified 
by co-localisation of LacZ along with cell-type-specific markers. This approach is especially 
useful if low expression levels are assumed, because the LacZ assay allows remarkable 
signal amplification (Isensee et al., 2009). 
 
Concerning the CoIP, several protocols were evaluated, (Filardo et al., 2007), (Devost und 
Zingg, 2003), (Okuma und Reisine, 1992), (Harvey et al., 2001), but in none of the cases 
was it possible to solubilise GPR30. For example, with the Ripa-buffer-based protocol used 
by Filardo et al. in 2007 where the interaction between GPR30 and a G protein was shown, 
in particular with the Gαs subunit, it was not possible in the laboratory where the work for this 
thesis was carried out to detect a specific band for GPR30, although every step of their CoIP 
protocol was followed. One explanation could be the use in their protocol of an anti-GPR30 
antiserum produced in their laboratory, therefore commercially not available (monospecific 
GPR30 antibody, 2F2, generated in BALB/C mice that were immunised with synthetic 
peptide CAVIPDSTEQSDVRFSSAV from the C terminus of human GPR30). Only after 
visiting the Laboratory of Prof. Guy Haegemann (Eukaryotic Gene Expression and Signal 
Transduction (LEGEST), Department of Molecular Biology, Ghent University, Gent, Belgium), 
a protocol for the confirmation of the interaction between GPR30 and the new hypothetical 
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proteins was finally found (Rondou et al., 2008). There, with few new experimental features 
(e.g. freezing/thawing before cell lysis, or the use of an antibody not employed before) it was 
very easy to solubilise and co-immunoprecipitate HA-tagged GPR30, using an anti-HA 
antibody (Results 3.3). In conclusion, for the successful CoIP protocol the choice of the lysis 
buffer together with the choice of the antibody was of crucial importance. Indeed, some 
antibodies require samples to be processed or treated in a specific manner, since many 
antibodies can recognise only proteins that reveal their epitopes in a particular state; for 
example, if the samples have been reduced and denatured the proteins can show epitopes 
otherwise obscured by secondary and tertiary folding. 
 
4.2   GPR30 interacts specifically with PATJ in mammalian cells 
 
Protein–protein interactions (PPI) represent a pivotal aspect of protein function. Almost every 
cellular process relies on transient or permanent physical binding of two or more proteins in 
order to accomplish the respective task. Prediction of protein interactions using bioinformatic 
tools and online software could be a first step to gain insight into this topic. Currently, publicly 
available PPI databases contain few entries from mammals, such as would be required for 
building a high-quality, manually curated database of protein–protein interactions. 
 
To check for new hypothetical interaction partners for GPR30, some of these bioinformatic 
tools were evaluated, i.e. the human Protein–protein Interaction Prediction (PIPs, 
http://www.compbio.dundee.ac.uk/www-pips/) (McDowall et al., 2009), the Biomolecular 
Object Network Databank (BOND, http://bond.unleashedinformatics.com/)  (Alfarano et al., 
2005) or the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, 
http://string-db.org/) (Snel et al., 2000). These databases use different sources: while the 
interactions in PIPs are calculated by combining information from expression, orthology, 
post-translational modifications, sub-cellular location of each protein and topology of the 
predicted interaction network, STRING and BOND base their prediction on experimental 
repositories, computational prediction methods and public text collections. 
Using PIPs, GPR30 does not have predicted interactions with a score of 1.0 or above, which 
indicates that the interaction is more likely to occur than not to occur (the higher the value, 
the greater the confidence that the predicted protein interacts with the main protein). With a 
score above 0.5, six proteins were identified (GPR63, OR5V1, OR3A3, TAAR8, OR1G1, 
EDNRA). With BOND the only interaction found was with E2, based on a literature record, 
and with STRING several interaction partners were detected, among them the two ERs, 
ESR1 and ESR2, as shown in Figure 29. 
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Figure 29: GPR30 and potential interaction partners using the bioinformatics tool STRING for 
the prediction of protein–protein binding 
 
Bioinformatic approaches can be a first step for the determination of protein interaction 
partners, but they can yield false results. For that reason these tools can be considered only 
as a suggestion, and other methods available to probe protein–protein interactions have to 
be used, i.e. yeast two-hybrid screening (Y2H) or tandem affinity purification (TAP). One of 
the most frequently used is the Y2H analysis, which, using a genetically engineered strain of 
yeast, screens for physical interactions between two proteins. 
 
Therefore, Y2H screenings were performed in a preliminary study (PhD project of Jörg 
Isensee) using the N- or the C-terminal domain of GPR30 as baits and a human heart cDNA 
library as prey. The N- and C-domains were selected, since they are most likely to adopt the 
native conformation when isolated from the receptor. C-tails have frequently been used as 
baits in Y2H screening, allowing the identification of numerous interaction partners (Bockaert 
et al., 2003). In contrast, intracellular loops such as the I3 loop (third intracellular loop) that 
mainly contacts the G protein are unlikely to adopt the native conformation. In line with the 
observation that the N-terminal domain of GPR30 is not well conserved between species, no 
putative interaction partners were identified in the N-terminal screen. Using the C-tail as bait, 
two candidates were found: PALS1-associated tight junction protein (PATJ), and FUN14 
domain-containing 2 (FUNDC2). It is of note that these two newly identified proteins were not 
predicted by STRING, underlining the importance of an experimental approach.  
 
To confirm the interaction between GPR30 and the newly identified interacting proteins, 
co-immunoprecipitation studies were performed. With this technique, only the interaction 
between GPR30 and PATJ was confirmed, while an interaction with the second potential 
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partner, FUNDC2, could not be verified, indicating a false positive interaction in the Y2H 
screening (Results 3.3). One explanation could be that although yeast is a well established 
model organism, not all interactions in higher eukaryotes have equivalent counterparts in 
unicellular systems (Huang und Bader, 2009).  
 
PATJ, a component of the evolutionarily conserved multi-protein complex CRB-PALS1-PATJ 
(Crumbs–PALS1, protein associated with Lin seven 1, and also known as Stardust–PATJ), is 
essential in the determination of epithelial polarity, (Shin et al., 2007). In an earlier study it 
was shown that a reduction of PATJ expression by RNA interference (RNAi) in Madin–Darby 
canine kidney II (MDCKII) cells leads to delayed tight-junction formation as well as to defects 
in cell polarisation. The authors therefore concluded that PATJ regulates tight junction 
formation and epithelial polarity (Shin et al., 2005). 
Several splicing variants have been reported for PATJ that encode up to 10 PDZ domains 
and an N-terminal L27 domain (Roh et al., 2002), (Lemmers et al., 2002). Through its PDZ 
domains, PATJ interacts with tight junction proteins such as claudins and zonula occludens 3 
(ZO-3) (Lemmers et al., 2002). The L27 domain of PATJ binds a complex containing the 
protein associated with Lin seven 1 (PALS1), human lin-7 homologue (LIN-7) and crumbs 
protein homolog 3 (CRB3) (Roh et al., 2002), (Lemmers et al., 2002). The CRB3-PALS1-
PATJ complex is a key component required for cell polarisation and localises to tight 
junctions at the apical site of the cell (Straight et al., 2006). In recent work, the association of 
PATJ in a protein complex with the membrane-associated scaffold protein Angiomotin (Amot) 
and the RhoA GTPase exchange factor protein Syx was demonstrated. The Amot/PATJ/Syx 
complex is involved in the migration of endothelial cells during zebrafish angiogenesis, 
adding a new hint in understanding vessel formation and suggesting how a guidance signal 
might be translated into directional migration (Ernkvist et al., 2009). 
 
The potential interaction site of PATJ with the C-terminal domain of GPR30 found by Y2H 
screening was within the last three C-terminal PDZ domains (amino acids 1381–1801). 
Numerous GPCR-binding proteins have been identified, and PDZ-domain-containing 
proteins might constitute the largest class of proteins that is involved in organising GPCR 
signalling complexes, (Bockaert et al., 2004). PDZ domains (PDZ is a common motif, ∼90 
amino acids in length) are found in 126 proteins in the human genome. These proteins have 
many functions, from regulating the trafficking and targeting of proteins to assembling 
signalling complexes and networks designed for efficient and specific signal transduction 
(Nourry et al., 2003). 
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PDZ domains bind PDZ ligands expressed at the C termini of GPCRs (Bockaert et al., 2004). 
PDZ ligands usually include three or four amino acids at the C terminus, although residues 
upstream may influence the specificity (Sheng und Sala, 2001). The PDZ-binding sites have 
been divided into three classes: class I (-E-S/T-x-V/I), class II (-φ-x-φ), and class III (-ψ-x-φ), 
where ψ and φ are acidic and hydrophobic residues, respectively (Sheng und Sala, 2001). 
The C-terminal sequence of GPR30 (S-S-A-V) is highly conserved and similar to class I PDZ 
ligands. Indeed, Vaccaro et al. determined the consensus ligand for seven isolated PDZ 
domains of human PATJ by screening a random peptide library displayed on the phage 
lambda and found that each PDZ domain had a unique peptide binding preference (Vaccaro 
et al., 2001). Remarkably, the consensus ligand of the eighth PDZ domain was -S-x-V-, 
indicating that the C-tail of GPR30 probably interacts with this domain. Experiments with a 
deletion mutant of PATJ lacking this hypothetical interacting PDZ domain would help to 
answer this question. 
In conclusion, the C-terminal tail of GPR30 probably represents a PDZ ligand that specifically 
binds a PDZ domain of PATJ, and the interaction may tether GPR30 to a signalling complex 
in endothelial cells during the formation of new vessels.  
 
4.3   GPR30 expression in primary endothelial cells upon fluid shear 
stress (FSS) 
 
Blood vessels are responsible for the transport of oxygen, blood and plasma throughout the 
body and are composed of various different cell types: endothelial cells, smooth muscle cells 
and  fibroblasts. Endothelial cells make up the inner layer of the blood vessels and are in 
direct contact with flowing blood. Blood vessels may also become affected by disorders such 
as thrombosis, restenosis, and atherosclerosis, which greatly affect the general health of 
adults (Risau, 1997). For instance, arterial occlusion can lead to increase of fluid shear 
stress (FSS) caused by the strong difference between the high pre-occlusive and the very 
low post-occlusive pressure regions (Schaper, 2009). In addition, an artery's constriction 
causes less oxygenated blood to flowing to various parts of the body and therefore, since 
tissue are exposed to prolonged hypoxic conditions, this phenomenon leads to cellular 
remodelling (Rey und Semenza).  
The expression of GPR30 in vessels of different tissues has been clearly demonstrated. 
Isensee et al. showed that GPR30 is expressed in small arterial vessels of several tissues 
(e.g. kidney, heart, peritoneum, genital tract), in particular in an endothelial cell subpopulation 
(Isensee et al., 2009). In a previous publication from another group the expression of GPR30 
mRNA was reported for human internal mammary arteries and saphenous veins (Haas et al., 
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2007). Moreover, one decade earlier, GPR30 was cloned using human umbilical vein 
endothelial cells (HUVECs) exposed to fluid shear stress (FSS) (Takada et al., 1997). 
 
Therefore the idea to establish an in vitro human cell model to assess the role of GPR30 in 
vessels potentially related to pathological conditions and the two models of 
ischemia/reperfusion (I/R) or FSS were evaluated. 
 
Since GPR30 was found to be up-regulated in a rat cardiac cell line after 2 hours of post-
ischemic re-oxygenation (Kimura et al., 2001), the first model evaluated was an in vitro 
approach of hypoxia/reoxygenation (I/R) using primary endothelial cells (HUVECs) and their 
derived cell line (EAhy926). The cells were exposed to oxygen glucose deprivation (OGD) in 
an hypoxic chamber (0.5% oxygen) for different time points. With this model only a minimal 
(and statistically not significant) change in the expression of GPR30 was detected, probably 
due to the use of a different cell types, i.e. endothelial cells instead of cardiac cells. 
Nevertheless, in the last year several groups have adduced evidence supporting the 
involvement of GPR30 in ischaemia/reperfusion. In particular, it was demonstrated that 
GPR30 can protect the heart against I/R injury (Deschamps und Murphy, 2009), (Weil et al.), 
(Patel et al.) and can play a role in neuronal survival after ischemia (Lebesgue et al., 2009). 
 
Subsequently, the data found by Takada et al., where GPR30 was up-regulated in HUVECs 
subjected to FSS (Takada et al., 1997), were confirmed by using a different, more accurate, 
approach, namely by quantitative real-time PCR (qRT-PCR) instead of semi-quantitative 
reverse-transcription PCR (RT-PCR) and using as positive control the expression of ICAM-1, 
a gene known to respond to FSS (Nagel et al., 1994), (Results, Section 3.5). Secondly, other 
primary endothelial cells isolated from different vessels (HUAECs, HAoECs) and the HMECs 
were investigated under the same conditions of FSS, and there GPR30 was found to be up-
regulated as well. The fact that the data were statistically not significant (HUAECs, HMECs) 
or the statistical analysis presented high standard deviations (HAoECs), could be explained 
by the relatively small number of replicates and the different origins of these cells (venous, 
arterial, aortic and primary cells compared with a cell line). A general comment is that GPR30 
mRNA levels were very low in the stationary controls for all the cells analysed, but increased 
in a time- and shear-stress-dependent manner. These data are supported by much other 
work in which other GPCRs were found to be regulated by FSS, suggesting that GPCRs are 
involved in mediating primary mechanochemical signal transduction in endothelial cells (Gudi 
et al., 1996), (Chachisvilis et al., 2006). 
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4.4   Gene expression profiling in human microvascular endothelial 
cells over-expressing GPR30 upon fluid shear stress (FSS) 
 
Microarrays provide a powerful method for investigating the effects of stimuli on global gene 
expression (Schena et al., 1995). In the study described here, microarrays were chosen for 
analysing the gene expression of Human Microvascular Endothelial Cells (HMEC-1), 
transfected with GPR30 and/or PATJ and stimulated with FSS. HMEC-1 cells are isolated 
from a human microvascular endothelium, the dermal tissue, and, after immortalisation by 
SV40 transformation, they present the same morphology, phenotype and functional 
characteristics of normal human microvascular endothelial cells (Ades et al., 1992). HMEC-1 
cells were preferentially chosen over HUVECs since the over-expression or knock-down of 
GPR30 was very difficult to achieve in primary cells and further, as already mentioned 
before, the expression of GPR30 was found in endothelial cells of small arteries (Isensee et 
al., 2009). Therefore, HMEC-1 were chosen as the best cell type suitable for this 
experimental approach. 
After stimulation with FSS the different groups of HMEC-1 cells transfected with an empty 
vector, GPR30 and/or PATJ were analysed in seven different comparisons, always 
evaluating the influence of only one parameter (i.e. the effect of the FSS or the effect of the 
over-expression).  
The patterns of gene expression of HMEC-1 cells were compared with changes in 
expression induced by over-expression of GPR30 and/or PATJ upon FSS stimulation; 
unstimulated cells were used as controls. In general, FSS had the strongest effect on gene, 
expression while the effect of the over-expression was not so great. A summary of the array 
data is presented, using a Venn diagram representation, showing all hypothetically possible 
logical relations between a finite collection of sets. The Venn diagram is shown in Figure 30. 
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Figure 30: Venn diagram summarises number of genes of the seven different groups altered by 
FSS, over-expression of GPR30 and/or PATJ or both FSS and over-expression 
 
In the control group (HMEC-1 upon FSS, Results 3.6.1) the global gene expression profile 
identified 217 genes up-regulated and 6 down-regulated and, as expected, the FSS alone 
induced the expression of a large number of genes involved in the vascular remodelling (e.g. 
VEGF, KLF2, JAG1) (Thi et al., 2007), (Dekker et al., 2002), (McCormick et al., 2001) while 
in general, the over-expression of either one of the two proteins or both together did not lead 
to a massive change in regulation of gene expression. In particular, in the group of HMEC-1 
over-expressing GPR30 only a meagre number of deregulated genes was identified, e.g. 
HSPA6, MRGBP and Synaptojanin 1. One possible explanation for this low level of 
deregulation in gene expression could be the lack of activation of GPR30 due to the potential 
absence of a specific ligand. However, it is important to mention here that the whole set of 
microarray experiments was performed culturing the cells with 7.5% foetal bovine serum 
(FBS) medium and with phenol red, normally used as a pH indicator. It is well known that the 
serum contains traces of E2 (~18.5 pg/ml) (Santanam et al., 1998) and the presence of 
phenol red may interfere as a weak E2 agonist (Berthois et al., 1986). 
 
The need of E2 for the activation of GPR30 in mediating the global gene expression has 
already been the object of other investigations. Indeed, in 2009 in the first microarray study 
aimed at characterising the transcriptional response to GPR30 signalling, human SKBr3 
breast cancer cells (lacking both ERα and ERβ but expressing GPR30) were stimulated with 
E2 or with hydroxytamoxifen (OHT), which is an ER antagonist but a GPR30 agonist. The 
cells, cultured in phenol-red-free and serum-deprived media, were treated for only 1 hour to 
detect the primary response. The mRNA levels of 175 genes were raised by a factor of at 
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least 1.3 compared with uninduced control cells. Furthermore, if GPR30 expression was 
knocked down with an antisense RNA, a number of genes showed an at least 1.3-fold 
reduction in activity, demonstrating that any observed ligand-induced changes in gene 
expression were mediated by GPR30 (Pandey et al., 2009). 
On the other hand, another study was performed with MCF-7 (ERs- and GPR30-positive) 
breast cancer cells to investigate the effect of E2-mediated extranuclear-initiated pathways 
on global gene expression. The cells treated with the E2 antagonist ICI 182,780 or knocked 
down for ERα, using siRNA, abolished E2-mediated gene stimulation, whereas GPR30 
knock-down or treatment with the new identified selective GPR30 agonist G1 (Bologa et al., 
2006) did not influence the gene expression. In this setting, it was shown that nuclear ERs 
and not GPR30 are the mediators of the rapid extranuclear E2 signalling (Madak-Erdogan et 
al., 2008). 
 
If the over-expression itself did not affect global gene expression to a large extent, a very 
different situation was encountered when the aim of the comparisons was to look at the 
influence of FSS. Indeed, all the experiments comparing groups of unstimulated HMEC-1 
cells with similar cells subjected to FSS identified a large number of deregulated genes 
(Results, Sections 3.6.3, 3.6.5 and 3.6.7). Surprisingly, here the effect of the shear stress in 
regulating the gene expression of cells differed, according to whether the cells were 
untransfected or over-expressing GPR30 alone or together with PATJ. For instance, many 
deregulated genes of the group of HMEC-1 cells over-expressing GPR30 upon FSS were not 
deregulated in cells transfected with empty vector upon exposure to FSS. These included 
genes which play an important role in vascular function and morphogenesis, e.g. plexin D1 
(PLXND1) and troponin I type 3 (TNNI3).  
Interestingly, when these deregulated genes of the group of HMEC-1 cells over-expressing 
GPR30 upon exposure to FSS were analysed with Ingenuity Pathways Analysis, one of the 
new networks found was Network 4, related to “Neurological disease”, “Drug metabolism” 
and “Endocrine system development and function”. Here a central position was occupied by 
E2 (Figure 3.13) which was associated with several deregulated genes, e.g. RERG (ras-
related and E2-regulated growth inhibitor) and S100A13.  
For RERG, it was shown that its expression was significantly decreased or lost in primary 
human breast tumours in an E2-dependent manner (Finlin et al., 2001). In a study aimed at 
identifying TFAP2C (transcription factor AP-2 gamma) regulation of physiological responses 
to E2 treatment in breast carcinoma, it was reported that knock-down of TFAP2C could alter 
the response of ERα target genes to E2 exposure; among these were RERG and GPR30 
(this is in line with one of the first cloning approaches for GPR30, which was performed using 
ERs-positive breast carcinoma cell lines (Carmeci et al., 1997)) (Woodfield et al., 2007).  
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Moreover, network 4 is of particular interest, since the role of GPR30 as a new estrogen 
receptor is still quite controversial and, although in this experiment no E2 stimulation was 
applied, the over-expression of GPR30 together with the fluid shear stress induced the 
expression of genes involved in the endocrine system development and function. One 
possible reason could be the aforementioned use of medium containing FBS with traces of 
E2 in these microarray experiments and its eventual contribution in E2-mediated signalling. 
Another possible explanation could be that GPR30 is simply activated by the FSS stimulus in 
a ligand-independent manner. 
 
4.5   Conclusions and outlook 
 
GPCRs interact with, and are regulated by, several other proteins. Since to date nothing is 
known about the relation and interaction of GPR30 with other proteins, screening of a human 
heart cDNA library using the Y2H assay was performed. Several interaction partners were 
identified for GPR30, among them the PALS1-associated tight junction protein (PATJ) and 
the FUN14 domain containing 2 (FUNDC2).  
In this work, these interactions were verified by co-immunoprecipitation (CoIP) experiments. 
For this purpose, several protocols were evaluated in order to set up conditions suitable to 
solubilise and immunoprecipitate GPR30. Hence, the interaction of GPR30 with PATJ was 
confirmed in a mammalian system (HEK293 cells over-expressing the two proteins). In 
addition, a partial cellular co-localisation was observed in cells overexpressing GPR30 and 
PATJ. However, the interaction between GPR30 and FUNDC2 could not be validated, 
underlining the importance of a CoIP experiment after the identification of new interaction 
partners for a particular protein found by Y2H, bioinformatic approaches or other methods. 
The interaction GPR30-PATJ was found in yeast between the C-terminal domain of GPR30 
and the last three C-terminal PDZ domains of PATJ. A further step towards a better 
comprehension of this interaction could be the determination of which PDZ domain of PATJ 
is involved, using for instance deletion mutants – i.e., removing one or the other PDZ domain 
either in yeast and/or in mammalian system. 
 
Since a previous study has demonstrated the expression of GPR30 in endothelial cells of 
small vessels and one of the cloning approaches for GPR30 was using HUVECs exposed to 
FSS, the involvement of GPR30 in the vascular system was hypothesized. First, the up-
regulation of GPR30 in HUVECs upon FSS was investigated and confirmed. Thereafter, 
GPR30 expression was analysed in other endothelial cells (HUAECs, HAoECs and HMEC-1) 
and was found to be up-regulated upon exposure to FSS, suggesting that GPR30 may 
indeed play a key role in vascular physiology.  
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Finally, a human cellular system to assess the potential role of GPR30 and the functional 
consequences of its interaction with PATJ in a vascular model was established. On this 
basis, the role of GPR30 and/or PATJ in the FSS response was investigated in HMEC-1 cells 
at the genome-wide transcript level. Interestingly, a different panel of genes was deregulated 
by FSS in cells over-expressing GPR30 then by FSS alone. These included genes that  play 
an important role in vascular function and blood vessel morphogenesis (e.g. plexin D1 and 
troponin I type 3) and in the development and function of the endocrine system (e.g. RERG 
which is involved in E2 signalling). 
 
Based on the results of this work, some questions are still to be answered. Mainly, which is 
the interaction domain between GPR30 and PATJ; if  a dimerisation of GPR30 in endothelial 
cells exist and, if so, which are the molecular consequences? Can the identified downstream 
effectors of GPR30 upon FSS be confirmed and, if so, which are their functional relevance? 
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6     APPENDICES 
 
6.1   Appendix result 3.6  
6.1.1 GPR30 knock-down in HUVECs 
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Figure 31: GPR30 knock-down in HUVECs  
Relative gene expression levels of GPR30 (left panel) and lamin A/C (right panel) by real time-PCR in 
HUVECs transfected with different siRNAs. When the gene expression was measured using GPR30 
primers, the expression of GPR30 was found to be reduced (left panel) but this was also the case for 
the positive control, lamin A/C. Therefore the silencing effect was considered to be an artefact. In 
contrast, when lamin A/C primers were used, a large reduction in the relative expression of lamin A/C 
was found (right panel). 
 
6.1.2 pEGFP-C1 transfection in HUVECs 
 
 
 
Figure 32: HUVECs transiently transfected with GPR30-EGFP 
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6.1.3 GPR30 knock-down in HMECs 
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Figure 33: GPR30 knock-down in HMECs 
Relative gene expression levels of GPR30 (left panel) and lamin A/C (right panel) by real time-PCR in 
HMECs transfected with different siRNAs. When the gene expression was measured using GPR30 
primers, GPR30 was not found to be reduced (left panel). Differently, using lamin A/C primers, a high 
reduction of the relative expression of lamin A/C was found (right panel). 
 
6.1.4 pEGFP-C1 transfection in HMECs 
 
 
 
Figure 34: HMECs transiently transfected with GPR30-EGFP 
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6.2   Appendix table 6. Effects of FSS on HMEC-1 cells 
Table 13: Deregulated genes in HMEC-1 cells upon FSS 
Change ratios (x-fold changes) are indicated in the column Ratio and q values at a ‘false discovery’ 
rate (FDR) of < 5%. 
ILLUMINA_ID Gene ID Gene Name Ratio 
q-
value(%) 
ILMN_2314169 PTHLH PARATHYROID HORMONE-LIKE HORMONE 7.61 0.00 
ILMN_1684306 S100A4 
S100 CALCIUM BINDING PROTEIN A4 (CALCIUM PROTEIN, 
CALVASCULIN, METASTASIN, MURINE PLACENTAL HOMOLOG) 4.68 0.00 
ILMN_1665035 KRT14 
KERATIN 14 (EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA, 
KOEBNER) 4.57 0.00 
ILMN_1765446 EMP3 EPITHELIAL MEMBRANE PROTEIN 3 4.31 0.00 
ILMN_1696048 C13orf33 HYPOTHETICAL PROTEIN FLJ14834 4.22 0.00 
ILMN_1787186 NOV NEPHROBLASTOMA OVEREXPRESSED GENE 4.12 0.00 
ILMN_1811790 FOXS1 FORKHEAD-LIKE 18 (DROSOPHILA) 4.06 0.00 
ILMN_1796423 CLIC3 CHLORIDE INTRACELLULAR CHANNEL 3 4.05 0.00 
ILMN_1706643 COL6A3 COLLAGEN, TYPE VI, ALPHA 3 3.92 0.00 
ILMN_1689431 APCDD1L HYPOTHETICAL PROTEIN FLJ90166 3.90 0.00 
ILMN_2041190 F2RL1 COAGULATION FACTOR II (THROMBIN) RECEPTOR-LIKE 1 3.87 0.00 
ILMN_1802205 RHOB RAS HOMOLOG GENE FAMILY, MEMBER B 3.81 0.00 
ILMN_1763837 ANPEP 
ALANYL (MEMBRANE) AMINOPEPTIDASE (AMINOPEPTIDASE N, 
AMINOPEPTIDASE M, MICROSOMAL AMINOPEPTIDASE, CD13, P150) 3.72 0.00 
ILMN_1714170 SPSB1 
SPLA/RYANODINE RECEPTOR DOMAIN AND SOCS BOX CONTAINING 
1 3.66 0.00 
ILMN_1800512 HMOX1 HEME OXYGENASE (DECYCLING) 1 3.62 0.00 
ILMN_1738742 PLAT PLASMINOGEN ACTIVATOR, TISSUE 3.46 0.00 
ILMN_1709674 GFPT2 GLUTAMINE-FRUCTOSE-6-PHOSPHATE TRANSAMINASE 2 3.42 0.00 
ILMN_2384122 GPR56 G PROTEIN-COUPLED RECEPTOR 56 3.30 0.00 
ILMN_1708534 PAX8 PAIRED BOX GENE 8 3.27 0.00 
ILMN_2413158 PODXL PODOCALYXIN-LIKE 3.17 0.00 
ILMN_2352097 GPR56 G PROTEIN-COUPLED RECEPTOR 56 3.07 0.00 
ILMN_1791679 DNER DELTA-NOTCH-LIKE EGF REPEAT-CONTAINING TRANSMEMBRANE 2.91 0.00 
ILMN_1735930 KLF2 KRUPPEL-LIKE FACTOR 2 (LUNG) 2.83 0.00 
ILMN_1803728 SLC35E4 SOLUTE CARRIER FAMILY 35, MEMBER E4 2.79 0.00 
ILMN_1665792 ITGA2 INTEGRIN, ALPHA 2 (CD49B, ALPHA 2 SUBUNIT OF VLA-2 RECEPTOR) 2.71 0.00 
ILMN_1807652 STRA6 STIMULATED BY RETINOIC ACID GENE 6 HOMOLOG (MOUSE) 2.69 0.00 
ILMN_1760160 STX1A SYNTAXIN 1A (BRAIN) 2.68 0.00 
ILMN_1768534 BHLHB2 BASIC HELIX-LOOP-HELIX DOMAIN CONTAINING, CLASS B, 2 2.66 0.00 
ILMN_1711311 PODXL PODOCALYXIN-LIKE 2.62 0.00 
ILMN_1669046 FOXQ1 FORKHEAD BOX Q1 2.62 0.00 
ILMN_2137789 KLF4 KRUPPEL-LIKE FACTOR 4 (GUT) 2.59 0.00 
ILMN_1657111 C14orf78 CHROMOSOME 14 OPEN READING FRAME 78 2.58 0.00 
ILMN_1679929 KLF13 KRUPPEL-LIKE FACTOR 13 2.52 0.00 
ILMN_1701461 TIMP3 
TIMP METALLOPEPTIDASE INHIBITOR 3 (SORSBY FUNDUS 
DYSTROPHY, PSEUDOINFLAMMATORY) 2.52 0.00 
ILMN_1760778 ENG ENDOGLIN (OSLER-RENDU-WEBER SYNDROME 1) 2.47 0.00 
ILMN_2269136 CENTG3 CENTAURIN, GAMMA 3 2.35 0.00 
ILMN_1712708 TRIM47 TRIPARTITE MOTIF-CONTAINING 47 2.31 0.00 
ILMN_2407703 SYN1 SYNAPSIN I 2.31 0.00 
ILMN_1762803 RFXDC2 REGULATORY FACTOR X DOMAIN CONTAINING 2 2.25 0.00 
ILMN_1807689 PKNOX2 PBX/KNOTTED 1 HOMEOBOX 2 2.20 0.00 
ILMN_1791447 CXCL12 CHEMOKINE (C-X-C MOTIF) LIGAND 12  2.17 0.00 
ILMN_1732609 KIAA1539 KIAA1539 PROTEIN 2.08 0.00 
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ILMN_1761425 OLFML2A OLFACTOMEDIN-LIKE 2A 2.05 0.00 
ILMN_1775501 IL1B INTERLEUKIN 1, BETA 2.03 0.00 
ILMN_1732197 MN1 MENINGIOMA (DISRUPTED IN BALANCED TRANSLOCATION) 1 2.00 0.00 
ILMN_1703531 EDG3 
ENDOTHELIAL DIFFERENTIATION, SPHINGOLIPID G-PROTEIN-
COUPLED RECEPTOR, 3 1.99 0.00 
ILMN_1756595 SH3TC1 SH3 DOMAIN AND TETRATRICOPEPTIDE REPEATS 1 1.95 0.00 
ILMN_1736178 AEBP1 AE BINDING PROTEIN 1 1.94 0.00 
ILMN_1785061 EPHB2 EPH RECEPTOR B2 1.94 0.00 
ILMN_1753286 MYO19 MYOSIN HEAD DOMAIN CONTAINING 1 1.91 0.00 
ILMN_1748124 TSC22D3 TSC22 DOMAIN FAMILY, MEMBER 3 1.91 0.00 
ILMN_1751576 TEK 
TEK TYROSINE KINASE, ENDOTHELIAL (VENOUS MALFORMATIONS, 
MULTIPLE CUTANEOUS AND MUCOSAL) 1.90 0.00 
ILMN_2111237 MN1 MENINGIOMA (DISRUPTED IN BALANCED TRANSLOCATION) 1 1.90 0.00 
ILMN_1787567 TSC22D1 TSC22 DOMAIN FAMILY, MEMBER 1 1.90 0.00 
ILMN_1682081 RNF19B IBR DOMAIN CONTAINING 3 1.80 0.00 
ILMN_1760412 SHISA2 TRANSMEMBRANE PROTEIN 46 1.75 0.00 
ILMN_1754842 DLGAP4 DISCS, LARGE (DROSOPHILA) HOMOLOG-ASSOCIATED PROTEIN 4 1.64 0.00 
ILMN_1717809 RNF24 RING FINGER PROTEIN 24 1.61 0.00 
ILMN_1673113 F2RL1 COAGULATION FACTOR II (THROMBIN) RECEPTOR-LIKE 1 3.96 0.91 
ILMN_1844408 PLXNA2 PLEXIN A2 3.45 0.91 
ILMN_2311537 HMGA1 HIGH MOBILITY GROUP AT-HOOK 1 2.97 0.91 
ILMN_1713449 TBX3 T-BOX 3 (ULNAR MAMMARY SYNDROME) 2.85 0.91 
ILMN_1659599 ADC ARGININE DECARBOXYLASE 2.84 0.91 
ILMN_1723971 SLC29A1 
SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTERS), 
MEMBER 1 2.80 0.91 
ILMN_1725852 S100A2 S100 CALCIUM BINDING PROTEIN A2 2.66 0.91 
ILMN_2337058 PORCN PORCUPINE HOMOLOG (DROSOPHILA) 2.66 0.91 
ILMN_2338963 SLC29A1 
SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTERS), 
MEMBER 1 2.61 0.91 
ILMN_1772824 WNT5B WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 5B 2.60 0.91 
ILMN_2050183 MYLK2 MYOSIN LIGHT CHAIN KINASE 2, SKELETAL MUSCLE 2.51 0.91 
ILMN_2401873 DUSP10 DUAL SPECIFICITY PHOSPHATASE 10 2.39 0.91 
ILMN_2082585 SNAI2 SNAIL HOMOLOG 2 (DROSOPHILA) 2.35 0.91 
ILMN_1652185 IL4R INTERLEUKIN 4 RECEPTOR 2.25 0.91 
ILMN_1762106 MMP2 
MATRIX METALLOPEPTIDASE 2 (GELATINASE A, 72KDA GELATINASE, 
72KDA TYPE IV COLLAGENASE) 2.24 0.91 
ILMN_1766334 MB MYOGLOBIN 2.18 0.91 
ILMN_1706969 C6orf65 CHROMOSOME 6 OPEN READING FRAME 65 2.14 0.91 
ILMN_1815130 MICALL1 MICAL-LIKE 1 2.10 0.91 
ILMN_1803811 TRIB1 TRIBBLES HOMOLOG 1 (DROSOPHILA) 2.07 0.91 
ILMN_1715684 LAMB3 LAMININ, BETA 3 2.05 0.91 
ILMN_2127298 F2RL3 COAGULATION FACTOR II (THROMBIN) RECEPTOR-LIKE 3 2.04 0.91 
ILMN_2176502 UNC5B UNC-5 HOMOLOG B (C. ELEGANS) 2.03 0.91 
ILMN_1674160 BIN1 BRIDGING INTEGRATOR 1 2.00 0.91 
ILMN_1728049 S100A16 S100 CALCIUM BINDING PROTEIN A16 1.96 0.91 
ILMN_1751464 TNFSF9 TUMOR NECROSIS FACTOR (LIGAND) SUPERFAMILY, MEMBER 9 1.96 0.91 
ILMN_1807919 TNS1 TENSIN 1 1.94 0.91 
ILMN_1772612 ANGPTL2 ANGIOPOIETIN-LIKE 2 1.93 0.91 
ILMN_1751161 COL7A1 
COLLAGEN, TYPE VII, ALPHA 1 (EPIDERMOLYSIS BULLOSA, 
DYSTROPHIC, DOMINANT AND RECESSIVE) 1.90 0.91 
ILMN_2309245 BIN1 BRIDGING INTEGRATOR 1 1.89 0.91 
ILMN_1771627 ZMIZ1 RETINOIC ACID INDUCED 17 1.89 0.91 
ILMN_1737163 SH3BGRL3 SH3 DOMAIN BINDING GLUTAMIC ACID-RICH PROTEIN LIKE 3 1.87 0.91 
ILMN_1745256 CXXC5 CXXC FINGER 5 1.87 0.91 
ILMN_1699651 IL6 INTERLEUKIN 6 (INTERFERON, BETA 2) 1.86 0.91 
ILMN_1701204 VEGFC VASCULAR ENDOTHELIAL GROWTH FACTOR C 1.86 0.91 
ILMN_2359287 ITGA6 INTEGRIN, ALPHA 6 1.86 0.91 
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ILMN_1705750 TGM2 
TRANSGLUTAMINASE 2 (C POLYPEPTIDE, PROTEIN-GLUTAMINE-
GAMMA-GLUTAMYLTRANSFERASE) 1.84 0.91 
ILMN_1668345 OAF OAF HOMOLOG (DROSOPHILA) 1.82 0.91 
ILMN_1700384 KIAA1522 KIAA1522 1.80 0.91 
ILMN_1742187 MAN1A1 MANNOSIDASE, ALPHA, CLASS 1A, MEMBER 1 1.77 0.91 
ILMN_1787919 PARVB PARVIN, BETA 1.76 0.91 
ILMN_1795342 MLPH MELANOPHILIN 1.75 0.91 
ILMN_1655595 SERPINE2 
SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN, PLASMINOGEN 
ACTIVATOR INHIBITOR TYPE 1), MEMBER 2 1.72 0.91 
ILMN_2289924 TRAK1 TRAFFICKING PROTEIN, KINESIN BINDING 1 1.69 0.91 
ILMN_1682717 IER3 IMMEDIATE EARLY RESPONSE 3 1.68 0.91 
ILMN_1732151 COL6A1 COLLAGEN, TYPE VI, ALPHA 1 1.63 0.91 
ILMN_1734276 PMEPA1 TRANSMEMBRANE, PROSTATE ANDROGEN INDUCED RNA 5.39 1.70 
ILMN_1692335 ELK3 ELK3, ETS-DOMAIN PROTEIN (SRF ACCESSORY PROTEIN 2) 2.42 1.70 
ILMN_1790228 FURIN FURIN (PAIRED BASIC AMINO ACID CLEAVING ENZYME) 2.30 1.70 
ILMN_1770467 GAGE7 G ANTIGEN 5 2.22 1.70 
ILMN_1714445 SLC6A9 
SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, 
GLYCINE), MEMBER 9 2.03 1.70 
ILMN_2066151 TEK 
TEK TYROSINE KINASE, ENDOTHELIAL (VENOUS MALFORMATIONS, 
MULTIPLE CUTANEOUS AND MUCOSAL) 1.90 1.70 
ILMN_2086077 JUNB JUN B PROTO-ONCOGENE 2.83 1.96 
ILMN_1663454 PKP1 
PLAKOPHILIN 1 (ECTODERMAL DYSPLASIA/SKIN FRAGILITY 
SYNDROME) 2.72 1.96 
ILMN_1663080 LFNG LUNATIC FRINGE HOMOLOG (DROSOPHILA) 2.67 1.96 
ILMN_2201596 CYTL1 CYTOKINE-LIKE 1 2.65 1.96 
ILMN_1665865 IGFBP4 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4 2.27 1.96 
ILMN_1728009 TMEM171 PROLINE-RICH PROTEIN PRP2 1.95 1.96 
ILMN_1750711 MYO19 MYOSIN HEAD DOMAIN CONTAINING 1 1.83 1.96 
ILMN_1704154 TNFRSF19 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 19 1.81 1.96 
ILMN_1677432 SRGAP1 SLIT-ROBO RHO GTPASE ACTIVATING PROTEIN 1 1.80 1.96 
ILMN_1702487 SGK SERUM/GLUCOCORTICOID REGULATED KINASE 1.76 1.96 
ILMN_1761540 SEMA3F 
SEMA DOMAIN, IMMUNOGLOBULIN DOMAIN (IG), SHORT BASIC 
DOMAIN, SECRETED, (SEMAPHORIN) 3F 1.72 1.96 
ILMN_2386100 BUB3 
BUB3 BUDDING UNINHIBITED BY BENZIMIDAZOLES 3 HOMOLOG 
(YEAST) 1.65 1.96 
ILMN_1729596 C14orf151 CHROMOSOME 14 OPEN READING FRAME 151 1.59 1.96 
ILMN_2309156 PMEPA1 TRANSMEMBRANE, PROSTATE ANDROGEN INDUCED RNA 5.53 2.36 
ILMN_1675453 HHIP HEDGEHOG INTERACTING PROTEIN 3.42 2.36 
ILMN_1661194 CLDN14 CLAUDIN 14 3.40 2.36 
ILMN_2203891 SMAD7 SMAD, MOTHERS AGAINST DPP HOMOLOG 7 (DROSOPHILA) 2.30 2.36 
ILMN_1685699 PRSS3 PROTEASE, SERINE, 3 (MESOTRYPSIN) 2.16 2.36 
ILMN_1744268 PLEC1 PLECTIN 1, INTERMEDIATE FILAMENT BINDING PROTEIN 500KDA 2.13 2.36 
ILMN_1671142 GPR68 G PROTEIN-COUPLED RECEPTOR 68 1.78 2.36 
ILMN_1792014 FAM70B FAMILY WITH SEQUENCE SIMILARITY 70, MEMBER B 1.77 2.36 
ILMN_1700690 VAT1 VESICLE AMINE TRANSPORT PROTEIN 1 HOMOLOG (T CALIFORNICA) 1.72 2.36 
ILMN_1696360 CTSB CATHEPSIN B 1.72 2.36 
ILMN_1694432 CRIP2 CYSTEINE-RICH PROTEIN 2 1.67 2.36 
ILMN_1666306 SRRD SIMILAR TO SRR1-LIKE PROTEIN 1.66 2.36 
ILMN_1712545 S100A3 S100 CALCIUM BINDING PROTEIN A3 3.31 2.52 
ILMN_1741917 OSCAR OSTEOCLAST-ASSOCIATED RECEPTOR 2.55 2.52 
ILMN_1729455 EML1 ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 1 2.28 2.52 
ILMN_1666924 PINK1 PTEN INDUCED PUTATIVE KINASE 1 2.27 2.52 
ILMN_1750664 PPT2 PALMITOYL-PROTEIN THIOESTERASE 2 2.19 2.52 
ILMN_2308338 BMF BCL2 MODIFYING FACTOR 1.95 2.52 
ILMN_1669362 IGFBP6 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 6 1.83 2.52 
ILMN_1711566 TIMP1 TIMP METALLOPEPTIDASE INHIBITOR 1 1.83 2.52 
ILMN_1656837 RBP1 RETINOL BINDING PROTEIN 1, CELLULAR 1.81 2.52 
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ILMN_2340052 NCOR2 NUCLEAR RECEPTOR CO-REPRESSOR 2 1.79 2.52 
ILMN_2367258 SMOX SPERMINE OXIDASE 1.73 2.52 
ILMN_2082244 FOXK1 FORKHEAD BOX K1 1.50 2.52 
ILMN_1658709 LAMB1 LAMININ, BETA 1 1.46 2.52 
ILMN_1700448 SIM2 SINGLE-MINDED HOMOLOG 2 (DROSOPHILA) 2.13 2.65 
ILMN_2111932 SERINC2 SERINE INCORPORATOR 2 1.90 2.65 
ILMN_1654563 EFNB1 EPHRIN-B1 1.87 2.65 
ILMN_2129161 LRRC32 LEUCINE RICH REPEAT CONTAINING 32 2.11 2.89 
ILMN_2408576 FAM129B CHROMOSOME 9 OPEN READING FRAME 88 2.04 2.89 
ILMN_1713499 WISP1 WNT1 INDUCIBLE SIGNALING PATHWAY PROTEIN 1 1.91 2.89 
ILMN_2365307 CD276 CD276 ANTIGEN 1.75 2.89 
ILMN_1652413 UCN2 UROCORTIN 2 2.50 3.37 
ILMN_1789358 ZNF628 ZINC FINGER PROTEIN 628 2.20 3.37 
ILMN_1707434 LOC653778 SIMILAR TO SOLUTE CARRIER FAMILY 25, MEMBER 37 2.20 3.37 
ILMN_1716265 PGM2L1 PHOSPHOGLUCOMUTASE 2-LIKE 1 2.08 3.37 
ILMN_1807169 TINAGL1 TUBULOINTERSTITIAL NEPHRITIS ANTIGEN-LIKE 1 2.03 3.37 
ILMN_1803686 ADA ADENOSINE DEAMINASE 1.84 3.37 
ILMN_1704353 IGSF3 IMMUNOGLOBULIN SUPERFAMILY, MEMBER 3 1.77 3.37 
ILMN_2110561 IFNA8 INTERFERON, ALPHA 8 1.72 3.37 
ILMN_1695432 TPST2 TYROSYLPROTEIN SULFOTRANSFERASE 2 1.72 3.37 
ILMN_1661755 FAM129B CHROMOSOME 9 OPEN READING FRAME 88 1.67 3.37 
ILMN_1731736 RIN3 RAS AND RAB INTERACTOR 3 1.56 3.37 
ILMN_1793302 WDR4 WD REPEAT DOMAIN 4 1.54 3.37 
ILMN_1774547 M-RIP MYOSIN PHOSPHATASE-RHO INTERACTING PROTEIN 1.39 3.37 
ILMN_1687721 PROC 
PROTEIN C (INACTIVATOR OF COAGULATION FACTORS VA AND 
VIIIA) 4.03 3.54 
ILMN_2188722 GLS GLUTAMINASE 2.75 3.54 
ILMN_1743367 FZD4 FRIZZLED HOMOLOG 4 (DROSOPHILA) 2.67 3.54 
ILMN_1676689 PPT2 PALMITOYL-PROTEIN THIOESTERASE 2 2.39 3.54 
ILMN_1677273 TH TYROSINE HYDROXYLASE 2.22 3.54 
ILMN_2383611 PTPRE PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, E 2.15 3.54 
ILMN_1743966 BCL9L B-CELL CLL/LYMPHOMA 9-LIKE 2.13 3.54 
ILMN_2098643 FADS3 FATTY ACID DESATURASE 3 1.85 3.54 
ILMN_1752046 SH2B3 LYMPHOCYTE ADAPTOR PROTEIN 1.83 3.54 
ILMN_1698419 NCOR2 NUCLEAR RECEPTOR CO-REPRESSOR 2 1.82 3.54 
ILMN_1719236 CDH5 CADHERIN 5, TYPE 2, VE-CADHERIN (VASCULAR EPITHELIUM) 1.78 3.54 
ILMN_1703955 FBXO32 F-BOX PROTEIN 32 1.77 3.54 
ILMN_1796755 ITGB5 INTEGRIN, BETA 5 1.75 3.54 
ILMN_2214910 EPHB4 EPH RECEPTOR B4 1.66 3.54 
ILMN_2318638 TGIF1 TGFB-INDUCED FACTOR (TALE FAMILY HOMEOBOX) 1.46 3.54 
ILMN_2357134 SPHK1 SPHINGOSINE KINASE 1 2.59 4.47 
ILMN_1766159 MIER2 KIAA1193 2.53 4.47 
ILMN_2415157 ARID5A AT RICH INTERACTIVE DOMAIN 5A (MRF1-LIKE) 2.44 4.47 
ILMN_1672295 ZC3H12A ZINC FINGER CCCH-TYPE CONTAINING 12A 2.27 4.47 
ILMN_1745964 IRAK2 INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 2 2.02 4.47 
ILMN_1691376 JAG1 JAGGED 1 (ALAGILLE SYNDROME) 1.87 4.47 
ILMN_2096719 GRK5 G PROTEIN-COUPLED RECEPTOR KINASE 5 1.85 4.47 
ILMN_1758542 BMP1 BONE MORPHOGENETIC PROTEIN 1 1.83 4.47 
ILMN_1702363 SULF1 SULFATASE 1 1.75 4.47 
ILMN_1754660 C10orf56 CHROMOSOME 10 OPEN READING FRAME 56 1.75 4.47 
ILMN_1671404 SVIL SUPERVILLIN 1.73 4.47 
ILMN_1697559 G6PD GLUCOSE-6-PHOSPHATE DEHYDROGENASE 1.72 4.47 
ILMN_1735052 ULK1 UNC-51-LIKE KINASE 1 (C. ELEGANS) 1.65 4.47 
ILMN_1742450 TAPBP TAP BINDING PROTEIN (TAPASIN) 1.54 4.47 
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ILMN_2374340 PLAUR PLASMINOGEN ACTIVATOR, UROKINASE RECEPTOR 1.39 4.47 
ILMN_2212878 ESM1 ENDOTHELIAL CELL-SPECIFIC MOLECULE 1 9.92 4.71 
ILMN_1722726 RICS RHO GTPASE-ACTIVATING PROTEIN 2.94 4.71 
ILMN_1741404 MSC MUSCULIN (ACTIVATED B-CELL FACTOR-1) 2.49 4.71 
ILMN_1803825 CXCL12 
CHEMOKINE (C-X-C MOTIF) LIGAND 12 (STROMAL CELL-DERIVED 
FACTOR 1) 2.31 4.71 
ILMN_2376403 TSC22D3 TSC22 DOMAIN FAMILY, MEMBER 3 2.20 4.71 
ILMN_1655740 SNAI2 SNAIL HOMOLOG 2 (DROSOPHILA) 2.19 4.71 
ILMN_1789505 ITPR1 INOSITOL 1,4,5-TRIPHOSPHATE RECEPTOR, TYPE 1 2.12 4.71 
ILMN_1659913 ISG20 INTERFERON STIMULATED EXONUCLEASE GENE 20KDA 2.08 4.71 
ILMN_1656940 ABLIM3 ACTIN BINDING LIM PROTEIN FAMILY, MEMBER 3 2.01 4.71 
ILMN_1714592 CDA CYTIDINE DEAMINASE 1.93 4.71 
ILMN_1687301 VCAN CHONDROITIN SULFATE PROTEOGLYCAN 2 (VERSICAN) 1.90 4.71 
ILMN_1772821 KIAA1671 KIAA1671 PROTEIN 1.77 4.71 
ILMN_1756676 PHF19 PHD FINGER PROTEIN 19 1.75 4.71 
ILMN_1724059 GAS2L1 GROWTH ARREST-SPECIFIC 2 LIKE 1 1.71 4.71 
ILMN_1795442 LAMA4 LAMININ, ALPHA 4 1.68 4.71 
ILMN_2064606 TBC1D2B TBC1 DOMAIN FAMILY, MEMBER 2B 1.57 4.71 
ILMN_1766359 GATAD2B GATA ZINC FINGER DOMAIN CONTAINING 2B 1.52 4.71 
ILMN_1803277 MVP MAJOR VAULT PROTEIN 1.42 4.71 
ILMN_1664434 TCF3 
TRANSCRIPTION FACTOR 3 (E2A IMMUNOGLOBULIN ENHANCER 
BINDING FACTORS E12/E47) 1.42 4.71 
ILMN_1794598 SCHIP1 SCHWANNOMIN INTERACTING PROTEIN 1 1.40 4.71 
     
ILMN_1795325 ACTG2 actin, gamma 2, smooth muscle, enteric -3.23 0.00 
ILMN_1671703 ACTA2 actin, alpha 2, smooth muscle, aorta -3.03 0.00 
ILMN_2354478 CYFIP2 cytoplasmic FMR1 interacting protein 2 -1.85 1.96 
ILMN_1785284 ALDH6A1 aldehyde dehydrogenase 6 family, member A1 -2.22 2.65 
ILMN_1725726 DHRS2 dehydrogenase/reductase (SDR family) member 2 -2.33 2.65 
ILMN_1763382 NPPB natriuretic peptide precursor B -3.85 2.65 
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6.3   Appendix table 8. Effects of over-expression of GPR30 in 
HMEC-1 cells upon FSS 
Table 14: Deregulated genes in HMEC-1 cells over-expressing GPR30 upon FSS 
Change ratios (x-fold changes) are indicated in the column Ratio and q values at a ‘false discovery’ 
rate (FDR) of < 5%. 
ILLUMINA_ID Gene ID Gene Name Ratio 
q-
value(%) 
ILMN_1766264 PI16 peptidase inhibitor 16 13.61 0.00 
ILMN_1787186 NOV nephroblastoma overexpressed gene 6.25 0.00 
ILMN_1802205 RHOB ras homolog gene family, member B 4.33 0.00 
ILMN_1738742 PLAT plasminogen activator, tissue 4.25 0.00 
ILMN_1696048 C13orf33 chromosome 13 open reading frame 33 3.57 0.00 
ILMN_1692177 TSC22D1 TSC22 domain family, member 1 3.55 0.00 
ILMN_1763837 ANPEP alanyl (membrane) aminopeptidase 3.49 0.00 
ILMN_1745132 GDF11 growth differentiation factor 11 3.46 0.00 
ILMN_2150851 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 3.40 0.00 
ILMN_1844408 PLXNA2 plexin A2 3.34 0.00 
ILMN_2413158 PODXL podocalyxin-like 3.17 0.00 
ILMN_2137789 KLF4 Kruppel-like factor 4 (gut) 3.13 0.00 
ILMN_2276952 TSC22D3 
TSC22 domain family, member 3; GRAM domain containing 
4 2.03 0.00 
ILMN_1807147 RC3H1 ring finger and CCCH-type zinc finger domains 1 1.82 0.00 
ILMN_1681724 FPGS folylpolyglutamate synthase 1.60 0.00 
ILMN_1717101 MINK1 misshapen-like kinase 1 (zebrafish) 1.33 0.00 
ILMN_1675546 KRTAP27-1 keratin associated protein 27-1 1.31 0.00 
ILMN_1720243 IL25 interleukin 25 1.27 0.00 
ILMN_1749304 LOC643389   1.19 0.00 
ILMN_1747314 MYO5B 
similar to acetyl-Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A thiolase);  1.16 0.00 
ILMN_1716857 LOC649762   1.12 0.00 
ILMN_1662016 SCRN2 secernin 2 1.01 0.00 
ILMN_2314169 PTHLH parathyroid hormone-like hormone 5.47 1.05 
ILMN_2376403 TSC22D3 
TSC22 domain family, member 3; GRAM domain containing 
4 3.63 1.05 
ILMN_2189027 LIPG lipase, endothelial 3.43 1.05 
ILMN_2307861 COL6A3 collagen, type VI, alpha 3 3.10 1.05 
ILMN_1684306 S100A4 S100 calcium binding protein A4 3.08 1.05 
ILMN_1759787 THBD thrombomodulin 2.94 1.05 
ILMN_1765446 EMP3 epithelial membrane protein 3 2.93 1.05 
ILMN_2363591 SDCBP syndecan binding protein (syntenin) 2.91 1.05 
ILMN_1709674 GFPT2 glutamine-fructose-6-phosphate transaminase 2 2.91 1.05 
ILMN_1913060   chemokine-like receptor 1 2.90 1.05 
ILMN_1787813 SLC5A3 
solute carrier family 5 (sodium/myo-inositol cotransporter), 
member 3 2.85 1.05 
ILMN_1726448 MMP1 matrix metallopeptidase 1 (interstitial collagenase) 2.82 1.05 
ILMN_1701461 TIMP3 TIMP metallopeptidase inhibitor 3 2.80 1.05 
ILMN_1708363 LOXL1 lysyl oxidase-like 1 2.77 1.05 
ILMN_1791679 DNER delta/notch-like EGF repeat containing 2.72 1.05 
ILMN_1712545 S100A3 S100 calcium binding protein A3 2.70 1.05 
ILMN_1665660 C11orf17 chromosome 11 open reading frame 17 2.70 1.05 
ILMN_1706643 COL6A3 collagen, type VI, alpha 3 2.67 1.05 
ILMN_2215119 SYNJ2 synaptojanin 2 2.61 1.05 
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ILMN_2384122 GPR56 G protein-coupled receptor 56 2.61 1.05 
ILMN_1665449 ROBO4 roundabout homolog 4, magic roundabout (Drosophila) 2.56 1.05 
ILMN_1673113 F2RL1 coagulation factor II (thrombin) receptor-like 1 2.56 1.05 
ILMN_2111237 MN1 meningioma (disrupted in balanced translocation) 1 2.48 1.05 
ILMN_2329927 ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 2.45 1.05 
ILMN_1756595 SH3TC1 SH3 domain and tetratricopeptide repeats 1 2.42 1.05 
ILMN_1657111 C14orf78 AHNAK nucleoprotein 2 2.41 1.05 
ILMN_1715863 MLKL mixed lineage kinase domain-like 2.36 1.05 
ILMN_1774685 IL24 interleukin 24 2.31 1.05 
ILMN_2310896 NLRP3 NLR family, pyrin domain containing 3 2.27 1.05 
ILMN_1732197 MN1 meningioma (disrupted in balanced translocation) 1 2.26 1.05 
ILMN_1735930 KLF2 Kruppel-like factor 2 (lung) 2.24 1.05 
ILMN_1722294 CPNE8 copine VIII 2.24 1.05 
ILMN_1758067 RGS4 regulator of G-protein signaling 4 2.20 1.05 
ILMN_1689037 LIPG lipase, endothelial 2.17 1.05 
ILMN_1748751 NLF2 family with sequence similarity 148, member B 2.08 1.05 
ILMN_1749944 DLGAP4 discs, large (Drosophila) homolog-associated protein 4 2.08 1.05 
ILMN_1757825 ZNF230 zinc finger protein 230 2.03 1.05 
ILMN_2169983 ATAD1 ATPase family, AAA domain containing 1 2.00 1.05 
ILMN_1808537 LOC339977 leucine rich repeat containing 66 1.99 1.05 
ILMN_1839422 JRK jerky homolog (mouse) 1.98 1.05 
ILMN_2313946 CPNE7 copine VII 1.94 1.05 
ILMN_1801923 ATF1 activating transcription factor 1 1.91 1.05 
ILMN_1662895 C14orf153 chromosome 14 open reading frame 153 1.91 1.05 
ILMN_1669928 ARHGEF16 Rho guanine exchange factor (GEF) 16 1.89 1.05 
ILMN_1671913 HTF9C TRM2 tRNA methyltransferase 2 homolog A (S. cerevisiae) 1.88 1.05 
ILMN_1693941 IGSF9 immunoglobulin superfamily, member 9 1.86 1.05 
ILMN_1692967 AXIN1 axin 1 1.84 1.05 
ILMN_2197750 LOC728137 
testis specific protein, Y-linked 3; testis specific protein, Y-
linked 2; testis specific protein, Y-linked 1; testis specific 
protein, Y-linked pseudogene 7 1.82 1.05 
ILMN_2412849 SLC5A10 
solute carrier family 5 (sodium/glucose cotransporter), 
member 10 1.80 1.05 
ILMN_1657589 LOC644650   1.79 1.05 
ILMN_1676844 NR1D2 nuclear receptor subfamily 1, group D, member 2 1.75 1.05 
ILMN_1746359 RERG RAS-like, estrogen-regulated, growth inhibitor 1.73 1.05 
ILMN_1713813 LOC400578 keratin 16; keratin type 16-like 1.73 1.05 
ILMN_1669692 IKZF3 IKAROS family zinc finger 3 (Aiolos) 1.71 1.05 
ILMN_2322747 ARHGAP5 Rho GTPase activating protein 5 1.68 1.05 
ILMN_1658243 PSD3 pleckstrin and Sec7 domain containing 3 1.62 1.05 
ILMN_1713471 ENOX1 ecto-NOX disulfide-thiol exchanger 1 1.61 1.05 
ILMN_2154115 PSD4 pleckstrin and Sec7 domain containing 4 1.58 1.05 
ILMN_1689852 PAQR6 progestin and adipoQ receptor family member VI 1.54 1.05 
ILMN_1800445 NEK10 NIMA (never in mitosis gene a)- related kinase 10 1.50 1.05 
ILMN_2401033 GOSR1 golgi SNAP receptor complex member 1 1.49 1.05 
ILMN_1762151 LOC126520 polo-like kinase 5 pseudogene 1.49 1.05 
ILMN_1775423 C10orf88 chromosome 10 open reading frame 88 1.48 1.05 
ILMN_1772890 C9orf57 chromosome 9 open reading frame 57 1.46 1.05 
ILMN_2316278 MAGED4B 
melanoma antigen family D, 4B; melanoma antigen family D, 
4 1.45 1.05 
ILMN_1748840 CALB2 calbindin 2 1.41 1.05 
ILMN_1768600 LOC652264   1.29 1.05 
ILMN_1677197 RARA retinoic acid receptor, alpha 1.13 1.05 
ILMN_1769201 ELF3 
E74-like factor 3 (ets domain transcription factor, epithelial-
specific ) 4.58 2.52 
ILMN_1810864 PMP22 peripheral myelin protein 22 3.60 2.52 
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ILMN_2409451 NCKAP1 NCK-associated protein 1 3.51 2.52 
ILMN_1713124 AKR1C3 
aldo-keto reductase family 1, member C3 (3-alpha 
hydroxysteroid dehydrogenase, type II) 3.48 2.52 
ILMN_1665035 KRT14 keratin 14 3.19 2.52 
ILMN_1676719 LOC644330 tropomyosin 3 pseudogene 3.16 2.52 
ILMN_1802646 EPHB6 EPH receptor B6 2.98 2.52 
ILMN_1689431 APCDD1L adenomatosis polyposis coli down-regulated 1-like 2.91 2.52 
ILMN_1669046 FOXQ1 forkhead box Q1 2.76 2.52 
ILMN_1748124 TSC22D3 
TSC22 domain family, member 3; GRAM domain containing 
4 2.70 2.52 
ILMN_1796423 CLIC3 chloride intracellular channel 3 2.65 2.52 
ILMN_1794442 ZNF469 zinc finger protein 469 2.56 2.52 
ILMN_2041190 F2RL1 coagulation factor II (thrombin) receptor-like 1 2.49 2.52 
ILMN_1711311 PODXL podocalyxin-like 2.46 2.52 
ILMN_1724138 HTATIP K(lysine) acetyltransferase 5 2.46 2.52 
ILMN_2370976 FER1L3 myoferlin 2.44 2.52 
ILMN_2348788 CD44 CD44 molecule (Indian blood group) 2.40 2.52 
ILMN_1705032 SEH1L SEH1-like (S. cerevisiae) 2.39 2.52 
ILMN_1762529 SLC12A8 
solute carrier family 12 (potassium/chloride transporters), 
member 8 2.36 2.52 
ILMN_1663417 C22orf33 chromosome 22 open reading frame 33 2.34 2.52 
ILMN_1693338 CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 2.31 2.52 
ILMN_1811426 TMTC1 transmembrane and tetratricopeptide repeat containing 1 2.30 2.52 
ILMN_1670215 FLJ46836 FLJ46836 protein 2.29 2.52 
ILMN_2401873 DUSP10 dual specificity phosphatase 10 2.27 2.52 
ILMN_1738589 MGLL monoglyceride lipase 2.20 2.52 
ILMN_1785141 MICAL2 
microtubule associated monoxygenase, calponin and LIM 
domain containing 2 2.18 2.52 
ILMN_1805466 SOX9 SRY (sex determining region Y)-box 9 2.13 2.52 
ILMN_2113490 NTN4 netrin 4 2.12 2.52 
ILMN_1775501 IL1B interleukin 1, beta 2.10 2.52 
ILMN_1695773 STK24 serine/threonine kinase 24 (STE20 homolog, yeast) 2.07 2.52 
ILMN_2229877 PCDH18 protocadherin 18 2.04 2.52 
ILMN_2066151 TEK TEK tyrosine kinase, endothelial 2.01 2.52 
ILMN_1714057 FCN2 
ficolin (collagen/fibrinogen domain containing lectin) 2 
(hucolin) 1.99 2.52 
ILMN_1675222 PLXND1 plexin D1 1.97 2.52 
ILMN_1799098 LOC652846   1.91 2.52 
ILMN_2361181 C1QTNF6 C1q and tumor necrosis factor related protein 6 1.89 2.52 
ILMN_2229922 C12orf35 chromosome 12 open reading frame 35 1.89 2.52 
ILMN_1659856 C1orf90 family with sequence similarity 167, member B 1.82 2.52 
ILMN_2387385 IGFBP1 insulin-like growth factor binding protein 1 1.74 2.52 
ILMN_1693452 GAL3ST4 galactose-3-O-sulfotransferase 4 1.72 2.52 
ILMN_1776656 BBS7 Bardet-Biedl syndrome 7 1.67 2.52 
ILMN_2200562 LOC595101 PI-3-kinase-related kinase SMG-1 pseudogene 1.66 2.52 
ILMN_1785768 PDE4A 
phosphodiesterase 4A, cAMP-specific (phosphodiesterase 
E2 dunce homolog, Drosophila) 1.65 2.52 
ILMN_1802248 RNF152 ring finger protein 152 1.65 2.52 
ILMN_2358382 ZFYVE1 zinc finger, FYVE domain containing 1 1.63 2.52 
ILMN_1671004 POLG2 polymerase (DNA directed), gamma 2, accessory subunit 1.62 2.52 
ILMN_1742032 CCDC144A 
coiled-coil domain containing 144B; coiled-coil domain 
containing 144A; coiled-coil domain containing 144C 1.60 2.52 
ILMN_1701700 KLHL4 kelch-like 4 (Drosophila) 1.57 2.52 
ILMN_1658636 MRE11A MRE11 meiotic recombination 11 homolog A (S. cerevisiae) 1.57 2.52 
ILMN_1794156 DYRK1A 
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 
1A 1.55 2.52 
ILMN_1814002 TEAD3 TEA domain family member 3 1.52 2.52 
ILMN_1805148 C2orf63 chromosome 2 open reading frame 63 1.51 2.52 
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ILMN_1808715 LOC389300 similar to hCG1654959 1.50 2.52 
ILMN_1736068 CNOT8 CCR4-NOT transcription complex, subunit 8 1.50 2.52 
ILMN_1782679 AHRR 
aryl-hydrocarbon receptor repressor; programmed cell death 
6 1.48 2.52 
ILMN_1675687 LOC644701   1.46 2.52 
ILMN_1793621 ZFYVE27 zinc finger, FYVE domain containing 27 1.44 2.52 
ILMN_1706644 BDNF brain-derived neurotrophic factor 1.42 2.52 
ILMN_1710495 PAPLN papilin, proteoglycan-like sulphated glycoprotein 1.42 2.52 
ILMN_1738707 S100A13 S100 calcium binding protein A13 1.42 2.52 
ILMN_1731175 XKR6 
XK, Kell blood group complex subunit-related family, member 
6 1.41 2.52 
ILMN_1681824 LOC652294   1.41 2.52 
ILMN_1678862 FUT11 fucosyltransferase 11 (alpha (1,3) fucosyltransferase) 1.41 2.52 
ILMN_1730809 SLC29A2 solute carrier family 29 (nucleoside transporters), member 2 1.41 2.52 
ILMN_1656647 LOC649944   1.40 2.52 
ILMN_1724234 TRPV1 
transient receptor potential cation channel, subfamily V, 
member 1 1.39 2.52 
ILMN_1673129 PCDH12 protocadherin 12 1.38 2.52 
ILMN_1722532 JMJD1A lysine (K)-specific demethylase 3A 1.37 2.52 
ILMN_1781656 SCGB1D1 secretoglobin, family 1D, member 1 1.35 2.52 
ILMN_1807050 SHC4 SHC (Src homology 2 domain containing) family, member 4 1.34 2.52 
ILMN_1736682 SPSB4 splA/ryanodine receptor domain and SOCS box containing 4 1.31 2.52 
ILMN_2401770 PHF14 PHD finger protein 14 1.30 2.52 
ILMN_1720452 LONRF3 LON peptidase N-terminal domain and ring finger 3 1.29 2.52 
ILMN_2399016 MMP28 matrix metallopeptidase 28 1.29 2.52 
ILMN_1713013 PLD3 phospholipase D family, member 3 1.29 2.52 
ILMN_1655537 ING1 inhibitor of growth family, member 1 1.28 2.52 
ILMN_1768637 TNNI3 troponin I type 3 (cardiac) 1.28 2.52 
ILMN_1702183 LOC613266 hypothetical LOC613266 1.28 2.52 
ILMN_1723004 CD72 CD72 molecule 1.27 2.52 
ILMN_1675819 FAM101A family with sequence similarity 101, member A 1.27 2.52 
ILMN_2211583 KIAA1279 KIAA1279 1.24 2.52 
ILMN_1729225 SORCS2 sortilin-related VPS10 domain containing receptor 2 1.23 2.52 
ILMN_1802550 PCSK6 proprotein convertase subtilisin/kexin type 6 1.22 2.52 
ILMN_1783827 LOC649397   1.21 2.52 
ILMN_1758597 NAGS N-acetylglutamate synthase 1.21 2.52 
ILMN_1712798 ZNF608 zinc finger protein 608 1.21 2.52 
ILMN_1652525 FAM125B family with sequence similarity 125, member B 1.20 2.52 
ILMN_1792635 LOC654253   1.19 2.52 
ILMN_1691697 C20orf38 serine palmitoyltransferase, long chain base subunit 3 1.18 2.52 
ILMN_1763673 LOC651212   1.18 2.52 
ILMN_1670959 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 1.14 2.52 
ILMN_2338038 AK3L1 adenylate kinase 3-like 2; adenylate kinase 3-like 1 1.14 2.52 
ILMN_1798837 PTPN20B 
protein tyrosine phosphatase, non-receptor type 20B; protein 
tyrosine phosphatase, non-receptor type 20A 1.14 2.52 
ILMN_1893532   hypothetical protein LOC285796 1.13 2.52 
ILMN_2041648 TMPRSS7 transmembrane protease, serine 7 1.12 2.52 
ILMN_1793630 SLC4A3 solute carrier family 4, anion exchanger, member 3 1.11 2.52 
ILMN_1729369 FGFR1 fibroblast growth factor receptor 1 1.10 2.52 
ILMN_2181748 PA2G4P4 
proliferation-associated 2G4, 38kDa; proliferation-associated 
2G4 pseudogene 4 1.09 2.52 
ILMN_1704332 LOC654147   1.08 2.52 
ILMN_1659327 LOC283683 hypothetical protein LOC283683 1.08 2.52 
ILMN_1796626 LOC283152 coiled-coil domain containing 153 1.08 2.52 
ILMN_1764605 FGF6 fibroblast growth factor 6 1.07 2.52 
ILMN_2108699 IL2RA interleukin 2 receptor, alpha 1.07 2.52 
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ILMN_1690846 LOC642412   1.07 2.52 
ILMN_1764496 LOC648476   1.06 2.52 
ILMN_1783427 LOC641975   1.06 2.52 
ILMN_1787897 CXCL1 
chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha) 1.02 2.52 
ILMN_1707686 LOC646713   1.02 2.52 
          
ILMN_1795325 ACTG2 actin, gamma 2, smooth muscle, enteric -3.45 0 
ILMN_1671703 ACTA2 actin, alpha 2, smooth muscle, aorta -3.70 0 
ILMN_1763382 NPPB natriuretic peptide precursor B -7.14 0 
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6.4   Appendix table 10. Effects of over-expression of PATJ in 
HMEC-1 cells upon FSS 
Table 15: Deregulated genes in HMEC-1 cells over-expressing PATJ upon FSS 
Change ratios (x-fold changes) are indicated in the column Ratio and q values at a ‘false discovery’ 
rate (FDR) of < 5%. 
Illumina ID Gene ID Gene Name Ratio 
q-
value(%) 
ILMN_1766264 PI16 peptidase inhibitor 16 6.11 0.00 
ILMN_1787186 NOV nephroblastoma overexpressed gene 4.97 0.00 
ILMN_1802205 RHOB ras homolog gene family, member B 3.29 0.00 
ILMN_2189027 LIPG lipase, endothelial 3.21 0.00 
ILMN_2307861 COL6A3 collagen, type VI, alpha 3 3.11 0.00 
ILMN_1799575 IL19 interleukin 19 3.11 0.00 
ILMN_1738742 PLAT plasminogen activator, tissue 3.03 0.00 
ILMN_2137789 KLF4 Kruppel-like factor 4 (gut) 3.01 0.00 
ILMN_1665035 KRT14 keratin 14 2.97 0.00 
ILMN_1844408 PLXNA2 plexin A2 2.94 0.00 
ILMN_1763837 ANPEP alanyl (membrane) aminopeptidase 2.80 0.00 
ILMN_2314169 PTHLH parathyroid hormone-like hormone 2.79 0.00 
ILMN_2150851 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 2.75 0.00 
ILMN_1659856 C1orf90 family with sequence similarity 167, member B 2.71 0.00 
ILMN_1696048 C13orf33 chromosome 13 open reading frame 33 2.69 0.00 
ILMN_2043306 EPB41L5 erythrocyte membrane protein band 4.1 like 5 2.59 0.00 
ILMN_1765446 EMP3 epithelial membrane protein 3 2.51 0.00 
ILMN_1709674 GFPT2 glutamine-fructose-6-phosphate transaminase 2 2.45 0.00 
ILMN_2413158 PODXL podocalyxin-like 2.44 0.00 
ILMN_1735930 KLF2 Kruppel-like factor 2 (lung) 2.44 0.00 
ILMN_1694755 FSD1 fibronectin type III and SPRY domain containing 1 2.36 0.00 
ILMN_1737406 KLF6 Kruppel-like factor 6 2.27 0.00 
ILMN_1736760 KRT16 keratin 16; keratin type 16-like 2.24 0.00 
ILMN_1711311 PODXL podocalyxin-like 2.14 0.00 
ILMN_2401878 DUSP10 dual specificity phosphatase 10 2.00 0.00 
ILMN_1797972 C2orf65 chromosome 2 open reading frame 65 1.82 0.00 
ILMN_1669046 FOXQ1 forkhead box Q1 2.49 2.31 
ILMN_1657111 C14orf78 AHNAK nucleoprotein 2 2.48 2.31 
ILMN_1680814 EDN2 endothelin 2 2.28 2.31 
ILMN_1653504 EDG1 sphingosine-1-phosphate receptor 1 2.27 2.31 
ILMN_1748881 MRAS muscle RAS oncogene homolog 2.24 2.31 
ILMN_1775501 IL1B interleukin 1, beta 2.20 2.31 
ILMN_1701461 TIMP3 TIMP metallopeptidase inhibitor 3 2.10 2.31 
ILMN_1778683 RTN4RL1 reticulon 4 receptor-like 1 1.93 2.31 
ILMN_1756595 SH3TC1 SH3 domain and tetratricopeptide repeats 1 1.89 2.31 
ILMN_1712230 LOC731035 
IQ motif and Sec7 domain 3; similar to IQ motif and Sec7 domain-
containing protein 3; similar to IQ motif and SEC7 domain-containing 
protein 3; similar to IQ motif and Sec7 domain 3 1.67 2.31 
ILMN_1670535 NDRG2 NDRG family member 2 1.31 2.31 
ILMN_2376403 TSC22D3 TSC22 domain family, member 3; GRAM domain containing 4 2.85 2.44 
ILMN_2276952 TSC22D3 TSC22 domain family, member 3; GRAM domain containing 4 2.34 2.44 
ILMN_1695475 SEMA3C 
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3C 2.21 2.44 
ILMN_1802646 EPHB6 EPH receptor B6 2.20 2.44 
ILMN_1693515 EGFL8 EGF-like-domain, multiple 8 2.15 2.44 
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ILMN_2092589 FAM5C family with sequence similarity 5, member C 2.08 2.44 
ILMN_2386040 MYO19 myosin XIX 1.96 2.44 
ILMN_2329927 ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 1.96 2.44 
ILMN_1732197 MN1 meningioma (disrupted in balanced translocation) 1 1.94 2.44 
ILMN_1687567 CUX1 cut-like homeobox 1 1.74 2.44 
ILMN_1724234 TRPV1 transient receptor potential cation channel, subfamily V, member 1 2.54 2.91 
ILMN_1689431 APCDD1L adenomatosis polyposis coli down-regulated 1-like 2.44 2.91 
ILMN_1673113 F2RL1 coagulation factor II (thrombin) receptor-like 1 2.33 2.91 
ILMN_2261379 SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 2.26 2.91 
ILMN_1665374 COL9A1 collagen, type IX, alpha 1 2.11 2.91 
ILMN_1769201 ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 2.02 2.91 
ILMN_1772359 LAPTM5 lysosomal multispanning membrane protein 5 2.01 2.91 
ILMN_1787567 TSC22D1 TSC22 domain family, member 1 2.01 2.91 
ILMN_1713471 ENOX1 ecto-NOX disulfide-thiol exchanger 1 2.37 4.55 
ILMN_2041190 F2RL1 coagulation factor II (thrombin) receptor-like 1 2.33 4.55 
ILMN_1712545 S100A3 S100 calcium binding protein A3 2.23 4.55 
ILMN_1693338 CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 2.17 4.55 
ILMN_1811426 TMTC1 transmembrane and tetratricopeptide repeat containing 1 2.09 4.55 
ILMN_2384122 GPR56 G protein-coupled receptor 56 2.04 4.55 
ILMN_2215119 SYNJ2 synaptojanin 2 1.94 4.55 
ILMN_1784287 TGFBR3 transforming growth factor, beta receptor III 1.88 4.55 
ILMN_1778876 KIAA0423 family with sequence similarity 179, member B 1.81 4.55 
ILMN_1675819 FAM101A family with sequence similarity 101, member A 1.68 4.55 
ILMN_1748614 RELT RELT tumor necrosis factor receptor 1.54 4.55 
ILMN_1692177 TSC22D1 TSC22 domain family, member 1 2.44 4.85 
ILMN_2380453 USP45 ubiquitin specific peptidase 45 1.70 4.85 
ILMN_1759622 G3BP2 GTPase activating protein (SH3 domain) binding protein 2 1.69 4.85 
 
_____________________________________________________________________________ APPENDICES 
   102 
6.5   Appendix table 12. Effects of over-expression of GPR30 and 
PATJ in HMEC-1 cells upon FSS 
Table 16: Deregulated genes in HMEC-1 cells over-expressing GPR30 and PATJ upon FSS 
Change ratios (x-fold changes) are indicated in the column Ratio and q values at a ‘false discovery’ 
rate (FDR) of < 5%. 
ILLUMINA ID Gene ID Gene Name Ratio 
q-
value(%) 
ILMN_1736760 KRT16 
KERATIN 16 (FOCAL NON-EPIDERMOLYTIC PALMOPLANTAR 
KERATODERMA) 10.95 0.00 
ILMN_1787186 NOV NEPHROBLASTOMA OVEREXPRESSED GENE 6.51 0.00 
ILMN_1766264 PI16 PEPTIDASE INHIBITOR 16 5.27 0.00 
ILMN_1669046 FOXQ1 FORKHEAD BOX Q1 3.87 0.00 
ILMN_1802205 RHOB RAS HOMOLOG GENE FAMILY, MEMBER B 3.83 0.00 
ILMN_1796423 CLIC3 CHLORIDE INTRACELLULAR CHANNEL 3 3.57 0.00 
ILMN_1844408 PLXNA2 PLEXIN A2 3.55 0.00 
ILMN_1799575 IL19 INTERLEUKIN 19 3.30 0.00 
ILMN_2137789 KLF4 KRUPPEL-LIKE FACTOR 4 (GUT) 3.27 0.00 
ILMN_1665035 KRT14 
KERATIN 14 (EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-
MEARA, KOEBNER) 3.27 0.00 
ILMN_1738742 PLAT PLASMINOGEN ACTIVATOR, TISSUE 2.94 0.00 
ILMN_1765446 EMP3 EPITHELIAL MEMBRANE PROTEIN 3 2.94 0.00 
ILMN_1762529 SLC12A8 HYPOTHETICAL PROTEIN FLJ23188 2.90 0.00 
ILMN_1712545 S100A3 S100 CALCIUM BINDING PROTEIN A3 2.90 0.00 
ILMN_1708534 PAX8 PAIRED BOX GENE 8 2.88 0.00 
ILMN_1684306 S100A4 
S100 CALCIUM BINDING PROTEIN A4 (CALCIUM PROTEIN, 
CALVASCULIN, METASTASIN, MURINE PLACENTAL HOMOLOG) 2.82 0.00 
ILMN_1696048 C13orf33 HYPOTHETICAL PROTEIN FLJ14834 2.74 0.00 
ILMN_2327860 MAL MAL, T-CELL DIFFERENTIATION PROTEIN 2.54 0.00 
ILMN_1693338 CYP1B1 CYTOCHROME P450, FAMILY 1, SUBFAMILY B, POLYPEPTIDE 1 2.53 0.00 
ILMN_2111237 MN1 MENINGIOMA (DISRUPTED IN BALANCED TRANSLOCATION) 1 2.50 0.00 
ILMN_2387214 PALM PARALEMMIN 2.35 0.00 
ILMN_1657111 C14orf78 CHROMOSOME 14 OPEN READING FRAME 78 2.33 0.00 
ILMN_1743367 FZD4 FRIZZLED HOMOLOG 4 (DROSOPHILA) 2.30 0.00 
ILMN_1711786 NFE2 NUCLEAR FACTOR (ERYTHROID-DERIVED 2), 45KDA 2.28 0.00 
ILMN_2407703 SYN1 SYNAPSIN I 2.26 0.00 
ILMN_1688780 S100A4 
S100 CALCIUM BINDING PROTEIN A4 (CALCIUM PROTEIN, 
CALVASCULIN, METASTASIN, MURINE PLACENTAL HOMOLOG) 2.26 0.00 
ILMN_1714445 SLC6A9 
SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER 
TRANSPORTER, GLYCINE), MEMBER 9 2.25 0.00 
ILMN_1763837 ANPEP 
ALANYL (MEMBRANE) AMINOPEPTIDASE (AMINOPEPTIDASE N, 
AMINOPEPTIDASE M, MICROSOMAL AMINOPEPTIDASE, CD13, 
P150) 2.24 0.00 
ILMN_2352097 GPR56 G PROTEIN-COUPLED RECEPTOR 56 2.23 0.00 
ILMN_1769201 ELF3 
E74-LIKE FACTOR 3 (ETS DOMAIN TRANSCRIPTION FACTOR, 
EPITHELIAL-SPECIFIC ) 2.20 0.00 
ILMN_2148527 H19 
H19, IMPRINTED MATERNALLY EXPRESSED UNTRANSLATED 
MRNA 2.17 0.00 
ILMN_1758067 RGS4 REGULATOR OF G-PROTEIN SIGNALLING 4 2.13 0.00 
ILMN_2384122 GPR56 G PROTEIN-COUPLED RECEPTOR 56 2.12 0.00 
ILMN_1701424 LAMC2 LAMININ, GAMMA 2 2.11 0.00 
ILMN_1677273 TH TYROSINE HYDROXYLASE 2.11 0.00 
ILMN_1735930 KLF2 KRUPPEL-LIKE FACTOR 2 (LUNG) 2.10 0.00 
ILMN_1775501 IL1B INTERLEUKIN 1, BETA 2.06 0.00 
ILMN_1714170 SPSB1 
SPLA/RYANODINE RECEPTOR DOMAIN AND SOCS BOX 
CONTAINING 1 2.02 0.00 
_____________________________________________________________________________ APPENDICES 
   103 
ILMN_1772821 KIAA1671 KIAA1671 PROTEIN 2.02 0.00 
ILMN_2308903 WFDC3 WAP FOUR-DISULFIDE CORE DOMAIN 3 2.00 0.00 
ILMN_2113490 NTN4 NETRIN 4 1.97 0.00 
ILMN_1679929 KLF13 KRUPPEL-LIKE FACTOR 13 1.96 0.00 
ILMN_1726597 C6orf32 CHROMOSOME 6 OPEN READING FRAME 32 1.95 0.00 
ILMN_2150851 SERPINB2 
SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 
2 1.95 0.00 
ILMN_1774685 IL24 INTERLEUKIN 24 1.94 0.00 
ILMN_1756595 SH3TC1 SH3 DOMAIN AND TETRATRICOPEPTIDE REPEATS 1 1.94 0.00 
ILMN_1701461 TIMP3 
TIMP METALLOPEPTIDASE INHIBITOR 3 (SORSBY FUNDUS 
DYSTROPHY, PSEUDOINFLAMMATORY) 1.94 0.00 
ILMN_2356578 TH TYROSINE HYDROXYLASE 1.94 0.00 
ILMN_1669362 IGFBP6 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 6 1.92 0.00 
ILMN_1771627 ZMIZ1 RETINOIC ACID INDUCED 17 1.91 0.00 
ILMN_1761968 PPP1R14A 
PROTEIN PHOSPHATASE 1, REGULATORY (INHIBITOR) SUBUNIT 
14A 1.89 0.00 
ILMN_2376403 TSC22D3 TSC22 DOMAIN FAMILY, MEMBER 3 1.88 0.00 
ILMN_2413158 PODXL PODOCALYXIN-LIKE 1.85 0.00 
ILMN_1668960 MID1IP1 
MID1 INTERACTING PROTEIN 1 (GASTRULATION SPECIFIC G12-
LIKE (ZEBRAFISH)) 1.83 0.00 
ILMN_2383077 SLC39A7 SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 7 1.81 0.00 
ILMN_1689431 APCDD1L HYPOTHETICAL PROTEIN FLJ90166 1.79 0.00 
ILMN_1691376 JAG1 JAGGED 1 (ALAGILLE SYNDROME) 1.79 0.00 
ILMN_1732197 MN1 MENINGIOMA (DISRUPTED IN BALANCED TRANSLOCATION) 1 1.78 0.00 
ILMN_1657708 MGLL MONOGLYCERIDE LIPASE 1.78 0.00 
ILMN_1738589 MGLL MONOGLYCERIDE LIPASE 1.77 0.00 
ILMN_2337058 PORCN PORCUPINE HOMOLOG (DROSOPHILA) 1.77 0.00 
ILMN_1737406 KLF6 KRUPPEL-LIKE FACTOR 6 1.76 0.00 
ILMN_2399174 TRAK1 TRAFFICKING PROTEIN, KINESIN BINDING 1 1.76 0.00 
ILMN_1748124 TSC22D3 TSC22 DOMAIN FAMILY, MEMBER 3 1.74 0.00 
ILMN_1812926 ANTXR2 ANTHRAX TOXIN RECEPTOR 2 1.74 0.00 
ILMN_2314169 PTHLH PARATHYROID HORMONE-LIKE HORMONE 1.74 0.00 
ILMN_1709674 GFPT2 GLUTAMINE-FRUCTOSE-6-PHOSPHATE TRANSAMINASE 2 1.74 0.00 
ILMN_1769876 TBC1D2 TBC1 DOMAIN FAMILY, MEMBER 2 1.72 0.00 
ILMN_1787567 TSC22D1 TSC22 DOMAIN FAMILY, MEMBER 1 1.71 0.00 
ILMN_1687978 PHLDA1 PLECKSTRIN HOMOLOGY-LIKE DOMAIN, FAMILY A, MEMBER 1 1.70 0.00 
ILMN_1669376 DRAM HYPOTHETICAL PROTEIN FLJ11259 1.70 0.00 
ILMN_1735014 KLF6 KRUPPEL-LIKE FACTOR 6 1.70 0.00 
ILMN_1690170 CRABP2 CELLULAR RETINOIC ACID BINDING PROTEIN 2 1.66 0.00 
ILMN_1724789 CD59 CD59 ANTIGEN, COMPLEMENT REGULATORY PROTEIN 1.66 0.00 
ILMN_1754842 DLGAP4 
DISCS, LARGE (DROSOPHILA) HOMOLOG-ASSOCIATED PROTEIN 
4 1.65 0.00 
ILMN_1760412 SHISA2 TRANSMEMBRANE PROTEIN 46 1.64 0.00 
ILMN_1761425 OLFML2A OLFACTOMEDIN-LIKE 2A 1.64 0.00 
ILMN_1671478 CKB CREATINE KINASE, BRAIN 1.63 0.00 
ILMN_1815023 PIM1 PIM-1 ONCOGENE 1.62 0.00 
ILMN_1666893 TRIML2 HYPOTHETICAL PROTEIN FLJ25801 1.61 0.00 
ILMN_1652777 CDC42EP2 CDC42 EFFECTOR PROTEIN (RHO GTPASE BINDING) 2 1.59 0.00 
ILMN_2066151 TEK 
TEK TYROSINE KINASE, ENDOTHELIAL (VENOUS 
MALFORMATIONS, MULTIPLE CUTANEOUS AND MUCOSAL) 1.58 0.00 
ILMN_1673113 F2RL1 COAGULATION FACTOR II (THROMBIN) RECEPTOR-LIKE 1 1.58 0.00 
ILMN_1807652 STRA6 STIMULATED BY RETINOIC ACID GENE 6 HOMOLOG (MOUSE) 1.56 0.00 
ILMN_2380237 C1QTNF1 
G PROTEIN COUPLED RECEPTOR INTERACTING PROTEIN, 
COMPLEMENT-C1Q TUMOR NECROSIS FACTOR-RELATED 1.55 0.00 
ILMN_1679262 DPYSL3 DIHYDROPYRIMIDINASE-LIKE 3 1.54 0.00 
ILMN_2041190 F2RL1 COAGULATION FACTOR II (THROMBIN) RECEPTOR-LIKE 1 1.54 0.00 
ILMN_1672102 PTPRB PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, B 1.54 0.00 
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ILMN_1700001 TCTA T-CELL LEUKEMIA TRANSLOCATION ALTERED GENE 1.53 0.00 
ILMN_1784287 TGFBR3 
TRANSFORMING GROWTH FACTOR, BETA RECEPTOR III 
(BETAGLYCAN, 300KDA) 1.51 0.00 
ILMN_1670926 
GALNAC4S-
6ST KIAA0598 GENE PRODUCT 1.49 0.00 
ILMN_1772612 ANGPTL2 ANGIOPOIETIN-LIKE 2 1.41 0.00 
ILMN_2374036 CTSL1 CATHEPSIN L 1.40 0.00 
ILMN_1805466 SOX9 
SRY (SEX DETERMINING REGION Y)-BOX 9 (CAMPOMELIC 
DYSPLASIA, AUTOSOMAL SEX-REVERSAL) 1.38 0.00 
ILMN_1659316 HEPACAM HEPATOCYTE CELL ADHESION MOLECULE 8.50 0.61 
ILMN_1675453 HHIP HEDGEHOG INTERACTING PROTEIN 2.65 0.61 
ILMN_1676689 PPT2 PALMITOYL-PROTEIN THIOESTERASE 2 2.32 0.61 
ILMN_2351466 HNT NEUROTRIMIN 2.30 0.61 
ILMN_2096719 GRK5 G PROTEIN-COUPLED RECEPTOR KINASE 5 2.19 0.61 
ILMN_1704154 TNFRSF19 
TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 
19 2.15 0.61 
ILMN_1809931 NDRG1 N-MYC DOWNSTREAM REGULATED GENE 1 2.10 0.61 
ILMN_1793474 INSIG1 INSULIN INDUCED GENE 1 2.05 0.61 
ILMN_2401822 FTSJ1 FTSJ HOMOLOG 1 (E. COLI) 1.96 0.61 
ILMN_1894911   FLJ45933 PROTEIN 1.95 0.61 
ILMN_1807689 PKNOX2 PBX/KNOTTED 1 HOMEOBOX 2 1.89 0.61 
ILMN_1665865 IGFBP4 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4 1.85 0.61 
ILMN_1761540 SEMA3F 
SEMA DOMAIN, IMMUNOGLOBULIN DOMAIN (IG), SHORT BASIC 
DOMAIN, SECRETED, (SEMAPHORIN) 3F 1.84 0.61 
ILMN_1700690 VAT1 
VESICLE AMINE TRANSPORT PROTEIN 1 HOMOLOG (T 
CALIFORNICA) 1.78 0.61 
ILMN_1803811 TRIB1 TRIBBLES HOMOLOG 1 (DROSOPHILA) 1.77 0.61 
ILMN_1714592 CDA CYTIDINE DEAMINASE 1.75 0.61 
ILMN_2161746 TRIP10 THYROID HORMONE RECEPTOR INTERACTOR 10 1.72 0.61 
ILMN_1803277 MVP MAJOR VAULT PROTEIN 1.70 0.61 
ILMN_1728049 S100A16 S100 CALCIUM BINDING PROTEIN A16 1.70 0.61 
ILMN_1791447 CXCL12 
CHEMOKINE (C-X-C MOTIF) LIGAND 12 (STROMAL CELL-DERIVED 
FACTOR 1) 1.69 0.61 
ILMN_1659599 ADC ARGININE DECARBOXYLASE 1.67 0.61 
ILMN_1803818 NMNAT2 NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE 2 1.67 0.61 
ILMN_1673363 CD97 CD97 ANTIGEN 1.65 0.61 
ILMN_1751576 TEK 
TEK TYROSINE KINASE, ENDOTHELIAL (VENOUS 
MALFORMATIONS, MULTIPLE CUTANEOUS AND MUCOSAL) 1.64 0.61 
ILMN_1753413 TRIOBP TRIO AND F-ACTIN BINDING PROTEIN 1.64 0.61 
ILMN_1694432 CRIP2 CYSTEINE-RICH PROTEIN 2 1.64 0.61 
ILMN_1688480 CCND1 CYCLIN D1 1.63 0.61 
ILMN_1715684 LAMB3 LAMININ, BETA 3 1.63 0.61 
ILMN_1723048 GJC2 GAP JUNCTION PROTEIN, ALPHA 12, 47KDA 1.63 0.61 
ILMN_1695423 CD9 CD9 ANTIGEN (P24) 1.62 0.61 
ILMN_1715969 SLC25A37 SOLUTE CARRIER FAMILY 25, MEMBER 37 1.60 0.61 
ILMN_1798256 UPP1 URIDINE PHOSPHORYLASE 1 1.59 0.61 
ILMN_2082585 SNAI2 SNAIL HOMOLOG 2 (DROSOPHILA) 1.59 0.61 
ILMN_1803825 CXCL12 
CHEMOKINE (C-X-C MOTIF) LIGAND 12 (STROMAL CELL-DERIVED 
FACTOR 1) 1.56 0.61 
ILMN_1651799 SLC38A2 SOLUTE CARRIER FAMILY 38, MEMBER 2 1.56 0.61 
ILMN_1719236 CDH5 CADHERIN 5, TYPE 2, VE-CADHERIN (VASCULAR EPITHELIUM) 1.51 0.61 
ILMN_1678215 RHOJ RAS HOMOLOG GENE FAMILY, MEMBER J 1.50 0.61 
ILMN_1812031 PALM PARALEMMIN 1.49 0.61 
ILMN_1786722 ZNF385A ZINC FINGER PROTEIN 385 1.46 0.61 
ILMN_1684210 NPAL3 NIPA-LIKE DOMAIN CONTAINING 3 1.43 0.61 
ILMN_1732923 SIPA1L2 SIGNAL-INDUCED PROLIFERATION-ASSOCIATED 1 LIKE 2 1.43 0.61 
ILMN_2289924 TRAK1 TRAFFICKING PROTEIN, KINESIN BINDING 1 1.42 0.61 
ILMN_1685580 CBLB 
CAS-BR-M (MURINE) ECOTROPIC RETROVIRAL TRANSFORMING 
SEQUENCE B 1.42 0.61 
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ILMN_1750664 PPT2 PALMITOYL-PROTEIN THIOESTERASE 2 1.42 0.61 
ILMN_1745223 CDC42EP4 CDC42 EFFECTOR PROTEIN (RHO GTPASE BINDING) 4 1.40 0.61 
ILMN_1680738 C5orf13 CHROMOSOME 5 OPEN READING FRAME 13 1.39 0.61 
ILMN_1735052 ULK1 UNC-51-LIKE KINASE 1 (C. ELEGANS) 1.39 0.61 
ILMN_1812995 CTSL1 CATHEPSIN L 1.37 0.61 
ILMN_1778681 EBF1 EARLY B-CELL FACTOR 1.23 0.61 
ILMN_1703946 ADORA2B ADENOSINE A2B RECEPTOR 1.23 0.61 
ILMN_1680814 EDN2 ENDOTHELIN 2 2.41 1.03 
ILMN_1800512 HMOX1 HEME OXYGENASE (DECYCLING) 1 2.22 1.03 
ILMN_1712708 TRIM47 TRIPARTITE MOTIF-CONTAINING 47 2.15 1.03 
ILMN_1717793 C19orf33 CHROMOSOME 19 OPEN READING FRAME 33 2.06 1.03 
ILMN_1772074 C19orf51 SIMILAR TO HYPOTHETICAL TESTIS PROTEIN FROM MACAQUE 1.96 1.03 
ILMN_1775268 HECW2 
HECT, C2 AND WW DOMAIN CONTAINING E3 UBIQUITIN PROTEIN 
LIGASE 2 1.83 1.03 
ILMN_1732609 KIAA1539 KIAA1539 PROTEIN 1.79 1.03 
ILMN_1760778 ENG ENDOGLIN (OSLER-RENDU-WEBER SYNDROME 1) 1.79 1.03 
ILMN_1750101 S100A11 S100 CALCIUM BINDING PROTEIN A11 (CALGIZZARIN) 1.78 1.03 
ILMN_1741404 MSC MUSCULIN (ACTIVATED B-CELL FACTOR-1) 1.77 1.03 
ILMN_1701655 SLC24A6 
SOLUTE CARRIER FAMILY 24 (SODIUM/POTASSIUM/CALCIUM 
EXCHANGER), MEMBER 6 1.75 1.03 
ILMN_1708041 PLEKHF1 
PLECKSTRIN HOMOLOGY DOMAIN CONTAINING, FAMILY F (WITH 
FYVE DOMAIN) MEMBER 1 1.69 1.03 
ILMN_1661194 CLDN14 CLAUDIN 14 1.68 1.03 
ILMN_1774602 FBLN2 FIBULIN 2 1.66 1.03 
ILMN_1742789 LPXN LEUPAXIN 1.59 1.03 
ILMN_1746013 SPOCK1 
SPARC/OSTEONECTIN, CWCV AND KAZAL-LIKE DOMAINS 
PROTEOGLYCAN (TESTICAN) 1 1.43 1.03 
ILMN_1756935 OSBPL6 OSBP-RELATED PROTEIN 6 1.43 1.03 
ILMN_1770338 TM4SF1 TRANSMEMBRANE 4 L SIX FAMILY MEMBER 1 1.42 1.03 
ILMN_2199389 VIPR1 VASOACTIVE INTESTINAL PEPTIDE RECEPTOR 1 1.39 1.03 
ILMN_1700384 KIAA1522 KIAA1522 1.38 1.03 
ILMN_1665510 ERRFI1 ERBB RECEPTOR FEEDBACK INHIBITOR 1 1.27 1.03 
ILMN_1717809 RNF24 RING FINGER PROTEIN 24 1.23 1.03 
ILMN_1756928 RTN1 RETICULON 1 8.00 1.68 
ILMN_1665449 ROBO4 ROUNDABOUT HOMOLOG 4, MAGIC ROUNDABOUT (DROSOPHILA) 3.77 1.68 
ILMN_1748751 NLF2 NUCLEAR LOCALIZED FACTOR 2 2.75 1.68 
ILMN_1760160 STX1A SYNTAXIN 1A (BRAIN) 2.26 1.68 
ILMN_1685699 PRSS3 PROTEASE, SERINE, 3 (MESOTRYPSIN) 2.01 1.68 
ILMN_1696316 CPT1A CARNITINE PALMITOYLTRANSFERASE 1A (LIVER) 1.83 1.68 
ILMN_1744268 PLEC1 PLECTIN 1, INTERMEDIATE FILAMENT BINDING PROTEIN 500KDA 1.81 1.68 
ILMN_2344373 MVP MAJOR VAULT PROTEIN 1.79 1.68 
ILMN_1739238 L1CAM L1 CELL ADHESION MOLECULE 1.79 1.68 
ILMN_1671142 GPR68 G PROTEIN-COUPLED RECEPTOR 68 1.65 1.68 
ILMN_1763638 BCAR3 BREAST CANCER ANTI-ESTROGEN RESISTANCE 3 1.63 1.68 
ILMN_1678904 ENO3 ENOLASE 1, (ALPHA) 1.54 1.68 
ILMN_1764850 HPCAL1 HIPPOCALCIN-LIKE 1 1.49 1.68 
ILMN_1702171 LPCAT1 ACYLTRANSFERASE LIKE 2 1.49 1.68 
ILMN_1669617 GRB10 GROWTH FACTOR RECEPTOR-BOUND PROTEIN 10 1.43 1.68 
ILMN_1751656 KLF11 KRUPPEL-LIKE FACTOR 11 1.40 1.68 
ILMN_2197128 OSR1 ODD-SKIPPED RELATED 1 (DROSOPHILA) 1.39 1.68 
ILMN_1755364 RALA 
V-RAL SIMIAN LEUKEMIA VIRAL ONCOGENE HOMOLOG A (RAS 
RELATED) 1.22 1.68 
ILMN_1741917 OSCAR OSTEOCLAST-ASSOCIATED RECEPTOR 1.18 1.68 
ILMN_2348788 CD44 CD44 ANTIGEN (INDIAN BLOOD GROUP) 1.17 1.68 
ILMN_1660942 LOC653352 
SIMILAR TO EUKARYOTIC TRANSLATION INITIATION FACTOR 3, 
SUBUNIT 8 6.21 2.44 
ILMN_2046750 PGLYRP3 PEPTIDOGLYCAN RECOGNITION PROTEIN 3 4.86 2.44 
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ILMN_2276952 TSC22D3 TSC22 DOMAIN FAMILY, MEMBER 3 4.48 2.44 
ILMN_1686989 INSIG1 INSULIN INDUCED GENE 1 2.91 2.44 
ILMN_1666924 PINK1 PTEN INDUCED PUTATIVE KINASE 1 2.44 2.44 
ILMN_1803728 SLC35E4 SOLUTE CARRIER FAMILY 35, MEMBER E4 2.23 2.44 
ILMN_1768391 ARL4C ADP-RIBOSYLATION FACTOR-LIKE 4C 2.18 2.44 
ILMN_1689037 LIPG LIPASE, ENDOTHELIAL 2.00 2.44 
ILMN_1689111 CXCL12 
CHEMOKINE (C-X-C MOTIF) LIGAND 12 (STROMAL CELL-DERIVED 
FACTOR 1) 1.83 2.44 
ILMN_1692177 TSC22D1 TSC22 DOMAIN FAMILY, MEMBER 1 1.83 2.44 
ILMN_1801516 GPC1 GLYPICAN 1 1.73 2.44 
ILMN_1815130 MICALL1 MICAL-LIKE 1 1.64 2.44 
ILMN_2390919 FBLN2 FIBULIN 2 1.62 2.44 
ILMN_2355225 LSP1 LYMPHOCYTE-SPECIFIC PROTEIN 1 1.51 2.44 
ILMN_1725852 S100A2 S100 CALCIUM BINDING PROTEIN A2 1.50 2.44 
ILMN_2315780 TACC2 TRANSFORMING, ACIDIC COILED-COIL CONTAINING PROTEIN 2 1.49 2.44 
ILMN_2401873 DUSP10 DUAL SPECIFICITY PHOSPHATASE 10 1.48 2.44 
ILMN_1742332 KCTD12 
POTASSIUM CHANNEL TETRAMERISATION DOMAIN CONTAINING 
12 1.48 2.44 
ILMN_1684576 CLN8 
CEROID-LIPOFUSCINOSIS, NEURONAL 8 (EPILEPSY, 
PROGRESSIVE WITH MENTAL RETARDATION) 1.46 2.44 
ILMN_1798360 CXCR7 CHEMOKINE ORPHAN RECEPTOR 1 1.42 2.44 
ILMN_1713829 PTGES PROSTAGLANDIN E SYNTHASE 1.42 2.44 
ILMN_1661755 FAM129B CHROMOSOME 9 OPEN READING FRAME 88 1.41 2.44 
ILMN_1791679 DNER 
DELTA-NOTCH-LIKE EGF REPEAT-CONTAINING 
TRANSMEMBRANE 1.41 2.44 
ILMN_1685397 ITGA3 
INTEGRIN, ALPHA 3 (ANTIGEN CD49C, ALPHA 3 SUBUNIT OF VLA-3 
RECEPTOR) 1.39 2.44 
ILMN_1802808 LOC654103 SIMILAR TO SOLUTE CARRIER FAMILY 25, MEMBER 37 1.39 2.44 
ILMN_1792495 AHNAK AHNAK NUCLEOPROTEIN (DESMOYOKIN) 1.34 2.44 
ILMN_1705144 ULK1 UNC-51-LIKE KINASE 1 (C. ELEGANS) 1.30 2.44 
ILMN_1703487 LMO4 LIM DOMAIN ONLY 4 1.18 2.44 
ILMN_1657077 SOCS6 SUPPRESSOR OF CYTOKINE SIGNALING 6 5.40 3.96 
ILMN_1774761 CCR2 CHEMOKINE (C-C MOTIF) RECEPTOR 2 4.16 3.96 
ILMN_1808777 EHD2 EH-DOMAIN CONTAINING 2 2.66 3.96 
ILMN_1683607 CYP1A2 CYTOCHROME P450, FAMILY 1, SUBFAMILY A, POLYPEPTIDE 2 2.47 3.96 
ILMN_1781867 FOXD4L1 FORKHEAD BOX D4-LIKE 1 2.45 3.96 
ILMN_1708363 LOXL1 LYSYL OXIDASE-LIKE 1 2.35 3.96 
ILMN_2129161 LRRC32 LEUCINE RICH REPEAT CONTAINING 32 2.22 3.96 
ILMN_1653042 HSD3B7 
HYDROXY-DELTA-5-STEROID DEHYDROGENASE, 3 BETA- AND 
STEROID DELTA-ISOMERASE 7 1.78 3.96 
ILMN_1776395 ARMC4 ARMADILLO REPEAT CONTAINING 4 1.75 3.96 
ILMN_1793729 C15orf39 DKFZP434H132 PROTEIN 1.73 3.96 
ILMN_1666122 HEG1 HEG HOMOLOG 1 (ZEBRAFISH) 1.72 3.96 
ILMN_2176502 UNC5B UNC-5 HOMOLOG B (C. ELEGANS) 1.68 3.96 
ILMN_1693515 EGFL8 PALMITOYL-PROTEIN THIOESTERASE 2 1.65 3.96 
ILMN_1735045 A4GALT 
ALPHA 1,4-GALACTOSYLTRANSFERASE 
(GLOBOTRIAOSYLCERAMIDE SYNTHASE) 1.64 3.96 
ILMN_1706643 COL6A3 COLLAGEN, TYPE VI, ALPHA 3 1.61 3.96 
ILMN_1794677 TMC6 TRANSMEMBRANE CHANNEL-LIKE 6 1.60 3.96 
ILMN_1710514 BCL3 B-CELL CLL/LYMPHOMA 3 1.59 3.96 
ILMN_1738558 RGS20 REGULATOR OF G-PROTEIN SIGNALLING 20 1.54 3.96 
ILMN_1890614   CHROMOSOME 1 OPEN READING FRAME 183 1.53 3.96 
ILMN_1661599 DDIT4 DNA-DAMAGE-INDUCIBLE TRANSCRIPT 4 1.51 3.96 
ILMN_1778087 ANXA8 ANNEXIN A8 1.48 3.96 
ILMN_2205999 OSMR ONCOSTATIN M RECEPTOR 1.46 3.96 
ILMN_1750338 C10orf47 CHROMOSOME 10 OPEN READING FRAME 47 1.45 3.96 
ILMN_1775743 BTG1 B-CELL TRANSLOCATION GENE 1, ANTI-PROLIFERATIVE 1.39 3.96 
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ILMN_1680579 ATP2B4 ATPASE, CA++ TRANSPORTING, PLASMA MEMBRANE 4 1.38 3.96 
ILMN_1794863 CAMK2N1 
CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II 
INHIBITOR 1 1.34 3.96 
ILMN_1687440 HIPK2 HOMEODOMAIN INTERACTING PROTEIN KINASE 2 1.30 3.96 
ILMN_1729455 EML1 ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 1 1.29 3.96 
ILMN_2371458 CXCR7 CHEMOKINE ORPHAN RECEPTOR 1 1.28 3.96 
ILMN_1756862 APOL3 TNF-INDUCIBLE PROTEIN CG12-1 1.22 3.96 
ILMN_2307861 COL6A3 COLLAGEN, TYPE VI, ALPHA 3 1.15 3.96 
ILMN_1705310 VEZF1 ZINC FINGER PROTEIN 161 1.15 3.96 
          
ILMN_1671703 ACTA2 actin, alpha 2, smooth muscle, aorta   -2.27 0 
ILMN_1725726 DHRS2 dehydrogenase/reductase (SDR family) member 2  -2.27 0 
ILMN_1763382 NPPB natriuretic peptide precursor B  -2.86 0 
ILMN_1795325 ACTG2 actin, gamma 2, smooth muscle, enteric  -2.22 0 
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